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Abstract 
Osteoarthritis (OA) is a common degenerative disease of synovial joints that 
principally affects older individuals. The genetic architecture of OA is highly complex, 
with heterogeneous pathological pathways converging on a common end phenotype 
characterised by the painful loss of articular cartilage. In this study, I investigated 
both genetic and epigenetic aspects of the OA disease process. The genetic 
investigation focused on the functional analysis of a female hip OA association signal 
that was discovered in the arcOGEN study, marked by the single nucleotide 
polymorphism (SNP) rs4836732. The signal surpasses the genome-wide 
significance threshold, with p = 6.11x10-10. The signal encompasses only two other 
SNPs that have a high degree of linkage disequilibrium (LD) with rs4836732. 
Functional studies using luciferase reporter assays, electrophoretic mobility shift 
assays (EMSAs) and a range of transformed cell lines did not identify any differential 
allelic activity between SNP alleles, but did identify differential EMSA banding 
patterns for the C allele of rs4836732 when compared to the T allele, suggestive of 
differential protein complex binding dependent on the allele present at rs4836732. 
Subsequent investigations focused on three genes in the immediate vicinity of the 
association signal: ASTN2, PAPPA and TRIM32. All three genes were expressed in 
cartilage, synovium and fat pad from OA patients, though none displayed differential 
allelic expression correlating with rs4836732 genotype in these tissues. This lack of 
positive evidence in end-stage disease tissue may be indicative of the association 
signal mediating risk during joint development or growth. Of the three genes, PAPPA 
was deemed the most likely candidate to have a functional affect in joint 
development. Knock-down of the gene in mesenchymal stem cells revealed that 
PAPPA is required for osteogenic and chondrogenic differentiation, providing support 
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for further investigation of this gene. My second line of investigation focused on OA 
epigenetics, specifically on subgroups of hip and knee OA patients who displayed 
altered cartilage methylation of inflammatory genes when analysed by high-density 
CpG methylation array. As part of this study, I developed pyrosequencing assays to 
determine the inflammatory subgroup of new patient cartilage samples, negating the 
need for a high-density array. I also further interrogated the inflammatory status of 
the patients, analysing serum markers of systemic inflammation and gathering 
biometric data to ascertain the primary cause of inflammation, with a focus on the 
metabolic status of patients in relation to body fat. Interestingly, no systemic 
differences in inflammation, circulating leptin or BMI were observed. This suggests 
the elevated inflammatory status may be local to the synovial joint, as opposed to 
being secondary to increased systemic inflammation. Overall, the two investigation 
routes that I have pursued further emphasise the heterogeneous nature of OA. They 
also highlight the importance of patient stratification for OA research and provide 
platforms to improve our comprehension of this debilitating disease.  
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Chapter 1 - General Introduction  
1.1 Synovial joint biology 
The term joint refers to the location at which two bones meet, and there are three 
main classes of joint in the human body: fibrous, cartilaginous and synovial. Of 
these, synovial joints are the most common. Synovial joints are mobile joints, which 
function to enable articulation between the opposing skeletal surfaces. They facilitate 
a range of movements, determined by joint location and architecture, and the 
arrangement of  the tissues in a healthy synovial joint permits friction-free and 
painless motion. However, there are over 200 defined types of musculoskeletal 
disorders which hinder normal joint articulation and result in restricted motion and 
pain [1]. 
 
1.1.1 Joint structure and function 
Synovial joints are highly sophisticated structures, each of which possesses a unique 
shape according to its biomechanical requirements. Synovial joints can be 
distinguished from other articulations in the body as they are surrounded by a thick 
and flexible joint capsule. The fibrous connective tissue of the joint capsule inserts 
into the two epiphyseal bones to provide both passive and active stability in order to 
support joint mobility. Synovial joints are further stabilised by surrounding ligaments, 
comprised primarily of type I collagen, which intersect the joint capsule [2]. Deep to 
the joint capsule lies the synovium, a soft tissue comprised of two predominant cell 
types. Type A synoviocytes act as resident macrophages, phagocytosing any 
detected waste and debris. Type B synoviocytes are fibroblast-like cells, which 
produce synovial fluid to lubricate the joint and minimise friction [3]. Articular 
cartilage lines the opposing bone surfaces and acts both a shock absorber during 
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movement, and provides a smooth articular surface with low friction coefficient [4]. 
Lubricin (also known as proteoglycan 4) and hyaluronic acid (HA), secreted by the 
synovium, nourish the articular cartilage by assisting in the exchange of carbon 
dioxide and metabolic waste for oxygen and nutrients [5].  
 
Specific synovial joints contain additional structures such as adipose tissue pockets, 
known as articular fat pads. Extrasynovial infrapatellar fat pad (IFP) is a tissue found 
only in the knee joint and is proposed to protect exposed articular surfaces and to 
assist in distribution of synovial fluid through this joint. The fat pad is also 
hypothesised to assist in the repair of the nearby avascular structures, namely the 
anterior cruciate ligament, given its extensive vascularisation.  Though the definite 
function remains unproven, studies indicate that the IFP is preserved during times of 
starvation even when subcutaneous fat is depleted, suggesting it is essential for 
knee function [6]. 
 
Chondrocytes are the sole cell type present in articular cartilage and their 
morphology and spatial arrangement varies according to their location (Figure 1.1).  
In adult articular cartilage, arrested chondrocytes form distinct zones. These zones 
are comprised of non-calcified cartilage, which is separated from the deeper zone 
containing calcified cartilage by a basophilic tidemark [7]. Chondrocytes are 
surrounded by an extracellular matrix (ECM), comprised of proteoglycans, of which 
aggrecan is the most abundant, collagen and water. Type II collagen is the 
predominant collagen in articular cartilage, and acts as a structural scaffolding 
protein, as well as providing tensile strength. The arrangement of collagen fibres 
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differs according to location within the articular cartilage. The most superficial fibres 
lie parallel to the joint surface, while the deepest fibres are radially orientated [8]. As 
the other abundant protein in the ECM, aggrecan is comprised of a protein core and 
three globular domains: G1, G2 and G3. Hyaluronic acid forms non covalent bonds 
with G1, while glycosaminoglycan (GAG) chains, which include chondroitin sulphate, 
are found between G2 and G3 [9].  
 
Chondrocytes in the superficial zone (zone 1), residing adjacent to the synovial 
space, appear flattened in morphology. These chondrocytes, like the synovium, 
produce lubricin. Unlike the densely packed fibres present in the superficial zone, 
chondrocytes in the middle zone (zone 2) are surrounded by a randomly organised 
collagen fibril domain. In the final non-calcified zone, the deep zone (zone 3), radially 
orientated collagen fibrils extend into the zone of calcified cartilage (zone 4) to 
anchor the layers together. In the deep zone, cells are aligned perpendicular to the 
subchondral bone.  Zone 4 contains hypertrophic chondrocytes, expressing markers 
of hypertrophy such as collagen X, which reside within a calcified matrix [10].  
 
The epiphyseal bone lying deep to the articular cartilage, known as the subchondral 
bone, consists of two zones. Separating calcified cartilage from the bone marrow is 
the subchondral bone plate. This region is densely calcified, owing to the formation 
of hydroxyapatite crystals, to support the cartilage and facilitate distribution of 
mechanical load. Beneath is the lesser calcified trabecular bone with a 
predominantly metabolic function [11]. Subchondral bone matrix is primarily 
comprised of type I collagen, in addition to proteins such as osteocalcin. The 
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calcified matrix contains osteoblasts and osteoclasts, which synthesise and degrade 
bone matrix components, facilitating bone growth and repair [12].  
 
Figure 1.1 
Histology and diagrammatic representation of adult articular cartilage structure.   
NCC – non-calcified cartilage; CC – calcified cartilage, SCB – subchondral bone.  
The photomicrograph depicts the osteochondral junction in an individual without 
OA, with red Safranin O dye staining of the proteoglycan rich cartilage. Zone 1, or 
the superficial zone, comprises 10-20% of the cartilage and contains densely 
packed collagen fibrils. 40-60% of articular cartilage is accounted for by zone 2, the 
middle zone, which is a region of randomly organised collagen fibres. Zone 3 is the 
deep zone, around 30% of articular cartilage, from which collagen fibres extend into 
the calcified zone (zone 4) to anchor the layers together. The tidemark (green 
arrow) separates the non-calcified and calcified cartilage.  Photomicrograph taken 
from [7].   
  
  
  
  
  
  
  
  
  
  
5 
 
1.1.2 Joint development 
Long bone formation during embryogenesis is initiated when mesenchymal cells 
condense to form distinctive limb buds, subsequently forming a hyaline cartilage core 
known as the anlage. Formation of synovial joints becomes morphologically evident 
when the uninterrupted cartilage anlage becomes separated by a region known as 
the joint interzone. Formation of the interzone is critical for joint formation and 
microsurgical removal of this region results in failure of joint morphogenesis [13]. 
Studies in mice have revealed that expression of Gdf5, encoding the 
growth/differentiation factor 5 protein, in the joint interzone induces cavitation of the 
joint to separate the opposing cartilaginous elements [14]. This is then succeeded by 
joint capsule formation. As the joint cavity enlarges, the interzone disperses and 
gives rise to articular cartilage and the synovium [15]. Murine fate mapping studies 
have identified that articular cartilage, and potentially all joint tissues, form from a 
specific group of Gdf5-expressing progenitor cells, which are distinct from those cells 
fated to become growth plate cartilage [16].  
 
Chondrogenic mesenchymal stem cells (MSCs) follow one of two pathways during 
joint development. Resting chondrocytes form articular cartilage on the opposing 
bones, with expression of cartilage-specific collagens II, IX and XI denoting the 
transition of MSCs to chondroprogenitor cells. Remaining chondrocytes undergo 
proliferation, controlled by the IHH/PTHrP axis, followed by terminal differentiation 
and hypertrophy, to facilitate endochondral ossification [8]. 
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Development of the long bones results in the formation of three distinct zones. The 
end of the long bones, the epiphysis, is separated from the middle region (the 
diaphysis) by the transitional zone between the two (the metaphysis). Between the 
epiphysis and metaphysis is a layer of cartilage known as the growth plate. During 
development, the long bones are created by endochondral ossification. This process 
occurs in two steps, firstly with differentiation of mesenchymal stem cells into 
chondrocytes to form a cartilage model. A centre of ossification forms within the 
diaphysis, within which chondrocytes are replaced by osteoblasts and undergo 
mineralisation. Later, a secondary centre of ossification appears in the epiphysis 
which allows continued growth of the bone as the cartilage between the ossification 
sites continues to expand until growth stops and the ossification sites fuse. In later 
life, fracture healing utilises a different process which does not require the formation 
of a cartilage model, known as intramembranous ossification. In this instance, 
mesenchymal stem cells differentiate directly into osteoblasts and secrete a mesh of 
trabecular bone matrix, which is later replaced with mature lamellar bone [17]. 
 
1.1.3 Joint homeostasis 
Tissues of the synovial joint are composed of an extracellular matrix (ECM) 
containing collagens, glycoproteins and proteoglycans. The components of the ECM 
are continually synthesised and degraded according to the balance of growth factors, 
enzymes and cytokines, as well as in response to mechanical factors such as joint 
loading.  
 
7 
 
The ECM in articular cartilage supports a sole cell type, the chondrocyte. Synthesis 
of ECM components by chondrocytes occurs in response to the metabolic state of 
the chondrocytes, influenced by surrounding chemical and biomechanical factors, 
which is maintained in a steady state in healthy adult cartilage. However, when this 
balance is disrupted, the integrity of the articular cartilage is disturbed. Joint 
development and subsequent growth are normal physiological processes which 
require matrix synthesis to supersede degradation [18]. Many growth factors, such 
as transforming growth factor β (TGFβ), bone morphogenetic proteins (BMPs), 
fibroblast growth factors (FGFs) and insulin-like growth factors (IGFs) are present in 
the joint during development and have roles in cartilage development and repair. 
TGF-β1, BMP-2, BMP-7 and IGF-I all stimulate cartilage ECM synthesis, which FGF-
18 has been shown to not only stimulate ECM production, but to induce chondrocyte 
proliferation [19,20]. 
 
Cartilage degradation is largely carried out by a two families of metalloproteinases: 
matrix metalloproteinases (MMPs) and the ADAMTS (a disintegrin and 
metalloprotease with thrombospondin motifs) family of metalloproteases. These 
proteinases primarily degrade collagen and aggrecan respectively. MMPs are sub 
grouped according to their target cleavage sites and their cellular location, and are 
synthesised in a pro-enzyme form to aid their regulation. Cleavage of an N-terminal 
fragment is necessary for MMP activation, a process performed by factors such as 
activated MMPs and reactive oxygen species (ROS). Connective tissue cells also 
synthesise tissue inhibitors of metalloproteinases (TIMPs), under the control of local 
growth factors. TIMPs provide additional regulation of MMPs by inhibiting pro-MMP 
cleavage and by preventing target substrate cleavage [21].  ADAMTS4 and 
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ADAMTS5 are potent enzymes which cleave the core protein of aggrecan, resulting 
in aggrecan protein truncation and reduced protein abundance [22].  
 
Subchondral bone undergoes constant remodeling, reliant on the three main cell 
types present in bone; osteoblasts, osteoclasts and osteocytes. Bone formation is 
greatest during childhood but with increasing age, homeostasis is disrupted in favour 
of increased bone resorption. The dynamic formation and resorption of bone is 
essential to repair damage and maintain metabolic homeostasis of calcium and 
phosphorus, and relies on the stringent coordination between osteoblasts and 
osteoclasts. Osteoblasts and osteoclasts operate under an opposite feedback loop, 
whereby active osteoblasts secrete a protein, RANKL, which binds the RANK 
receptor on osteoclast precursors, stimulating the formation of mature osteoclasts 
[23]. Osteoclasts resorb bone to expose the underlying mineral matrix, which 
releases osteotrophic factors such as IGF1. This stimulates the differentiation of 
MSCs into osteoblasts to enable new bone formation [24]. Osteoblasts which 
become isolated in the bone matrix become osteocytes. Osteocytes possess long 
cellular processes and facilitate communication between cells in response to stimuli 
such as altered mechanical forces [25]. 
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1.2 Osteoarthritis 
Osteoarthritis (OA) is defined by NICE guidelines as ‘a clinical syndrome of joint pain 
accompanied by varying degrees of functional limitation’ [26]. It is the most prevalent 
chronic joint disease worldwide and is estimated to affect a third of the UK population 
over the age of 45 [27]. 
 
1.2.1 Incidence and distribution of OA  
OA can present in any synovial joint, but is most common in the hip, knee and hand. 
Age and sex adjusted data from the Fallon Community Health Plan in Massachusetts 
(USA) concluded OA to be most prevalent in the knee, with intermediate rates for 
hand OA and lowest observed rates for hip OA [28]. A later study in the Dutch 
population corroborated with these conclusions, finding knee OA to comprise the 
highest number of OA cases as seen by general practitioners in 2000 [29]. The study 
reported knee OA figures of 1.18 and 2.8 per 1000 for men and women respectively, 
while the figures were 0.9 and 1.6 per 1000 for hip OA. More recently, estimates 
from the 2010 Global Burden of Disease Study found radiographically-defined 
symptomatic knee OA to be more prevalent worldwide than hip OA, indicating a 
prevalence of 3.80% and 0.85% respectively [30]. 
 
OA prevalence positively correlates with increasing age, with 49% of women and 
42% of men over the age of 75 years having sought treatment for OA in the UK [27].  
The number of people suffering from OA is therefore anticipated to rise in coming 
years, reflective of our ageing population. A report commissioned by Arthritis Care 
estimates 17 million people will be diagnosed with OA in the UK by 2030 [31]. 
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OA epidemiology also varies according to geographical location.  Studies by the 
Community Oriented Program for Control of Rheumatic Disorders (COPCORD) 
identified knee OA incidence in Asia to vary from as much as 1.4% in urban Filipinos 
to 19.3% in rural Iranian communities [32]. The COPCORD studies went on to 
identify an increase in clinically diagnosed knee OA, after adjusting for age and sex, 
in urban compared to rural Indian communities. This difference may be attributed to 
differences in the socioeconomic and physical environments. 
 
1.2.2 Pathology of synovial joint tissues 
OA is often misconceived to be a disease affecting solely the articular cartilage.  
However, pathological changes have been described in all tissues found within the 
synovial joint, emphasising the notion that OA is an active response to joint injury 
as opposed to merely a passive degenerative course. While articular cartilage 
degradation is a vital feature of OA, many other joint abnormalities are also 
apparent, such as subchondral bone thickening, synovial inflammation and 
ligament degeneration [4] (Figure 1.2).   
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Figure 1.2 
A comparative diagram of the pathological changes in OA joint tissues. In OA, the 
articular cartilage is eroded and abnormalities are noted in other structures, such 
as the formation of subchondral bone cysts and synovitis. In later stages of the 
disease, there may be narrowing of the joint space and formation of osteophytes, 
which are postulated to reflect a reparatory response to joint damage, though this 
remains debated [33,34]. 
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The disrupted homeostasis of OA cartilage results in the abnormal activation of 
chondrocytes and leads to recapitulation of developmental events,  causing 
chondrocytes to become hypertrophic and calcify [4]. Further to this, OA 
chondrocytes express MMPs, ADAMTSs and cytokine receptors which upregulate 
the inflammatory and catabolic response. Degradation of the matrix results in a 
positive feedback loop, as matrix protein fragments such as collagen and fibronectin 
stimulate production of MMPs and proinflammatory cytokines which cause further 
matrix degradation [35].   
 
One of the earliest changes noted in the OA joint is bone remodeling, though it 
remains disputed as to whether this is a disease trigger factor, or a secondary 
consequence of cartilage degradation [36]. Changes in subchondral trabecular bone 
density have been identified in numerous studies and a systematic review of 139 
studies concluded tibial bone area and bone marrow lesions to be independently 
associated with the structural progression of knee OA [37]. The process of skeletal 
adaptation also gives rise to boney projections, called osteophytes, along the joint 
margins. Though their function remains unproven, they are suggested to develop in 
an attempt to stabilise the joint, thus reducing further damage [38].   
 
Synovitis is another common feature of OA and has been shown to correlate with 
radiographic disease severity [39]. Synovial infiltration of inflammatory mediators, 
such as macrophages, have been detected in over 50% of knee OA patients, and 
synovial hyperplasia and fibrosis can also occur [40]. Activated synoviocytes 
promote a catabolic response in the joint owing to secretion of MMPs and cytokines, 
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such as IL1β, IL6 and TNFα. Studies have shown this not only results in synovial 
joint inflammation, but alters the metabolic state of chondrocytes to increase their 
production of MMPs and aggrecanases, thus promoting cartilage destruction [41].  
 
Our comprehension of the pathological changes associated with OA has been 
greatly improved by genetic, transcriptomic, epigenetic and proteomic analyses. It is 
now apparent that numerous pathological pathways converge on the same endpoint 
of symptomatic OA and as such, there is a large degree of pathologic heterogeneity 
both between patients and within the affected joint. Inflammation, however, is 
emerging as a vital feature of OA pathology. Though genetic studies do not support 
the notion that variation in inflammatory genes increases disease risk, inflammation 
appears to be highly relevant to disease pathology [42]. Of particular interest, 
research has suggested that OA patients may separate into those in whom 
inflammation is a key factor in disease pathology, and those in whom it is not [43]. 
This has clear implications both in terms of improving our understanding of the 
pathological changes occurring in synovial tissues in OA and may be vital in guiding 
future patient stratification in clinical trials.  
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1.2.3 OA diagnosis and treatment 
Symptomatically, OA presents as a combination of pain and functional impairment 
and 80% of patients suffer from decreased joint mobility [33]. Clinical examination of 
the joint to detect signs such as stiffness and pain, which usually occur in 
conjunction with significant functional impairment, is required for OA diagnosis. Pain 
is normally associated with activity, for example walking or rising out of a chair in the 
case of knee OA [44]. In the more advanced stages of disease progression, OA can 
also be characterised radiographically, owing to the presence of subchondral bone 
cysts, subchondral sclerosis, narrowing of the joint space and abnormal bone 
contour [45]. OA can be clinically subtyped into one of two categories; primary OA 
has no discernible cause, while secondary OA is diagnosed in the presence of a 
causative episode, for example injury, infection or avascular necrosis [46].  
 
Various scales have been developed in attempts to quantify OA severity. One of the 
most commonly used systems is the Kellgren and Lawrence (KL) scale, which 
grades severity on a scale of 0-4 on plain radiographs. Here, 0 represents no 
disease-associated joint abnormality and scores greater than 2 are indicative of 
radiographic OA [47]. The Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) is another common system, comprising a set of standardised 
questionnaires which measure three subscales, developed to measure patient-
reported outcomes. The WOMAC assesses five items for pain (score range 0–20), 
two for stiffness (score range 0–8), and 17 for functional limitation (score range 0–
68) [48].  
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To date, no disease-modifying drugs have been approved for the treatment of OA 
and therapeutic intervention is limited to pain relief, and eventual joint replacement 
[49]. Consequently, the onus lies with effective disease management and current 
universal guidelines recommend a combination of pharmacological and non-
pharmacological measures [50]. NICE recommends exercise as a core treatment, 
with the intention to strengthen local muscles and reduce body weight, therefore 
reducing joint stress and minimising abnormal joint biomechanics [26].  
 
Pain relief is provided using paracetamol, non-selective NSAIDs with selective COX-
2 inhibitors and opioids. NSAIDs predominantly target COX-1 and COX-2, the two 
isoforms of the enzyme cyclooxygenase, which generates prostanoids. These 
signalling molecules are a biological mediator of pain and inflammation. However, 
NSAIDs have been identified to cause adverse gastrointestinal (GI) effects, mediated 
by the widely expressed COX-1 isoform. This prompted the development of COX-2 
specific inhibitors, such as celecoxib and rofecoxib [51]. While NSAIDs and COX-2 
inhibitors have been found to be marginally more effective than paracetamol at 
reducing pain, paracetamol is recommended as the first line of pharmacological 
intervention owing to its lower toxicity. More recent research though indicates 
3000mg/day paracetamol may cause similar gastrointestinal blood loss to 
1200mg/day ibuprofen, with combination therapy being additive [52]. Further to these 
safety concerns, an ongoing evidence review by the MHRA (Medicines and 
Healthcare Products Regulatory Agency) has revealed reduced effectiveness of 
paracetamol in OA management compared to what was previously believed [26]. As 
such, NICE intend to carry out a full review of evidence regarding pharmacological 
recommendations in the near future. It is also to be noted that published evidence on 
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OA treatment is limited by the fact that most studies are of short duration using a 
single therapy, primarily in knee OA. Consequently, the genuine effectiveness of 
interventions is likely to differ given that patients tend to have pain in more than one 
joint and are on combined therapies [26].  
 
Though pain relief is essential to improve quality of life, the key focus for 
pharmacological intervention is the generation of disease modifying drugs. Many 
clinical trials have been conducted in attempts to limit disease progression using 
various approaches, yet none have proved successful. A recent multicentre, 
randomised, double-blind trial comparing chondroitin sulphate plus glucosamine 
hydrochloride (CS+GH) versus celecoxib in 606 knee OA patients concluded the 
compounds to have comparable effect to celecoxib, but with no improvement in loss 
of cartilage loss [53]. Another method to reduce cartilage degradation is to inhibit the 
mediators of breakdown, such as MMPs. Systemic delivery of agents such as 
tacrolimus, an inhibitor of MMP-13, NF-κB, and bone matrix remodeling, have been 
shown to reduce pain-associated behaviours in the monoiodoacetic acid (MIA) and 
medial meniscal tear/medial collateral ligament tear rat OA models [54]. However, 
the benefits of such drugs are hampered by adverse reactions due to the inevitable 
broad protease inhibition [55].  
 
For patients with ongoing functional impairment and pain, total joint arthroplasty is 
indicated and total knee replacement is the most commonly performed arthroplasty 
procedure in the UK [56].  However, joint replacements are finite and so, are only 
considered for those individuals who experience prolonged functional limitation and 
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pain refractory to the non-surgical core treatments. The selection of patients for 
arthroplasty is highly subjective and remains a key hurdle for clinicians. This is 
especially true when patients present at younger ages, with elevated BMI or 
additional associated co-morbidities present [56]. In order to help streamline this 
process, new screening techniques have been developed, particularly in the 
assessment of pain and stiffness, in attempts to predict post-operative patient 
dissatisfaction [57]. 
 
Attempts to minimise the current treatment gap between non-surgical interventions 
and arthroplasty have yielded procedures such as arthroscopic lavage and 
debridement. However, a randomised controlled trial conducted by Mosely and 
colleagues concluded there is no difference between these procedures and sham 
surgery [58]. An alternative surgical option for some younger patients with OA that is 
confined to either the lateral or medial compartment of the knee, is femoral or tibial 
osteotomy. This involves realignment of the femur or tibia, in order to reduce the load 
on the affected compartment [59]. This will often alleviate symptoms for a few years 
before knee replacement is considered.    
 
Though risk factors for OA have been identified, we are yet to establish any robust 
prevention strategies. One of the most extensively studied areas for prophylactic 
intervention against OA is in OA occurring secondary to sports injury. Anterior 
cruciate ligament (ACL) damage is of particular interest, as an estimated 25% of the 
knee OA population have sustained previous ACL rupture. Consequently, ACL 
reconstruction has been investigated as a candidate prophylactic approach. Though 
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reported to improve short- and mid-term outcomes, longitudinal studies have found 
50% of patients with ACL injury develop OA within 20 years of injury [60]. A 
subsequent literature review also found little evidence to support ACL reconstruction 
in the prevention of OA [61]. Given that most ACL injury occurs in the young 
population, evidence implies injury prevention in this subgroup would greatly reduce 
OA incidence. As such, implementation of evidence-based neuromuscular and 
biomechanical interventions are an area of great promise [62].  
 
When reviewed as a collective, the absence of disease modifying drugs and the 
current passive, symptomatic nature of treatment emphasises the requirement for 
improved knowledge of OA pathogenesis with the aim to divert interventions to more 
active, prophylactic treatment. 
 
1.3 OA risk factors 
The complex aetiology of OA is poorly understood, though multiple risk factors have 
been identified, both modifiable and non-modifiable (Figure 1.3). It is becoming 
increasingly apparent, through molecular and clinical studies, that numerous risk 
factors and different pathophysiological pathways contribute to disease susceptibility 
and progression.  
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Figure 1.3 
Factors contributing to increased OA risk. Various modifiable and non-modifiable 
systemic risk factors increase overall OA susceptibility. Local factors then act to 
determine site and severity of disease in the form of modifiable risks, such as muscle 
weakness, and non-modifiable risks, including joint deformities.   
 
Age is the greatest risk factor for all joints, with female sex being a further 
predominant non-modifiable risk factor [63].  Prevalence of OA increases in women 
after the menopause, resulting in the suggestion that decreasing oestrogen levels 
may be a risk factor. However, clinical trials assessing the effect of oestrogen 
replacement therapy on OA development do not support this hypothesis [64].  
Data from the Johnston County Osteoarthritis Project indicates obesity to be one of 
the main modifiable risks, finding individuals who are obese to be at twice the risk of 
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developing knee OA compared to those with normal or low BMI [65].  Furthermore, 
disease risk positively correlates with increasing body mass index (BMI). Though 
obesity results in abnormal loading through joints, there is also increased incidence 
of hand OA in obese individuals. As such, the effect of obesity cannot be wholly 
attributed to an increase in joint loading. It is hypothesised that increased risk is 
therefore likely to be mediated by the deregulation of metabolic and inflammatory 
factors [66]. 
 
OA risk is also influenced by race and ethnicity, with an increase in hip OA incidence 
having been observed in the Johnston County cross-sectional study in comparison to 
the Caucasian cohort [65]. Other ethnic difference have also been identified, such as 
an increase in knee OA prevalence in Chinese compared to Caucasian females [67]. 
 
The importance of understanding the impact of co-morbidity on health outcomes in 
OA patients has been highlighted in the recent population cohort study by Hawker et 
al. [68]. OA patients with pre-existing cardiovascular disease and increased baseline 
pain were found to have significantly decreased survival rates. A significant 
association was also found between OA-related disability and increased all-cause 
mortality, as well as serious cardiovascular events. This consequently indicates OA 
associated functional impairment as a potentially modifiable factor for serious 
cardiovascular events and death. 
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1.4 OA genetics 
The genetic component of OA was first highlighted by family aggregation studies in 
the 1940s, which identified the disproportionately increased occurrence of 
Heberden’s nodes in first degree relatives of patients with this indicator of hand OA 
[69]. Subsequent twin concordance studies, which allow for the separation of 
environmental and genetic factors, have identified that between 40% - 70% of OA 
risk can be accounted for by genetics [70]. What these studies have also identified is 
that OA is not a monogenic disease, but is caused by inheriting multiple 
polymorphisms in various genes, each of which contribute a very small amount to 
the overall risk.  
 
1.4.1 Candidate gene studies 
With the confirmation that genetic factors contribute to OA susceptibility, further 
investigation has sought to identify the molecular basis for these hereditary factors. 
As such, when prior research indicates a gene has a role in joint biology or in a 
process potentially important in OA pathology, hypothesis-led candidate gene 
studies may be used. Perhaps the most compelling candidate gene studies 
performed have been on GDF5, a member of the TGF-β superfamily known to be 
necessary for skeletogenesis and joint formation [71]. A study by Miyamoto and 
colleagues identified a significant association between SNP rs143383 in the 5' UTR 
of GDF5 and OA within the Asian population, with functional work indicating 
rs143383 to be a cis-acting expression quantitative trait locus (cis-eQTL) [72]. 
Subsequent research identified the T allele to be associated with OA in a Spanish 
and UK cohort, with studies showing GDF5 expression in cartilage to be reduced in 
the presence of the T allele at rs143383 [73]. However, candidate-led studies have 
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resulted in many false positive results, with a meta-analysis study of 199 genes 
associated with OA concluding only two, COL11A1 and VEGF, to be significantly 
associated with OA [74].  
 
The major caveat with the candidate gene approach is that it is reliant on prior 
comprehension of the disease process. Given our incomplete knowledge of OA 
pathogenesis, this makes it highly likely that important genes may not be 
investigated were this to be the sole approach.  
 
1.4.2 Genome wide association studies 
Candidate genes studies have been largely replaced by genome wide association 
studies (GWAS). GWAS are superior in that they require no prior gene knowledge 
and are extremely powerful owing to large cohort sizes and extensive genome 
coverage. They work by comparing single nucleotide polymorphisms (SNPs) in a 
cohort of patients with a disease compared to a cohort without, or to population 
controls. This approach was made possible upon completion of the human genome 
sequencing project and the International Human HapMap project [75,76].  The 
phenomenon of linkage disequilibrium (LD), the non-random association of alleles at 
different loci, can be exploited so fewer SNPs need to be genotyped than the total 
number in the genome.  
 
To date, several high-powered OA GWAS, genotyping ≥ 500,000 SNPs, have been 
performed and, in combination with candidate studies, this has facilitated the 
identification of 14 replicated OA susceptibility loci which reached genome-wide 
significance (defined as p ≤ 5.0 x 10-8) [77].  In addition to this, a further 11 loci have 
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been identified which are suggestive of OA association (p ≤ 5.0 x 10-5).  A summary 
of these findings is shown in Table 1.1, except the association signals identified by 
the arcOGEN consortium, which are discussed in Chapter 1.5.  The identification of 
these loci has reinforced the genetic heterogeneity of OA, with many showing joint-
specific or sex-specific effects (Table 1.1). 
 
SNP p value Nearest gene Stratum Study 
rs3204689 1.10 x 10-11 ALDH1A2 Hand [78] 
rs143383 6.20 x 10-11 GDF5 Knee [79] 
rs6094710 7.90 x 10-09 NCOA3 Hip [80] 
rs4730250 9.17 x 10-09 COG5 Knee [81] 
rs11842874 2.10 x 10-08 MCF2L Hip & knee [82] 
rs143383* 1.80 x 10-13 GDF5 Hip [72] 
rs7639618 7.30 x 10-11 DVWA Knee [83] 
rs7775228 2.43 x 10-08 HLA-DQB1 Knee [84] 
rs10947262 6.73 x 10-08 BTNL2 Knee [84] 
     
     
SNP p value Nearest gene Stratum 
 
Study 
rs12982744 7.80 x 10-08 DOT1L Hip [85] 
rs3815148 8.00 x 10-08 HBP1 Knee & hand [86] 
 rs12901499 7.50 x 10-06 SMAD3 Hip & knee [87] 
rs4907986 1.29 x 10-05 COL11A1 Hip [74] 
rs833058 1.35 x 10-05 VEGF Male hip [74] 
rs225014 2.02 x 10-05 DIO2 Female hip [88] 
D-repeat D13/D14 1.30 x 10-06 ASPN Knee [89] 
rs10980705 2.60 x 10-05 LPAR1 Knee [90] 
 
Table 1.1 
Replicated OA susceptibility loci identified by candidate gene studies and GWAS. 
The top panel shows those which reached genome-wide significance (p ≤ 5.0 x 10-8), 
and the bottom panel are those suggestive of OA association (p ≤ 5.0 x 10-5). p 
values shown are the combined discovery and replication values. *Indicates where 
the same association polymorphism was identified in different population cohorts. 
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1.5 Overview of the arcOGEN study 
Funded by Arthritis Research UK, the arcOGEN Consortium was a UK-wide 
collaboration, which aimed to perform well-powered GWAS studies to identify 
genetic factors implicated in OA. The initial stage 1 GWAS comprised 3,177 OA 
cases and 4,894 controls from the UK, but failed to identify any association signals 
reaching genome-wide significance [91]. In stage 2, a GWAS comparing 7,410 
unrelated OA patients and 11,009 unrelated controls from UK cohorts, 129 potential 
signals were identified [92]. Subsequent in silico replication using 5,064 OA cases 
and 40,619 controls, followed by de novo replication of the 26 of the most significant 
SNPs in 2,409 cases and 2,319 controls from European ancestry identified five loci 
as having genome-wide significance (p = 5.0 x 10-8) for association with OA (Table 
1.2). An additional three loci were just below the significance threshold for OA-
association.  
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Table 1.2   
Table of the 5 most significant signals from the arcOGEN study. Five loci display 
genome wide levels of significance for OA association, p = 5.0 x 10-8.  rs11177 and 
rs6976 are in perfect linkage disequilibrium (LD) (r2=1) and so, represent one signal  
[92]. TJR=total joint replacement. THR=total hip replacement.  Hip = radiographically 
confirmed OA, prior to joint replacement surgery. p values shown are the combined 
discovery and replication values. 
 
1.5.1 Expression quantitative trait loci (eQTL) 
SNPs identified to be associated with a disease via GWAS studies mark a 
susceptibility locus in which other polymorphisms may reside. As such, it may be that 
a different SNP in high LD with the association SNP is in fact the causal variant. It is 
therefore necessary to first narrow down the region and identify the causal SNP, 
prior to then investigating the mechanism driving the disease association. In the 
event that the causal SNP is non-synonymous, an amino acid change leading to 
altered protein structure or function may cause the disease association, while 
synonymous mutations could result in aberrant gene transcription or splicing. The 
causal SNP may alternatively reside in an intron or be intergenic and thus, be non-
SNP Chromosomal location Nearest gene(s) p-value Stratum 
rs11177 
 
rs6976 
3p21.1 
3p21.1 
GNL3 
GLT8D1 
7.24 x 10-10 
1.25 x 10-10 
TJR 
rs4836732 9q33.1 ASTN2 6.11 x 10-10 THR-female 
rs9350591 6q14.1 FILIP1 
SENP6 
2.42 x 10-09 Hip 
rs10492367 12p11.22 PTHLH 
KLHDC5 
1.48 x 10-08 Hip 
rs835487 12q23.3 CHST11 1.64 x 10-08 THR 
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coding but regulate disease risk by regulating gene expression, for example by 
disrupting transcription factor binding and altering the enhancer or promoter activity 
of the region [83]. In this scenario, when regulation of gene expression is mediated 
by the genomic locus, the SNP is known as an expression quantitative trait locus 
(eQTL). When the genomic locus in which the causal SNP resides is in close 
proximity to the regulated gene, it is known as a cis-eQTL.  
 
1.5.2 rs4836732 discovery and stratum 
Table 1.3 shows the population data available for rs4836732. The T allele is the 
most common in the European and Asian populations, while TT homozygotes are 
uncommon in the West African population.  
 
 Genotype Alleles 
Population 
group 
CC CT TT C T 
European 0.23 0.51 0.26 0.49 0.51 
Han Chinese 0.19 0.47 0.35 0.42 0.58 
Japanese  0.19 0.47 0.35 0.42 0.58 
West African 0.56 0.37 0.07 0.74 0.26 
Table 1.3 
Genotype frequencies of rs4836732. The C and T allelic frequencies and 
homozygote and heterozygote genotype frequencies are displayed according to 
population group. Population frequency data obtained from dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). 
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rs4836732 is a C/T polymorphism residing on chromosome 9q33.1 within intron 18 
of the ASTN2 gene. The arcOGEN study identified the C allele to associate with 
female hip OA (p=6.11 x 10-10) (Table 1.2) [92]. It does not correlate with any other 
variants which code for non-synonymous polymorphisms. Therefore, the association 
signal marked by rs4836732 is anticipated to influence OA-susceptibility by a cis-
acting regulatory effect on gene expression, as discussed previously.  Three genes 
reside in the LD region demarcated by rs4836732 (Figure 1.4) and as such, are 
candidates for regulation by the SNP.  
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Figure 1.4 
Plot of the rs4836732 association region and genes within the locus. Case-control 
association results of genotyped SNPs in the region (shown as circles), for the 
female hip stratum, are plotted against genomic position. rs4836732 is denoted in 
the discovery set by the purple diamond and in the final meta-analysis by a purple 
square.  The circle colour is reflective of the r2 of the genotyped SNP and red lines 
show estimated recombination rates in cM/Mb. rs4836732 is in intron 18 of ASTN2, 
with PAPPA residing upstream and TRIM32 downstream, both of which are 
transcribed from the opposite strand. Arrows indicate the direction of gene 
transcription.  Figure taken from [92]. 
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1.5.3 ASTN2 
ASTN2 (astrotactin 2) is a poorly characterised gene, about which little scientific 
literature is available. The gene was first described by Wilson and colleagues in 
2010 after being identified as a homologue to ASTN1, a gene encoding the ASTN1 
protein which is required for glial-guided migration of cerebral cortex output neurons 
[93]. Murine models indicated the gene to be abundantly expressed in cerebral 
granule neurons during glial-guided neural migration and identified that ASTN2, like 
ASTN1, is a membrane-bound protein. Further to this, ASTN2 was shown to 
complex with ASTN1 and consequently facilitate ASTN1 polarisation during 
migration, thus modulating surface ASTN1 [93].   
 
Bis et al. documented an association between nine SNPs within ASTN2 and 
hippocampal volume in a GWAS of a young, heterogeneous sample of 7,794 
individuals [94].  In the same study, a largely independent sample (n=1563) found 
the ASTN2 SNP rs7852872 to associate with accelerated global cognitive decline 
and accelerated memory loss. This is hypothesised to relate to the function of glial-
guided neuronal migration, especially in the dentate gyrus which functions in 
formation of new episodic memories and is essential for cognition and spatial 
memory.   
 
A  meta-analysis of GWASs interrogating genetic variants influencing schizophrenia 
and bipolar in European-American samples (653 bipolar cases and 1034 controls, 
1172 schizophrenia cases and 1379 controls) noted ASTN2 variants to be 
associated with attention deficit/hyperactivity disorder and schizophrenia [95]. 
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Together, research to date suggests ASTN2 is required for neuronal development 
and function, with no evidence as of yet for a role in joint development or 
homeostasis.    
 
1.5.4 TRIM32 
Tripartite motif containing 32, or TRIM32, is a small gene which resides within an 
intron of ASTN2, and is transcribed from the opposite strand. The TRIM32 protein is 
a member of the ring finger family of zinc finger nucleases and is known to interact 
with the HIV-1 Tat protein, a regulator of transcriptional activation [96]. However, 
cotransfection of TRIM32 with a Tat expression vector did not enhance the function 
of Tat, meaning no conclusions could be made in relation to a role in transcription 
[96].  
 
 
A case-control study of limb-girdle muscular dystrophy type 2H (LGMD2H) and 100 
controls identified a mutation at position 487 (D487N) of TRIM32 to be causative of 
LGMD2H [97]. This mutation was subsequently identified to be identical to the 
causative mutation in sacrotubular myopathy, a Hutterite population specific disease 
[98]. Further analysis revealed TRIM32 is a E3 ubiquitin ligase, acting alongside 
ubiquitin-conjugating enzymes UbcH5a, UbcH5c, and UbcH6 [99]. The same group 
identified differential expression of the TRIM32 protein confined mainly to skeletal 
muscle, with induction in the event of muscle remodelling in response to increased 
loading. This implies that TRIM32 levels change in response to physiological 
conditions. TRIM32 specifically interacts with myosin to cause ubiquitination of actin, 
indicating a likely participation in myofibrillar protein turnover.  A more recent study 
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found TRIM32 is expressed in myogenic progenitors in mouse, with global knockout 
resulting in disrupted myogenic differentiation [100]. A LGMD2H-like phenotype was 
also observed, concluded to be due to impaired muscle regeneration owing to 
aberrant regulation of the transcription factor c-myc, a protein which blocks skeletal 
muscle stem cell differentiation.  
 
TRIM32 is also required during neurogenesis. Four mutations in the gene have been 
identified as the cause of LGMD2H, while a fifth was identified to result in Bardet-
Biedl syndrome type 11 [99]. With higher expression of Trim32 in the brain compared 
to skeletal muscle, a mouse knock-out revealed decreased concentration of 
neurofilaments and a reduction in myelinated motor axon diameters compared to 
wild type, for the first time defining a role for TRIM32 in neurogenic function. 
 
Schwamborn and colleagues showed polarisation of TRIM32 to daughter cells during 
mitosis of neural progenitor cells in Drosophila, suggesting that it plays a role in the 
balance between proliferation and differentiation [101]. Overexpression was shown 
to induce neural differentiation, while inhibition maintains progenitor status in 
daughter cells. This balance is suggested to be mediated via control of c-myc 
degradation, which is required for MSC self-renewal, and TRIM32 ubiquitination by 
the N terminus targets c-myc for degradation [101]. Studies in mice have also shown 
mutual transcriptional regulation of TRIM32 and the transcription factor p73, with 
dysregulation affecting both neural development and potentially oncogenesis [102].  
Furthermore, a screen of clinical microarray DNA datasets from 64114 patients with 
neurodevelopmental disorders (NDDs) and 44 085 population-based controls 
identified an enrichment of 3′ ASTN2 deletions (a group of which included TRIM32) 
in the NDD subjects (p = 0.002) [103]. NDD individuals with these deletions were 
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observed to have frequent phenotypes including speech delay, autism spectrum 
disorder (ASD) and attention deficit hyperactivity disorder (ADHD). It is therefore not 
unreasonable to hypothesise that both ASTN2 and TRIM32 have a key role in 
human neurodevelopment and psychopathologies. 
 
1.5.5 PAPPA 
PAPPA, or pregnancy-associated plasma protein A, is the most extensively studied 
of the genes within the rs4836732 susceptibility locus. The first pathologic 
association with this gene was published in 1985 in relation to stage I breast 
carcinoma recurrence [104].  The main body of subsequent work focused on 
circulating PAPPA and it was identified as a maternal serum marker of foetal 
chromosomal disease. PAPPA screening is now performed routinely in the first 
trimester of pregnancy in combination with beta-HCG and nuchal translucency 
measurements to detect Down's syndrome foetuses, together having a reported 
successful detection rate of 90% [105]. 
 
The first publication of direct importance to OA research was provided by Qin and 
colleagues [106]. They noted that the putative Zn-motif of PAPPA is identical to the 
active site Zn-motif of matrix metalloproteinases. It was subsequently identified that 
PAPPA is the IGF-II-dependent IGF-binding protein (IGFBP)-4 protease, with 
IGFBP2, 4 and 5 being the PAPPA-cleavable IGFBPs. Given that IGFs are one of 
the key factors which stimulate bone growth, and also modulate cartilage 
homeostasis by regulation of proteoglycan synthesis and degradation, this finding 
thus suggests PAPPA may have the capacity to regulate bone and cartilage 
development and maintenance. As such, mouse models suggest PAPPA cleavable 
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IGFBs are inhibitory to IGF function in bone, and all three IGFBPs were confirmed to 
be produced by osteoblasts in vitro. Qin et al. demonstrated that osteoblast-specific 
PAPPA expression in mouse increased bone size, indicative of PAPPA-cleavable 
IGFBPs exerting a regulatory effect over IGF bioavailability in skeletal tissues. This 
suggests PAPPA to have an anabolic role in bone formation and metabolism.  
 
In a global mouse PAPPA knock-out, a significant decrease in trabecular volume 
was recorded, progressing with age, alongside an age-associated decrease in 
fracture resistance [107]. Measurement of dynamic serum parameters associated 
with bone formation indicated reduced bone formation in young knockout mice (4 
and 6 months). By 6 months, bone resorption was also impaired compared to 
controls, although this was followed by an increase in resorption markers at 12 
months. Osteoblast numbers were reduced by 45-60% and osteoclasts by 50-60% 
compared to wild type littermates at 2 and 6 months, and 6 months respectively. As 
such, PAPPA appears to be necessary for both embryonic and postnatal bone 
development.    
 
Global gene expression profiling of the collagen-induced arthritis mouse, a model for 
rheumatoid arthritis which display aberrant bone formation at disease onset, 
identified a fold change increase of 2.3 of Pappa in days 0-3 of disease onset 
compared to during weeks 1-2 [108]. This therefore provides further evidence for an 
anabolic role in bone formation in vivo. 
 
 
 
 
34 
 
1.6 OA epigenetics 
As well as heritable genetic variation, epigenetic alterations have also been 
associated with OA. Coined by developmental biologist Conrad Waddington, the 
term epigenetics describes mitotically heritable changes in gene expression which 
occur without changes to the nucleic acid sequence of the DNA [109].  
 
1.6.1 Mechanisms of epigenetic modifications 
Various types of epigenetic modification have been identified and these can regulate 
gene expression either at the level of gene transcription, or by exerting post-
transcriptional influences. The key mechanisms by which this occurs are histone 
modifications, non-coding RNAs (ncRNAs) and DNA methylation. Owing to its 
importance to this thesis, DNA methylation is discussed in more detail in Section 
1.6.2, while histone modifications and ncRNAs are summarised below.  
 
Histones are positively charged proteins which associate with DNA to condense it 
into chromatin. DNA is wrapped around a histone octamer (two copies of histone 
proteins H2A, H2B, H3, and H4) to create a nucleosome, which then is wrapped into 
a 30nm solenoid spiral with surrounding nucleosomes. H1 histone proteins, so-called 
‘linker’ proteins, maintain the chromosome structure within the condensed chromatin 
[110]. Over 150 histone modifications, including acetylation, phosphorylation, 
ubiquitination and methylation of histone residues, have been identified and these 
can have variable effects on gene transcription [77]. Dysregulation of histone 
modifications has been described in numerous diseases and global alterations in 
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histone modifications have been well characterised in diseases such as cancer 
[111,112].  
 
ncRNAs can interfere with gene expression by affecting transcription, splicing or 
translation and include microRNAs (miRNAs) and long non-coding  RNAs [109]. It is 
reported that over a third of mammalian mRNAs are regulated by miRNAs, 
highlighting the vital role of this epigenetic mechanism in gene regulation [113]. 
miRNAs are short 20- to 23- nucleotide single stranded non-coding RNAs 
transcribed from intergenic and intronic regions of the genome which regulate 
transcript stability by promoting degradation of mRNA or repressing subsequent 
translation [114]. The creation of mouse knock-outs of specific miRNAs has revealed 
an essential regulatory role for miRNAs in normal development. Relevant to OA, 
severely impaired skeletogenesis has been described in mice null for the miRNA 
processing enzyme, Dicer [115].  
 
1.6.2 DNA methylation 
Occurring primarily at cytosine-guanine (CpG) dinucleotide pairs, DNA methylation of 
mammalian cells involves addition of a methyl group to a cytosine base by DNA 
methyltransferases (DNMT) [116]. Different DNMT enzymes are implicated in the 
establishment of methylation compared to the maintenance of methylation 
signatures. The mitotic inheritance of DNA methylation in primarily regulated by the 
maintenance enzyme DNMT1, which is essential to transfer patterns of methylation 
following DNA replication [114]. De novo DNA methylation however, is largely 
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regulated by DNMT3a and DNMT3B, which are responsible for establishing DNA 
methylation patterns, primarily during early development [110]. 
 
Regions of DNA with a high frequency of CpG sequences are termed ‘CpG islands’, 
and around 30% of genes have CpG islands near their promoters, the majority of 
which are unmethylated [114]. There are two main models as to how DNA 
methylation affects gene transcription. Firstly, they can have a direct effect on gene 
expression by interfering with transcription factor binding [117]. Further to this, 
methylated cytosines can act as docking sites for DNA binding proteins, such as 
MeCP2. This can result in indirect repression of gene expression as the binding 
proteins recruit co-repressors, which alter chromatin conformation. 
 
Though DNA methylation is an essential mechanism required for normal regulation 
of cell-specific gene expression, aberrant methylation has been increasingly 
associated with OA pathophysiology [118]. The majority of DNA methylation studies 
in OA have focused on articular cartilage. These have highlighted a distinct cartilage 
methylome not only when comparing non-OA and OA cartilage, but also according to 
the OA affected joint site [118, 119].  Furthermore, our group published research 
which identified separation of knee and hip OA patients into distinct clusters 
according to cartilage CpG site methylation [43]. The distinct methylation landscapes 
identified both between and within hip and knee cartilage is suggestive of differential 
gene regulation and cellular characteristics at different joint sites, thus further 
reinforcing the heterogeneity of OA pathophysiology.  
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The precise role of DNA methylation in OA is only more recently beginning to be 
elucidated. DNA methylation changes in both isolated chondrocytes and OA 
cartilage have been associated with altered gene expression of genes, including 
GDF5 [120]. Targeted analyses have demonstrated that methylation of certain CpG 
sites in cartilage DNA can interfere with transcription factor binding, suggested to 
then affect gene transcription [109]. Genome-wide DNA methylation studies have 
revealed a potentially exciting association between CpG site methylation in OA 
cartilage and the cartilage expression of inflammatory genes [121].  As such, gene 
regulation in OA, especially in relation to inflammatory genes, appears to be 
influenced by an interplay between genetic and epigenetic mechanisms.  
 
1.6.3 Epigenetics and inflammatory gene expression 
One of the most compelling associations between epigenetics and gene expression 
in OA has come from two microarray studies, performed by our group and 
Fernandez-Tajes et al., which identified separation of OA patients into two distinct 
clusters, according to inflammatory gene CpG methylation in cartilage DNA [43, 
122]. The study by our group, however, observed substantially more differentially 
methylated CpGs compared to the study by Fernandez-Tajes et al., likely to be 
reflective of the use of both a larger sample size including both hip and knee 
cartilage, as well as a more high-powered CpG methylation array. 
 
The study by Rushton et al. used the Illumina Infinium HumanMethylation450 
BeadChip array, which allows the annotation of ∼480,000 CpG sites, to compare 
methylation in chondrocyte DNA extracted from 23 hip OA patients, 73 knee OA 
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patients, and 21 non-OA control patients with neck of femur fractures [43].  
Comparison of hip OA patients and non-OA controls identified 5,322 differentially 
methylated loci (DMLs). Further to this, a differential methylation profile was found 
when comparing hip and knee OA samples, revealing 5,547 DMLs between these 
groups.  
 
Perhaps most interestingly, the hip OA samples were found to cluster into two 
distinct groups due to differential methylation at 15,239 loci, with an enrichment of 
genes involved in inflammation (Figure 1.5). Knee OA samples also formed two 
clusters, though less well defined compared to the hip samples. 
 
Figure 1.5 
Unsupervised hierarchical clustering of the global CpG β methylation values in hip 
OA cartilage samples. Each end branch represents an individual patient. Figure 
taken from [43].  
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Further investigation using RNA from the hip cartilage of samples analysed on the 
array concluded promoter hypomethylation of inflammatory genes in one of the 
identified groups was accompanied by increased gene expression, as measured by 
real-time quantitative PCR (qPCR) [121]. Analysis of 6 patients with hypomethylation 
at the promoters of TNF, IL6, IL1A, CXCR2, CCL5 and CCL2 found significantly 
increased expression of these genes in the cartilage compared to both 5 non-OA 
controls and 5 OA hip cartilage samples from patients in the non-inflammatory group. 
Together, these two studies therefore identify a distinct subgroup of OA hip patients 
with epigenetically and transcriptionally unique articular cartilage profiles. This 
finding may prove important for future clinical studies and for stratification of patients 
in OA research. It also poses the question as to whether aberrant inflammatory gene 
expression is also present in the cartilage of the knee subgroup, and vitally, what it is 
that is mediating this increased inflammation.  
 
1.7 Summary 
Our ageing population is creating undeniable socioeconomic strain and increasing 
the global healthcare burden. Osteoarthritis (OA) is a highly prevalent chronic 
disease, which is particularly associated with increasing age. While characterised by 
loss of articular cartilage, OA causes pathologic changes to all synovial joint tissues 
and has been identified to have a distinct inflammatory component. At present, no 
disease modifying drugs have been established and so, therapeutic options remain 
inadequate.  
 
40 
 
OA is a multifactorial disease, influenced by genetic and non-genetic factors. 
Genetic, epigenetic and transcriptomic studies have demonstrated the heterogeneity 
in OA pathophysiology, highlighting that multiple different pathways contribute to 
result in the same disease endpoint. As such, investigations into both genetic and 
epigenetic aspects of the OA disease process are essential in order to further our 
understanding of OA and to help guide future clinical trials.  
 
From a genetic stance, OA is highly polygenic, with multiple susceptibility alleles 
contributing to disease pathogenesis. Through the arcOGEN GWAS, several regions 
of the genome have been associated with OA including chromosome 9q33.1, 
marked by the rs4836732 single nucleotide polymorphism (SNP). Demonstrating 
significant association with female hip osteoarthritis, this SNP resides within an 
intron of the ASTN2 gene and in the immediate vicinity of PAPPA and TRIM32.  As 
such, functional analysis of this locus to establish the mechanism by which it 
influences OA risk would improve our understanding of the disease process and may 
potentially yield novel therapeutic possibilities.  
 
Epigenetic research has identified various aberrances in epigenetic regulation in OA 
patients, both compared to non-OA controls and within the disease group. CpG 
microarray analysis in OA cartilage DNA has identified a subgroup of OA patients 
who display divergent gene methylation, with a particular enrichment of inflammatory 
genes, which is reflected by increased expression of inflammatory genes in OA hip 
cartilage. Further investigation into the mechanism driving the elevated inflammatory 
gene expression in these patients, and also to establish whether these patients 
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display elevated systemic inflammation, would greatly assist in our knowledge of 
disease mechanisms and would help to direct future clinical trials.  
 
1.8 Overall aims 
The broad aim of this research is to investigate both genetic and epigenetic 
pathways which contribute to OA pathophysiology. This will be achieved by 
investigating:  
• Allelic functionality  
• Gene expression 
• Transcription factor binding 
• DNA methylation  
• Systemic inflammation  
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Chapter 2: Materials and methods 
2.1 Database searches to characterise the rs4836732 association signal 
The UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) was 
initially used to characterise the association signal, through which various data 
including the NCBI RefSeq collection of annotated gene transcripts and data 
generated by the ENCODE Consortium, was accessed.  The dbSNP online 
database (http://www.ncbi.nlm.nih.gov/SNP/) was used to obtain genotype 
frequencies for the SNPs, while the Broad Institute online software 
(http://www.broadinstitute.org/mpg/snap/) was used to identify SNPs in LD r2>0.7 
with the association SNP.  
 
2.2 Tissue sample collection 
Informed written consent for the use of joint tissues was obtained from patients who 
had undergone knee or hip arthroplasty at the Freeman Hospital and the Royal 
Victoria Infirmary, Newcastle-upon-Tyne. Ethical approval was granted by the 
Newcastle and North Tyneside Research Ethics Committee (REC reference number 
09/H0906/72). Following surgery, samples were stored at 4oC in Hank’s Balanced 
Salt Solution supplemented with nystatin, penicillin, and streptomycin. Articular 
cartilage, infrapatellar fat pad and synovium were isolated from the samples and 
snap frozen at -80oC on the day of surgery.  
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2.3 Nucleic acid extraction from human tissue 
Having been snap frozen at -80oC on the day of surgery, human tissue was 
subsequently ground under liquid nitrogen with a Retsch Mixer Mill MM 200 (Retsch, 
Leeds, UK). 
 
2.3.1 Nucleic acid extraction from fat pad and synovium 
Extraction of genomic DNA (gDNA) and RNA from fat pad and synovium was 
performed from 250 mg of ground tissue using the Omega E.Z.N.A. DNA/RNA 
Isolation Kit (Omega Bio-Tek, Georgia, USA), according to manufacturer protocol. 
Nucleic acids were quantified using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, USA). Samples were diluted in 
diethylpyrocarbonate (DEPC)-treated H2O (Invitrogen, Life Technologies, UK). DNA 
was stored at -20oC at 50 ng/μl and RNA at -80oC at a concentration of 250 ng/μl.   
 
2.3.2 Nucleic acid extraction from cartilage 
gDNA was extracted from 250 mg ground cartilage tissue using the Omega E.Z.N.A. 
DNA/RNA Isolation Kit (Omega Bio-Tek, Georgia, USA), according to manufacturer 
protocol. Briefly, ground tissue was vortexed with 700 μl GTC Lysis Buffer, then 
centrifuged for 5 minutes (min) at 11,700 revolutions per minute (rpm). The 
supernatant was transferred to a HiBind® column and centrifuged at 10,300 rpm for 
1 min. The centrifugation was repeated after the addition of HB Buffer, and then 
following addition of DNA Wash Buffer. The column membrane was then dried by 
centrifugation at 13,000 rpm for 2 min. The DNA was then eluted in 100 μl Elution 
Buffer. 
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To extract RNA, 1 ml of TRIzol Reagent (Ambion, Life Technologies, UK) was added 
to 250 mg of ground cartilage tissue and subsequently homogenised by vortexing 
thoroughly. Samples were then incubated at room temperature for 15 min and 
subsequently centrifuged for 3 min at 13,000 rpm at 4oC. The supernatant was 
transferred to a fresh Eppendorf tube and 200 μl of chloroform was added. The tube 
was shaken vigorously for 15 seconds (sec), then incubated at room temperature for 
3 min. The gDNA, total RNA and protein phases were then separated by 
centrifugation for 15 min at 13,000 rpm and 4oC. RNA, contained in the top aqueous 
phase, was transferred to a fresh tube and total RNA was then extracted using an 
RNeasy kit (QIAGEN, Crawley, UK) according to the manufacturer’s instructions. 
The remaining phases were discarded. The eluted RNA was quantified using a 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, USA) 
and stored at  -80oC, at a concentration of 250 ng/μl.   
 
2.4 Polymerase chain reaction optimisation 
For all primer pairs, the polymerase chain reaction (PCR) annealing conditions were 
optimised prior to use (Appendix A: Table A.1, Table A.2 and Table A.5). AmpliTaq 
Gold® Taq Polymerase (Applied Biosystems, Life Technologies, USA) was used for 
the basic PCR reactions for genotyping, pyrosequencing and cloning, while 
Titanium® Taq DNA Polymerase (Clontech Laboratories, Inc., France) was used for 
PCR using bisulphite converted DNA.  
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2.4.1 Optimisation of PCR conditions using AmpliTaq Gold® Taq DNA 
Polymerase 
Annealing temperatures from 55oC to 70oC were tested along with MgCl2 
concentrations of 1 mM, 1.50 mM and 2 mM to determine the optimum conditions. 
PCR reactions were carried out in a total volume of 15 μl, containing: 1 x PCR Buffer 
II (Applied Biosystems, Life Technologies, USA), 0.50 μM of both the forward and 
reverse primers (Sigma-Aldrich, UK), 200 μM deoxynucleotide triphosphates 
(dNTPs; Bioline, UK), 0.40 U AmpliTaq Gold® Taq Polymerase (Applied Biosystems, 
Life Technologies, USA), MgCl2 (Applied Biosystems, Life Technologies, USA) and 
50 ng gDNA. PCR cycling conditions were as follows: initialisation of reaction for 14 
min at 94oC, denaturation for 30 sec at 94oC, annealing for 30 sec and extension for 
1 min per 1 kb of template, at 72oC. This was performed for 35 cycles, followed by 
an elongation step for 5 min at 72oC. To confirm a product had been amplified, 4 μl 
of the PCR product was loaded onto a 2% weight/volume (w/v) agarose 
Tris/borate/EDTA (TBE) gel containing 20 μg ethidium bromide per 100 ml total 
volume. The gel was run at 100 V for approximately 30 min, and the products were 
then visualised using a G:BOX gel visualisation system (Syngene, UK) under 
ultraviolet (UV) light. 
 
2.4.2 Optimisation of PCR conditions using Titanium® Taq DNA Polymerase 
Annealing temperatures from 55oC to 70oC were tested to identify the optimum 
condition. Each reaction comprised a total volume of 20 μl, containing: 1 x Titanium® 
Taq PCR Buffer (Clontech Laboratories, Inc., France), 0.20 μM of both the forward 
and reverse primers (Sigma-Aldrich, UK), 0.20 μM reverse primer (Sigma-Aldrich, 
UK), 200 μM dNTPs (Bioline, UK), 1 x Titanium® Taq DNA Polymerase (Clontech 
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Laboratories, Inc., France) and 50 ng bisulphite converted DNA (Chapter 2.14). PCR 
cycling conditions were as follows: initialisation for 5 min at 95oC, denaturation for 30 
sec at 95oC, annealing for 30 sec and extension for 1 min at 68oC. This was 
repeated for 35 cycles, followed by an elongation step for 5 min at 68oC. To confirm 
a product had been amplified, 4 μl of the PCR product was loaded onto a 2% 
weight/volume (w/v) agarose Tris/borate/EDTA (TBE) gel containing 20 μg ethidium 
bromide per 100 ml total volume. The gel was run at 100 V for approximately 30 min, 
and the products were then visualised using a G:BOX gel visualisation system 
(Syngene, UK) under ultraviolet (UV) light. 
 
2.5 Genotyping at the sentinel SNP by restriction fragment length 
polymorphism (RFLP) 
2.5.1 Restriction fragment length polymorphism (RFLP) primer design to 
rs4836732 
In order to establish the genotype at rs4836732, the DNA sequence flanking ~200 bp 
either side of the SNP was obtained using the UCSC Genome Browser. Forward and 
reverse primers were then designed to the SNP using the Primer3 Input online 
software (http://primer3.wi.mit.edu/; Appendix A: Table A.1) [123]. A BLAST-like 
alignment tool (BLAT) search of the primers was performed, using the UCSC 
Genome Browser BLAT software [124], to ensure the primers were specific to the 
SNP. The NEBcutter online software (http://tools.neb.com/NEBcutter2/) was used to 
identify that the restriction enzyme RsaI cut at the SNP site [125].  
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2.5.2 Restriction fragment length polymorphism (RFLP) assay 
DNA amplification was performed using AmpliTaq Gold® Taq DNA Polymerase, as 
described in Chapter 2.4.1, using 2 mM MgCl2 and an annealing temperature of 
55oC. 7.50 μl of amplified DNA was then digested in a final volume of 15 μl 
containing: 5 U RsaI restriction enzyme (New England BioLabs, UK) and 1 x reaction 
buffer (New England BioLabs, UK) as recommended by the manufacturer. The 
reaction was incubated at 37oC overnight and the resulting DNA fragments were the 
electrophoresed through a 3% (w/v) agarose TBE gel containing 20 μg ethidium 
bromide per 100 ml total volume. Restriction fragments were visualised under UV 
light in a G:BOX gel visualisation system (Syngene, UK). In the presence of a T 
allele, a 202 bp band would be present, while 36 bp and 166 bp bands would be 
produced in the presence of the C allele.  
 
2.6 SNP genotyping by pyrosequencing 
Pyrosequencing primers (Sigma-Aldrich, UK) were designed using PyroMark Assay 
Design Software 2.0 (QIAGEN, Crawley, UK) and PCR cycling conditions were 
optimised as described in Chapter 2.4.1 (Appendix A: Table A.1). gDNA was then 
PCR amplified and 10 μl of the amplified product was added to the wells of a 0.20 ml 
24-well PCR plate (STARLAB, Milton Keynes, UK). The product was agitated for 10 
min using a 96-well plate shaker with a mix of: 40 μl PyroMark binding buffer 
(QIAGEN, Crawley, UK), 2 μl streptavidin-coated sepharose beads (GE Healthcare, 
UK) and 28 μl deionised water. Using a PyroMark Q24 Vacuum Workstation 
(QIAGEN, Crawley, UK), the sepharose beads were captured on the filter probes, 
before 5 sec aspirations of 70% ethanol, 0.20 M sodium hydroxide and PyroMark 
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wash buffer (QIAGEN, Crawley, UK). The beads were released into a PyroMark Q24 
24-well plate (QIAGEN, Crawley, UK) containing 24.75 μl PyroMark annealing buffer 
(QIAGEN, Crawley, UK) and 0.75 μl sequencing primer (Sigma-Aldrich, UK) per well. 
The plate was heated for 2 min at 80oC to denature the gDNA, followed by primer 
annealing for 5 min at room temperature. PyroMark Gold Q24 Reagents (QIAGEN, 
Crawley, UK) were loaded into a PyroMark Cassette (QIAGEN, Crawley, UK) and 
pyrosequencing was performed in a PyroMark Q24 Pyrosequencing machine 
(QIAGEN, Crawley, UK). Prior to genotype analysis of patient samples, the ability of 
the assays to differentiate between allelic quantities was validated in duplicate by 
comparing known synthetic allelic ratios with the ratios detected by the 
Pyrosequencing machine (Chapter 3: Figure 3.15).  
 
2.7 Luciferase reporter assays 
2.7.1 Cloning of DNA into pGL3-Promoter Luciferase Reporter Vectors 
Both the minor and major alleles of rs4836732, rs4837613 and rs13283416 
were PCR amplified in two 20 µl reactions, using primers introducing XhoI and 
MluI restriction enzyme sites (for primer sequences and conditions see 
Appendix A: Table A.2). Each reaction contained 1x PCR Buffer II (Applied 
Biosystems, Life Technologies, USA), 0.5 μM forward primer (Sigma-Aldrich, 
UK), 0.5 μM reverse primer (Sigma-Aldrich, UK), 200μM dNTPs (Bioline, UK), 2 
mM MgCl2, 0.4 U AmpliTaq Gold® Taq Polymerase (Applied Biosystems, Life 
Technologies, USA) and 50ng DNA. The products were purified using the 
QIAGEN Gel Extraction Kit, according to manufacturer protocol (QIAGEN, 
Crawley, UK). A double digest was performed with 1µg of the purified PCR 
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product and pGL3-Promoter Vector using 10U of Mlu1 and XhoI restriction 
enzymes (New England BioLabs, UK),  1 x NEB Buffer 3 (50 mM Tris-HCl, 10 
mM MgCl2, 100 mM NaCl and 1 mM DTT, pH 7.9) in a 30µl reaction. The digest 
was performed overnight at 37°C. Following digestion, the PCR product and 
pGL3-Promoter Vector were electrophoresed through a 1% TAE EtBr gel and 
extracted under UV light. Subsequent purification was performed using the 
QIAquick Gel Extraction Kit (QIAGEN, Crawley, UK) following manufacturer 
instructions. The products were eluted in 50 μl of DEPC water.   
 
The products were ligated into the digested pGL3-Promoter Vector using a 5:1 
fragment to plasmid ratio, along with 400 U T4 ligase (New England BioLabs, 
UK) and 10x T4 buffer (New England BioLabs, UK) and incubated overnight at 
16oC. Plasmid DNA was then transformed into One Shot® Mach1™ T1 Phage-
Resistant Chemically Competent E. coli cells (Invitrogen, Life Technologies, 
UK), according to manufacturer guidelines. Transformed cells were plated onto 
LB agar plates containing 100 µg/ml ampicillin (Sigma-Aldrich, UK) and 
incubated overnight at 37°C. Between 8 and 10 colonies were selected and 
individually transferred into 1ml LB media and 1/1000 ampicillin. Successful 
insertion of the PCR fragment into the plasmid was confirmed by colony PCR 
using previously designed primers. Products were run on a 1% agarose TBE 
EtBr gel and  3 µl of each positive clone was then placed in 3 ml LB broth 
(Sigma-Aldrich, UK) and 100 μg/ml ampicillin (Sigma-Aldrich, UK), then grown 
overnight with shaking at 37oC and 180 rpm.  
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Glycerol stocks were prepared by adding a 1:1 ratio of 200 µl of bacterial 
culture to 200µl of glycerol (Sigma-Aldrich, UK) and stored at -80oC.   The 
identity of the DNA insert was confirmed using sequencing performed by 
Source BioScience, UK to confirm that the sequences were correct, and only 
differed at the SNP of interest. 
 
2.7.2 Purification of plasmid DNA by miniprep   
For transfection, plasmid cultures were purified using the Promega PureYieldTM 
Plasmid Miniprep System (Promega, UK).  5µl of the glycerol bacteria stock 
was added to 3 ml of LB broth containing ampicillin (100 µg/ml) and incubated 
at 37°C with shaking for 2-3 hours. 1.5 ml of the overnight culture was 
centrifuged in an Eppendorf tube at 13,000 rpm for 30 sec and the supernatant 
discarded. This was repeated with the remaining 1.5 ml of culture. The cell 
pellet was resuspended in 600 µl DEPC water and 100 µl Cell Lysis Buffer was 
added, then mixed by inverting the tube 6 times for a maximum of 2 min. 
Following addition of 350 µl of cold Neutralisation Solution, the tube was 
inverted again to mix thoroughly, with subsequent centrifugation for 3 min at 
13,000 rpm. The supernatant was transferred to a PureYieldTM Minicolumn and 
centrifuged at 13,000 rpm for 15 sec. The flow through was then discarded and 
200 µl Endotoxin Removal Wash added. The mix was centrifuged at 13,000 
rpm for 15 sec and the flow through discarded. 400 µl Column Wash Solution 
was added before centrifuging at 13,000 rpm for 30 sec. The Minicolumn was 
then transferred to a new Eppendorf tube and 30 µl of DEPC water added. 
Following incubation at room temperature for 1 min, plasmid DNA was eluted 
by centrifuging at 13,000 rpm for 15 sec. DNA was then diluted to achieve a 
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concentration of 50 ng/µl, using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, USA), and stored at -20oC until required. 
 
2.7.3. Cell line culture 
Three cell lines were used for luciferase reporter analyses, SW872 (human 
liposarcoma line from a 36 year old Caucasian male), SW1353 
(chondrosarcoma line from a 72 year old Caucasian female) and U2OS 
(osteosarcoma line from a 15 year old Caucasian female). The cells were 
cultured in the appropriate culture medium, as follows, in Corning vented 
T75cm2 flasks (Sigma-Aldrich, UK) at 37°C in a 5% (v/v) CO2 atmosphere to 
80% confluency.   
 
SW872 medium- Dulbecco’s modified eagle’s medium (DMEM): Hams F12 
Glutamax medium in a 3:1 ratio (GIBCO, Life Technologies, UK) containing 5%  
(v/v) fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Sigma-Aldrich, UK).  
SW1353 medium- DMEM: Hams F12 medium in a 1:1 ratio (GIBCO, Life 
Technologies, UK) containing 10% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM of L-glutamine (Sigma-Aldrich, UK). 
U2OS medium- DMEM containing 10% v/v FBS, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma-Aldrich, UK).  
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2.7.4 Transfection of cell lines  
SW1353 and U2OS cells were seeded at a density of 6000 cells per well, while 
SW872 cells were seeded at 10,000 cells per well, in a Corning Costar 96-well cell 
culture plate (Sigma-Aldrich, UK) and cultured for 24 hours prior to transfection at 
37oC with 5% CO2.  Cells in each well were transfected with a 100 µl master mix 
containing 50 ng luciferase vector DNA, 1.5 ng Renilla Luciferase Reporter Vector 
(Promega, UK) and 0.3 µl per well of FuGene HD Transfection Reagent (Promega, 
UK) in the appropriate medium. Eight technical and six biological repeats were 
performed per SNP allele. Cells were then incubated in a 37oC 5% CO2 incubator 
overnight.   
 
2.7.5 Luciferase assay readings  
After 24 hours, transfected cells were washed in 1 x phosphate-buffered saline 
(PBS) and lysed in 30 μl 1 x passive lysis buffer (Promega, UK) for 20 min with 
constant rocking. 20 µl of the lysate was used to quantify the luciferase and Renilla 
activity using the Dual Luciferase Assay system (Promega, UK) with the MicroLumat 
Plus LB96V Luminometer (Berthold Technologies UK, Harpenden, UK).  Luciferase 
values were normalised to the appropriate Renilla luciferase values and 
subsequently normalised to the mean of the corresponding empty pGL3 vector 
control. The Mann-Whitney U test was used to assess statistical significance.  
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2.8 Electrophoretic mobility shift assay (EMSA)  
2.8.1 Prediction of protein binding sites 
A publicly available online search tool was used to predict protein binding to 
rs4836732: PROMO version 3.0 (http://alggen.lsi.upc.es) [126, 127]. The UCSC 
Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) was also used as a 
predictor of protein binding, based on experimental cell line chromatin 
immunoprecipitation (ChIP) assays with sequencing (ChIP-Seq) data from ENCODE 
[124, 128]. 
 
2.8.2 Nuclear protein extraction method 
Two buffers were used for the preparation of nuclear extract for EMSA experiments:  
 
Hypotonic Buffer -10 mM HEPES, pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 10 
mM NaF, 1 mM Na3VO4, 0.1% Tergitol (v/v), 1x complete protease inhibitor cocktail 
tablet per 50 ml solution (Roche, UK).  
High Salt Buffer -20 mM HEPES, pH 7.9, 420 mM NaCl, 20% glycerol (v/v), 1 mM 
DTT, 10 mM NaF, 1 mM Na3VO4, 1x complete protease inhibitor cocktail tablet per 
50 ml of buffer (Roche, UK).  
 
Cells were seeded onto Corning 500 cm2 cell culture dishes (Sigma-Aldrich, UK) 
until 70-80% confluent. Culture medium was then removed and cells were washed in 
ice cold PBS. Cells were then removed from the surface into 5 ml of fresh PBS and 
centrifuged for 30 sec at 10,000g at 4°C. The cell pellet was resuspended in 1 ml of 
hypotonic buffer and incubated on ice for 15 min. Cells were centrifuged as before 
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and the pellet was resuspended in ice cold hypotonic buffer, supplemented with 0.25 
M sucrose to fractionate the nuclei. Cells were centrifuged and the pellet was 
resuspended in 1 ml high salt buffer. This was incubated for 30 min on ice, then cells 
were centrifuged at 10,000g for 2 min at 4°C. The supernatant containing nuclear 
protein was immediately stored at -80°C.      
  
2.8.3 Preparation of probes             
Fluorescently labelled (5′DY682) C and T oligonucleotides (Eurofins MWG Operon, 
Ebersberg, Germany) spanning 15 bp upstream and 15 bp downstream of each 
allele were resuspended in DEPC H20 (Invitrogen, Life Technologies, UK) at a 
concentration of 100 pmol/μl (For sequences see Appendix A: Table A.3). The 
complementary forward and reverse oligonucleotides were then heated for 5 min at 
95oC with annealing buffer (100 mM Tris-HCl, 500 mM NaCl, 10 mM EDTA), before 
cooling to room temperature and storage at -80oC. The annealed probes were 
subsequently diluted in DEPC to achieve a working stock of 100 fmol, which was 
stored at -20oC.  
 
2.8.4 EMSA reagents 
- Nuclear proteins 
- Fluorescently labelled oligonucleotides (Eurofins MWG Operon, Ebersberg, 
Germany)  
- EMSA Annealing Buffer: 100 mM Tris HCl, 500 mM NaCl, 10 mM EDTA.  
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- 5x TBE buffer: 445 mM Tris, 445 mM Boric Acid, 10 mM EDTA, pH8.  
- 5% (weight/volume (w/v)) acrylamide gel (prepared with TEMED and ammonium 
persulfate (APS)). 
- Buffers and loading dye: Odyssey Infrared EMSA kit (LiCor Biosciences, 
Cambridge, UK).  
- rs4836732 Optimal Binding Reaction: 1x Binding Buffer, 25 mM DTT, 2.5% Tween-
20, 1 μg/μl Poly (dI:dC), 100 mM MgCl2, 200 fmol annealed oligonucleotide and 5 μg 
nuclear extract.  
- 5x (1 pmol), 10x (2 pmol), 25x (5 pmol), 50x (10 pmol) unlabelled competitor 
oligonucleotide (For competitor sequences see Appendix A: Table A.3).  
- 2 μg candidate antibody (Appendix C: Table C.1).  
 
 
2.8.5 EMSA gel preparation and electrophoresis 
The native 5% (v/v) acrylamide gel (1 x TBE, 1:1,000 TMED and 0.07% [v/v] 
ammonium persulphate) was prepared and set at 4°C overnight. The gel was then 
run for 30 min in 0.5x TBE buffer at 100 V 4oC prior to loading of samples in order to 
remove traces of APS and equilibrate ions in the running buffer. The 20 µl binding 
reactions were prepared using the above Odyssey Infrared EMSA kit components 
(LiCor Biosciences, Cambridge, UK) and incubated in the dark at room temperature 
for 20 min. Each 20 μl reaction contained 200 fmol of labelled probe. For competition 
EMSAs, unlabelled competitors were added at 5 x (1 pmol), 10 x (2 pmol), 25 x (5 
pmol), and 50 x (10 pmol) that of the labelled probe concentration. For supershift 
EMSAs, 3 μg or 6 μg of antibody was added to the reaction (Appendix C: Table C.1). 
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Appropriate control reactions were used containing either no competitor or a 
species-matched IgG antibody for competition EMSAs and supershift EMSAs 
respectively. Orange G loading dye was then added (1x final concentration) and the 
samples were loaded onto the gel. Electrophoresis was performed at 100V at 4°C in 
the dark for approximately 4 hours/ until the dye front reached the end of the gel. The 
gel was visualised using the LiCor Odyssey Infrared Imager (LiCor Biosciences, 
Cambridge, UK). 
 
2.9 Complementary DNA (cDNA) synthesis  
2.9.1 Reverse transcriptase polymerase chain reaction (RT-PCR) method 
In order to remove contaminating DNA, 1 μg of total RNA was incubated with 1 U 
TURBOTM DNase (Invitrogen, Life Technologies, UK) and 1 x TURBOTM DNase 
Buffer (Invitrogen, Life Technologies, USA) at 37oC for 30 min. The DNase was then 
inactivated by addition of 100 mM EDTA and incubation at 75oC for 10 min. The total 
RNA was then incubated at 65oC for 5 min in a volume of 8 μl containing: 1 μg 
random primers (Invitrogen, Life Technologies, USA), 10 μM dNTP mix and the 
required volume of diethylpyrocarbonate (DEPC)-treated water (Invitrogen, Life 
Technologies, USA). The reaction was then incubated for 1 min at 25oC with 1 x First 
Strand Buffer (Invitrogen, Life Technologies, USA), 5 mM MgCl2 (Applied 
Biosystems, Life Technologies, USA), 10 mM DTT (Invitrogen, Life Technologies, 
USA) and 40 U RNaseOUTTM (Invitrogen, Life Technologies, USA). Reverse 
transcription of the total RNA into complementary DNA (cDNA) was then performed 
following the addition of 200 U SuperScriptTM II Reverse Transcriptase (Invitrogen, 
Life Technologies, USA). The reaction was incubated for 10 min at 25oC, 50 min at 
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42oC and 10 min at 70oC. Any remaining complementary RNA was then degraded by 
incubation at 37oC for 20 min, following the addition of 2 U E. coli RNase H 
(Invitrogen, Life Technologies, USA). cDNA was stored at -20oC. 
 
2.9.2 Polymerase chain reaction (PCR) to assess complementary DNA (cDNA) 
integrity 
After synthesis by RT-PCR, cDNA integrity was assessed by PCR amplification with 
HBP1 primers, which span an intron:exon boundary to enable cDNA and residual 
gDNA contamination to be distinguished  (for primer sequences see Appendix A: 
Table A.4). In a total volume of 15 μl, 0.50 μl of cDNA added to a 14.50 μl master 
mix containing 2 mM MgCl2 and PCR amplified using an annealing temperature of 
60oC as described in Chapter 2.4.1. Only cDNA containing no contaminating gDNA 
was carried forward for downstream applications. 
 
2.10 Allelic expression imbalance analysis by pyrosequencing 
2.10.1 Online database search for transcript single nucleotide polymorphisms 
(SNPs) 
Transcript SNPs in each gene of interest were identified using the online software 
from the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) [124]. 
The Broad Institute (http://www.broadinstitute.org/mpg/snap/) online software was 
used to conduct pairwise searches to assess the LD between the transcript SNPs 
and rs4836732 [129]. 
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2.10.2 Pyrosequencing method 
PyroMark Assay Design Software 2.0 (QIAGEN, Crawley, UK) was used to design 
pyrosequencing primers for transcript SNPs within the genes of interest (for primer 
sequences see Appendix A: Table A.1).  PCR conditions for the primers (Sigma-
Aldrich, UK) were optimised as described in Chapter 2.4.1. The ability of the assays 
to differentiate between allelic quantities was validated, in duplicate, prior to use by 
comparing known synthetic allelic ratios with the ratios detected by the 
Pyrosequencing machine (Chapter 3: Figure 3.15). gDNA and cDNA from cartilage, 
fat pad and synovium samples were PCR amplified and the products were then 
taken forward for pyrosequencing, as described in Chapter 2.6. Each reaction was 
performed in triplicate for DNA and cDNA and significance was assessed using a 
Mann-Whitney U test. 
 
2.11 Cell culture for PAPPA siRNA knock down analyses 
2.11.1 SW1353 cell culture 
SW1353 (chondrosarcoma line from a 72 year old Caucasian female) cells 
were cultured in DMEM: Hams F12 medium in a 1:1 ratio (GIBCO, Life 
Technologies, UK) containing 10% (v/v) FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM of L-glutamine (Sigma-Aldrich, UK). Cells were cultured 
in Corning vented T75cm2 flasks (Sigma-Aldrich, UK) at 37°C in a 5% (v/v) CO2 
atmosphere to 80% confluency. 
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2.11.2 Human mesenchymal stem cell (hMSC) culture 
hMSCs from OA patients were isolated from trabecular bone under sterile conditions 
in a laminar flow hood. Extracted bone was passed through a 100µm Cell Strainer 
(BD Biosciences, Oxford, UK) with PBS containing 100U/ml penicillin and 100µg/ml 
streptomycin (Sigma-Aldrich, UK). hMSCs were isolated via Ficoll density 
centrifugation (GE Healthcare, UK) and seeded with hMSC medium containing: 1g/L 
glucose DMEM (GIBCO, Life Technologies, UK), supplemented with 10% (v/v) FBS, 
100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM of L-glutamine (Sigma-Aldrich, 
UK). Cells were cultured in Corning vented T75cm2 flasks (Sigma-Aldrich, UK) at 
37°C in a 5% (v/v) CO2 atmosphere to 80% confluency. Cell purity was assessed by 
flow cytometric analysis (FACs) to confirm a single phenotypic population positive for 
the defined hMSC cell surface markers CD29, CD44, CD71 and CD106. 
 
hMSCs from individuals without OA (Lonza, UK) were seeded at a density of 17,500 
cells/cm2  and cultured at 37oC for 48 hours in Mesenchymal Stem Cell Growth 
Medium (Lonza, UK) supplemented with 5 ng/ml FGF-2 (R&D Systems, UK). The 
medium was then replaced with 1 g/L glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (GIBCO, Life Technologies, UK), supplemented with 20% (volume/volume 
(v/v)) fetal bovine serum (FBS), 8 ng/µl bovine- fibroblast growth factor (FGF) 
(Millipore, UK), 2 mM of L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin 
(Sigma-Aldrich, UK). Cells were incubated in standard cell culture conditions: a 
sterile, 37°C, humidified, 5% CO2/95% air environment, with cell medium refreshed 
every 72 hours. 
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2.11.3 RNA mediated interference (RNAi) of PAPPA in human mesenchymal 
stem cell (hMSC) and SW1353 cells 
On-TARGETplus SMART pool human PAPPA siRNA (Dharmacon, GE Healthcare, 
UK, cat no. L-005130-00-0005) was resuspended in 250 μl of 1x siRNA Buffer 
(Dharmacon, GE Healthcare, UK) to make 20 μM siRNA. On-TARGETplus Non-
targeting (NT) pool siRNA (Dharmacon, GE Healthcare, UK, cat no. D-001810-10-20) 
at 20µM was used as a control (for sequences see Appendix D: Table D.1). 
 
hMSCs and SW1353 were seeded at a density of 1.2 million cells into three 10 cm 
tissue culture dishes per cell line (for untransfected, NT siRNA and PAPPA siRNA). 
The cells were cultured at 37 °C for 24 hours in DMEM media to reach 80% 
confluency. 35 μl siRNA and 665 μl serum free DMEM media (SFM) were combined 
and incubated for 5 min at room temperature as were 14 μl Dharmafect transfection 
reagent 1 (Dharmacon, GE Healthcare, UK) and 686 μl SFM. The two reaction mixes 
were then combined (total volume 1.4 ml) and incubated for a further 20 min at room 
temperature. Cells were transfected by removing the appropriate amount of media 
before adding the transfection mix, followed by incubation at 37 °C for 48 hours. 
Subsequently, cells were lifted off the surface using trypsin and counted. hMSCs 
were seeded into 12 well plates for osteogenesis (100,000 cells/well in 1 ml 
osteogenic medium) or into 96 well v-bottom plates for chondrogenesis (30,000 
cells/well in 200 µl chondrogenic medium) for differentiation according to the 
previously described protocols. Untransfected cells and cells transfected with NT 
siRNA were used as controls and three repeats were performed per condition in 
each cell line, with an additional well seeded for all three treatment groups on day 
three for immunoblot analysis (Chapter 2.12).  
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2.11.4 Human mesenchymal stem cell (hMSC) differentiation into osteoblasts 
hMSCs were seeded in a 12 well culture plate at a density of 1.3 x 104/cm2 in 
standard hMSC medium and incubated for three hours to adhere, before adding 1 ml 
fresh osteogenic media (1 g/L DMEM, 2 mM of L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 10% FBS, 0.1 µM dexamethasone, 10 mM β-glycerophosphate, 
50 µM ascorbic acid). Media was refreshed every 72 hours, with ascorbic acid added 
freshly to the medium each time. Cells were harvested on days 0, 3 and 10 of 
differentiation. On day 3, differentiated cells were stained for alkaline phosphatase to 
confirm successful osteogenic differentiation. Wells were rinsed in ice-cold PBS 
followed by 70% ethanol before fixing in 4% PFA for 10 min. Alkaline phosphatase 
activity was detected following incubation in a 0.1% Fast blue RR salt/ napthol 
phosphate solution (Sigma-Aldrich, UK) at room temperature for 45 min. RNA was 
extracted from cells and used to synthesise cDNA in confirm differentiation had 
occurred by real-time gene expression analysis of ALPL, RUNX2 and COL1A1 
(Chapter 2.13). 
 
2.11.5 Human mesenchymal stem cell (hMSC) differentiation into chondrocytes 
Following monolayer culture to 80% confluency, trypsinised hMSCs were seeded at 
a density of 0.3x105/well into a UV-irradiated V bottomed 96 well plate (Greiner Bio-
One Ltd, Stonehouse, UK) with 150 µl of chondrogenic differentiation media (1g/L 
DMEM, 2 mM  L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1% ITSL 
premix, 40 μg/mL L-proline and 100 nM dexamethasone). The plate was then 
centrifuged at 500g for 5 min and incubated at 37°C in a humidified, 5% CO2/ 95% 
air environment. Media was refreshed every 3 days and cells were harvested for 
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analysis on days 0, 3 and 10 of chondrogenesis. Successful differentiation was 
confirmed by real-time gene expression analysis of ACAN and SOX9 (Chapter 2.13). 
 
2.12 Immunoblotting 
2.12.1 Protein extraction and quantification 
Total protein was extracted from cells on day 3 of differentiation for all conditions 
using a spin column extraction kit according to the manufacturer’s instructions 
(Nucleospin RNA/protein, Macherey-Nagel, supplied by Thermo Fisher Scientific, 
UK). The extracted total protein was snap-frozen on dry ice, before storage at -80oC. 
Protein was quantified in a microplate using the MACHEREY-NAGEL Protein 
Quantification Assay, according to the manufacturer’s microplate assay procedure 
protocol. Absorbances were read at 595 nm using a Tecan Sunrise Microplate 
Absorbance Reader (Tecan, Reading, UK). 
 
2.12.2 Immunoblotting method 
To confirm successful PAPPA depletion, equal amounts of extracted protein were 
resolved on a NUPAGE 4-12% Bis-Tris GEL (Thermo Fisher Scientific, UK) before 
being transferred to a Immobilon-P polyvinylidene fluoride (PVDF) membrane (Merck 
Millipore, UK) by electroblotting in a Scie-Plas V20-SDB 20x20 semi-dry blotter 
(Scie-Plas, Cambridge, UK). The membrane was then blocked for non-specific 
protein binding by incubation at room temperature for 30 min in 1x PBS containing 
5% (v/v) Marvel milk and 0.02% (v/v) Tween-20. The membrane was washed for 5 
min in 1 x PBS containing 0.02% (v/v) Tween-20, then incubated at 4°C overnight 
with the PAPPA (B-7) mouse monoclonal primary antibody (Santa Cruz 
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Biotechnology, USA; Catalogue number sc-365226), raised against amino acids 
666-840, diluted 1:2,000 in 1 x PBS containing 5% (w/v) Marvel milk and 0.02% (v/v) 
Tween-20. The membrane was washed as previously described, followed by 
incubation with the polyclonal horse anti-mouse horseradish peroxidise (HRP) 
conjugated secondary antibody (Cell Signalling Technologies inc., MA, USA; 
Catalogue number 7076S), diluted 1:2,000, for 1 hour at room temperature. A rabbit 
monoclonal GAPDH primary antibody (Cell Signalling Technologies inc.; Catologue 
number 5174S) was used as a loading control (1:10,000) with subsequent incubation 
using goat anti-rabbit horseradish peroxidise (HRP) conjugated secondary antibody 
(Cell Signalling Technologies inc., MA, USA; Catalogue number 7074S), diluted 
1:2,000. Detection was carried out using X-ray film (Kodak Film, Sigma-Aldrich, UK) 
with Immobilon Western Chemiluminescent HRP Substrate (Millipore, UK) in a 
G:BOX gel visualisation system (Syngene, UK). 
 
2.13 Quantitative real-time polymerase chain reaction (qPCR) following PAPPA 
siRNA knock down 
2.13.1 cDNA synthesis  
For the siRNA experiments, cells were lysed in 30 µl Cells-to-cDNA II cell lysis buffer 
(Ambion, Life Technologies, UK) and transferred to a 96 well plate before being 
heated to 75oC for 15 min. 10 ng random primers (Invitrogen, Life Technologies, UK) 
and 10 mM dNTP mix (Invitrogen, Life Technologies, UK) were added to 8 μl of the 
cell lysate and incubated at 70oC for 5 min. To the reaction, 1x reaction buffer (50 
mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2; Invitrogen), 100 U MMLV reverse 
transcriptase (Invitrogen, Life Technologies, UK) and 10 mM DTT (Invitrogen, Life 
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Technologies, UK) were added, along with DEPC water to create a final reaction 
volume of 20 μl. The samples were incubated at 37 °C for 50 min and 75 °C for 15 
min. Then 30 μl of water was added and samples were stored at -20oC. 
 
2.13.2 Quantitative Real-Time Polymerase Chain Reaction (qPCR) using 
PrimeTime Quantitative Real-Time-PCR (qPCR) Assays 
cDNA was diluted 1:20 and 2.5µl was then used in 10 µl total volume reactions with 
TaqMan® Fast Universal PCR Master Mix (Applied Biosystems, Life Technologies, 
USA) and PrimeTime qPCR Assays (IDT, Iowa, USA; For primer and probe 
sequences, see Appendix A: Table A.4). The qPCR reaction was carried out using 
the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Life 
Technologies, USA) with fast cycling conditions (95°C for 20 sec followed by 40 
cycles of 95°C for 1 sec and 60°C for 20 sec) in MicroAmp® Fast Optical 96-well 
Reaction Plates (Applied Biosystems, Life Technologies, USA). Gene expression 
was normalised to the housekeeping genes 18S, HPRT1 and GAPDH using the 
delta delta ct method (2-(ct test gene)-(ct mean of housekeepers)). Each sample was 
analysed in triplicate. 
 
2.14 CpG methylation analysis 
For methylation analysis, 1 µg E.Z.N.A – extracted cartilage genomic DNA (Omega 
Bio-Tek, Georgia, USA) was bisulphite converted using the EZ DNA Methylation™ 
Kit (Zymo Research, California, USA) according to manufacturer’s instructions, and 
eluted in a volume of 20 µL. Bisulphite DNA was stored at -20oC. 
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2.14.1 Polymerase chain reaction (PCR) of bisulphite converted DNA 
PyroMark Assay Design Software 2.0 (QIAGEN, Crawley, UK) was used to design 
pyrosequencing primers to the selected CpG sites (for primer sequences see 
Appendix A: Table A.5).  PCR conditions for the primers (Sigma-Aldrich, UK) were 
optimised as described in Chapter 2.4.2. PCR was performed on 50 ng bisulphite 
converted DNA using 1 x Titanium® Taq DNA Polymerase (Chapter 2.4.2).   
  
2.14.2 CpG methylation analysis by pyrosequencing method 
DNA methylation analysis was performed on a PyroMark Q24 workstation (QIAGEN, 
Crawley, UK) and analysed with the PyroMark CpG software (QIAGEN, Crawley, 
UK), as previously described (Chapter 2.6). Prior to methylation analysis of patient 
samples, the ability of the assays to detect methylation levels was validated by 
comparing expected methylation values, as determined by the high-density CpG 
methylation array, with the methylation detected by the Pyrosequencing machine. 
Each sample was analysed in duplicate and the mean methylation value calculated.   
 
2.14.3 Batch correction  
The methylation values derived from the β values provided by the high-density CpG 
methylation array at CpG sites cg12245706 and cg21944234 were batch corrected, 
using a regression of the difference in observed and expected values as a function of 
beta values. The correction factor (as determined below) was then applied to the 
methylation value derived from the original β value: 
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cg12245706 correction factor = (-29.83 x β value) – 1.77 
cg21944234 correction factor = (66.83 x β value) – 19.20 
 
2.14.4 Statistics 
Statistical analysis of CpG methylation were performed with the aid of JMP Pro 
Version 11.2 Statistical Data Visualization Software (JMP, Marlow, 
Buckinghamshire).   
 
2.15 Isolation of patient serum 
Prior to joint arthroplasty surgery, approximately 3 ml of peripheral blood was 
collected in a BD Gold-top serum separating Vacutainer ®, containing clotting 
activator (Becton, Dickinson and Company, Franklin Lakes, New Jersey) from 
consenting patients. This was spun at room temperature at 1800g for 12 min, and 
the clear serum was aliquoted into 1.2 ml Eppendorf tubes. Serum was frozen at -
80°C until subsequent use. 
 
2.16 Electrochemiluminescent Meso Scale Discovery (MSD) assays 
2.16.1 Method 
For the electrochemiluminescence studies of human serum, the V-PLEX Human 
leptin kit, V-PLEX custom Human Cytokine, V-PLEX Human Proinflammatory Panel 
1 and V-PLEX Human CRP kit (catalogue numbers K151BYC-1, K151A0H-1, 
K15049D-1 and K151STD-1 respectively)  were used according to the 
manufacturer’s instructions (Mesco Scale Discovery (MSD), Gaithersburg, USA). 
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MSD plates were analysed on the MSD Analysis-SECTOR imager (MSD, 
Gaithersburg, USA). Standards were measured in duplicate and patient samples in 
singlicate. 
 
2.16.2 Statistics 
Statistical analyses were performed using Graph-Pad Prism 5.0 (GraphPad 
Software, La Jolla, USA). Analysis of two groups of data was performed using the 
Wilcoxon–Mann–Whitney test. *p<0.05 **p<0.01 ***p<0.001.  For comparison of 
multiple groups, Kruskal-Wallis one-way ANOVA was used to calculate statistical 
significance. *p<0.05 **p<0.01 ***p<0.001. Where appropriate, Bonferroni multiple 
comparison correction was applied. 
 
2.17 Quantitative real-time polymerase chain reaction (qPCR) of inflammatory 
genes in OA cartilage 
2.17.1 Quantitative Real-Time Polymerase Chain Reaction (qPCR) method 
using SYBR® Green technology 
Cartilage RNA was extracted as previously described (Chapter 2.3.2) and reverse 
transcriptase polymerase chain reaction (RT-PCR) performed to syntheses cDNA 
(Chapter 2.9). Subsequently, inflammatory gene expression was quantified in a 10µl 
total volume containing: KiCqStart® SYBR® Green qPCR ReadyMix™ with ROX 
(Sigma-Aldrich, UK), 0.5 μM of both the forward and reverse primers (Sigma-Aldrich, 
UK) and 2.5µl of 1:20 diluted cDNA.  For primer sequences see Appendix A: Table 
A.6. Each reaction was performed in triplicate using the ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems, Life Technologies, USA). The 
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thermal cycling conditions were: 95oC for 10 min, 40 cycles of 95oC for 3 sec and 
60oC for 35 seconds, followed by a dissociation stage of 95oC for 15 sec, 60oC for 15 
sec and 95oC for 15 sec. Expression of target genes was measured relative to the 
housekeeping gene GAPDH, and relative expression was calculated using the 2-ΔΔCt 
method, as described previously (Chapter 2.13.2).   
 
2.17.2 Statistics 
Statistical analyses of inflammatory gene expression were performed using Graph-
Pad Prism 5.0 (GraphPad Software, La Jolla, USA) using the Wilcoxon–Mann–
Whitney test or the Student’s t test. *p<0.05 **p<0.01 ***p<0.001.  
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Chapter 3: Functional analysis of the rs4836732 signal 
3.1 Introduction  
One of the five genome-wide significant loci associated with OA in the arcOGEN 
GWAS was marked by the C allele of the rs4836732 SNP (p = 6.11 x 10-10), on 
chromosome 9q22.32 [92]. The SNP was associated with female hip OA in a 
European patient cohort, with an odds ratio (OR) of 1.20. 
 
In order to assess this signal and identify the SNP most likely to cause the OA risk 
association, it was necessary to identify SNPs in high LD (defined as r2 ≥ 0.7) with 
rs4836732.  This chapter then sought to functionally analyse candidate SNPs by 
investigating their capacity to modulate enhancer or repressor activity in relevant cell 
lines and by interrogating differential trans-acting factor binding to the SNP alleles.   
 
There are no non-synonymous polymorphisms which associate with rs4836732 and 
therefore, I hypothesise that OA risk is likely to be modulated by regulation of gene 
transcription.  Identification of candidate genes in the association region that may be 
regulated by the potential cis-acting eQTL was consequently required to functionally 
dissect the association signal. Gene expression of candidate genes was previously 
quantified by Dr Emma Raine (Prof. Loughlin’s group, Institute of Cellular Medicine, 
Newcastle University), which confirmed their expression in OA cartilage. This 
chapter will characterise the rs4836732 OA association signal by investigating the 
expression of candidate genes according to rs4836732 genotype.   
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3.2 Aims  
The overall aim of this chapter was to characterise the female hip OA association 
signal marked by rs4836732 and its functionality. In order to achieve this, I sought to: 
 
• Perform database searches to characterise the rs4836732 association region. 
• Clone DNA fragments of the two rs4836732 alleles and of other 
polymorphisms in high LD with this SNP into pGL3-promoter vectors. 
• Identify any allele-specific differences in SNP activity in chondrosarcoma, 
liposarcoma and osteosarcoma cell lines, assessed by luciferase activity. 
• Use online databases to identify proteins predicted to differentially bind to the 
two rs4836732 alleles. 
• Assess differential nuclear protein binding to the rs4836732 C/T alleles using 
EMSA assays in chondrosarcoma, liposarcoma and osteosarcoma cell lines. 
• Identify candidate genes in the LD region which may be regulated by the 
potential cis-eQTL marked by rs4836732.  
• Characterise the expression profiles of ASTN2, PAPPA and TRIM32 in OA 
hip and knee cartilage, using data previously generated by Dr Emma Raine. 
• Investigate whether rs4836732 marks a cis-eQTL by analysing allelic 
expression imbalance of ASTN2, PAPPA and TRIM32 transcription in 
cartilage, fat pad and synovium samples.  
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3.3 Results  
3.3.1 Identification and initial database searches of candidate SNPs  
To identify the SNP within the rs4836732 locus causing the susceptibility signal, the 
SNAP online search tool was used to identify SNPs in linkage disequilibrium (LD; r2 ≥ 
0.7) with rs4836732 [129]. The search only identified two other SNPs in high LD with 
rs4836732, both of which were in intron 17 of ASTN2 and so, may influence OA risk 
by acting as eQTLs (Table 3.1; Figure 3.1).  
 
SNP Effect 
allele 
Genomic 
location 
r2 relative to 
sentinel SNP 
D' relative to 
sentinel SNP 
rs4836732  C ASTN2 intron 18  Sentinel  Sentinel  
rs4837613  C  ASTN2 intron 17  0.807  0.929  
rs13283416  G  ASTN2 intron 17  0.712  1.0  
 
Table 3.1  
All SNPs in LD r2 ≥ 0.7 with rs4836732. The D′ considers the recombination rate 
only, with complete LD (D′ = 1.00) denoting no recombination between the two loci. 
r2 however, also considers the allelic frequencies. Perfect LD (D′ = 1.00, r2 = 1.00) 
therefore denotes two loci with identical allelic frequencies, between which there is 
no recombination. Both D′ and r2 are measured on a scale of 0.00 to 1.00. 
 
Online database searches, as described in Chapter 2.1, were used to perform 
primary analyses of the candidate SNPs prior to functional analyses (Figure 3.2). 
None of the SNPs reside within a DNase I hypersensitivity region, though rs4837613 
does lie less than 50bp upstream to a region of hypersensitivity (Figure 3.2 B) [130]. 
Sensitivity to DNase I digestion is indicative of a region which is in an open 
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conformation and so, is more likely to be exposed to transcription factor binding that 
could regulate nearby gene expression. Indeed, several transcription factors are 
predicted to bind to the rs4837613 region, including USF1 (upstream transcription 
factor 1) and TCF12 (transcription factor 12) [131]. No transcription factors are 
known to bind to either rs4836732 or rs13283416 (Figures 3.2 A and 3.2 C). 
Chromatin state modelling of the regions shows clear differences in functionality 
dependant on the cell line under investigation, with the green boxes of the track 
representing an area of active transcription, orange boxes denoting a region with 
strong enhancer activity, yellow weak enhancer activity and grey boxes indicating 
regions of heterochromatin [132]. Both rs4836732 and rs4837613 reside in regions 
of active transcription and in predicted enhancer regions, while rs13283416 is in a 
region of heterochromatin. Consequently, the database searches indicate rs4836732 
and rs4837613 are the most promising candidates, as rs13283416 appears to be in 
an inactive region.  
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Figure 3.1 
UCSC Genome Browser screenshot of the 9q33.1 locus and representation of SNP 
location. The position of each candidate SNP is denoted by a red line. ASTN2, 
PAPPA and TRIM32 all reside in the rs4836732 association region. The top panel 
represents the p and q arms of chromosome 9 respectively. The first track displays 
RefSeq genes, with the scale line depicting 200 kb in distance. The multiple 
transcripts indicate known isoforms of the genes, while vertical blue lines indicate 
exons and horizontal blue lines indicate the gene introns. The red arrows indicate the 
direction of gene transcription, with PAPPA and TRIM32 transcribed from the 
opposite strand to ASTN2. Adapted from UCSC genome browser using the hg19 
reference genome (http://genome.ucsc.edu/cgi-bin/hgGateway).  
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Figure 3.2 
UCSC Genome Browser screenshot of the candidate SNPs rs4836732 (A), 
rs4837613 (B) and rs13283416 (C). The tracks for DNase I-hypersensitivity (1), 
where increasing colour gradients of boxes from grey to black indicate increasing 
hypersensitivity, Transcription Factor ChIP-Seq (2), indicating transcription factors 
identified to bind to the region, and Chromatin State Segmentation (3), where green 
boxes indicate an area of active transcription, grey boxes regions of heterochromatin 
and yellow/orange boxes denoting a region with medium/strong enhancer activity 
respectively,  are shown for each SNP. The images were obtained using the hg19 
reference genome. 
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3.3.2 Imputation of novel candidate SNP association with OA  
Although rs13283416 and rs4837613 were not analysed in the arcOGEN GWAS 
[92], imputed data was obtained for the association of their effect allele with OA (data 
generated by Dr Kalliope Panoutsopoulou, Wellcome Trust Sanger Institute). It was 
only possible to impute p values for the discovery analysis of the arcOGEN study.  
Based on the p values, this data indicates rs4836732 is the most likely causal SNP, 
though it does not comprehensively eliminate the other two SNPs (Table 3.2).    
 
 
SNP Location Effect 
allele 
p value 
(discovery) 
 p value   
(replication) 
rs4836732 
(sentinel) 
ASTN2 intron 18 C 1·19×10−05  6.11×10-10 
 
rs4837613 ASTN2 intron 17 C 3.59x-05  
rs13283416 ASTN2 intron 17 G 3.11x10-4  
Table 3.2  
Imputed discovery p values for association of rs4837613 and rs13283416 with 
female hip OA in the discovery analysis component of the arcOGEN study. The data 
for rs4836732 is that from the direct genotyping of this SNP and includes the 
replication analysis p value.  
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3.3.3 The investigation of SNP allele functionality using luciferase reporter 
assays  
To investigate the functionality of the two alleles of each of the three candidate SNPs 
in relation to their regulatory capacity, pGL3 luciferase promoter vector constructs 
were created. The pGL3 promoter vector contains a minimal SV40 promoter and a 
multiple cloning site upstream of the luciferase gene, but lacks enhancers and 
repressors. This enables analysis of the functional effects of a target region on gene 
expression.  
 
Regions surrounding each of the SNPs were cloned into a pGL3 luciferase promoter 
vector (Chapter 2.7.1) by ligation into the MluI and XhoI restriction enzyme sites, 
using primers listed in Appendix A: Table A.2. Sequencing then confirmed the 
ligation of the fragments into the plasmid. The plasmids were then transfected, along 
with Renilla as an internal control, into the SW1353 chondrosarcoma cell line, the 
U2OS osteosarcoma cell line and the SW872 liposarcoma cell line. Luciferase and 
Renilla reporter gene expressions were then quantified after 24 hours, with the 
empty pGL3 promoter vector used as a control. The luciferase value was divided by 
the Renilla value of the control plasmid to give a value of 1 for normalisation of the 
data (Figure 3.3).  
 
 
In general, it appears that all three regions analysed display functional activity in the 
cell lines analysed. In the SW872 liposarcoma cell line, all three SNPs exhibited 
enhancer functionality when compared to the empty pGL3 promoter vector, indicated 
by normalised y-axis values >1 (Figure 3.3 A). An allele-specific difference was seen 
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for rs4837613 in this cell line, with the C allele displaying greater enhancer activity 
compared to the G allele (p = 0.0023). However, this differential allelic activity was 
not present in SW1353 (Figure 3.3 B) or U2OS (Figure 3.3 C) cell lines. In these two 
cell lines, only rs4837613 displayed enhancer activity, while both rs13283416 and 
rs4836732 acted as repressors, with the exception of the rs13283416 T allele in 
U2OS cells.   
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Figure 3.3 
Luciferase reporter gene expression following transfection with pGL3 promoter 
vector containing each allele of rs4836732, rs4837613 or rs13283416. The 
experiment was performed in SW872 cells (A), SW1353 cells (B) and U2OS cells 
(C). Luciferase activity was quantified 24 hours post transfection and normalised to 
the Renilla internal control.  The data was then normalised to the empty pGL3 
promoter vector. Eight technical replicates and six biological repeats were performed 
for each SNP allele in each cell line. Statistical significance was assessed using the 
Mann-Whitney U test.  Error bars = SEM. ** p < 0.01, *** p < 0.001.  
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3.3.4 In Silico characterisation of the binding region  
Having identified enhancer and repressor functionality of polymorphisms within the 
association interval, I next aimed to investigate the transcription factors that could be 
responsible for the functional effects. Though no consistent differential allelic activity 
was evidenced in the luciferase reporter assays, it is possible that differential 
transcription factor binding exerts functional effects at specific times in synovial joint 
development or during the disease process. As such, the next stage of the 
investigation sought to further characterise the association region by assessing if 
there are any differences in protein binding to the C and T alleles of rs4836732. Only 
rs4836732 was taken forward for analysis owing to the fact that this signal had been 
replicated successfully in the arcOGEN GWAS [92]. Online databases were used to 
identify proteins predicted to bind to the C and T allele of rs4836732 according to 
sequence complementarity, as described in Chapter 2.8.1.  Table 3.3 shows the 
factors predicted to bind, their consensus sequences and the database used. 
 
Table 3.3 
Consensus sequences of proteins predicted to bind to rs4836732. Shown are the 
trans-acting factors predicted to bind to the rs4836732 sequence, their consensus 
sequence and the database used for identification. The sequence flanking 
rs4836732 is displayed in black and the two SNP alleles are underlined.  
 
 
 
Transcription 
Factor
Consensus 
sequence(s)
Corresponding rs4836732 SNP sequence   
(C allele)
Corresponding rs4836732 SNP sequence      
(T allele)
Database
GRα CCTAC/TGAGG GAGAGACAGCACCTACTTTCTGAGGTCTAAG GAGAGACAGCACCTATTTTCTGAGGTCTAAG PROMO 3.0
GRβ CTATT GAGAGACAGCACCTATTTTCTGAGGTCTAAG PROMO 3.0
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3.3.5 Optimisation of EMSA binding conditions  
Having identified predicted transcription factor binding to the rs4836732 locus, I next 
used EMSAs, a technique which analyses protein binding to specific DNA 
sequences, to further investigate this in cell lines. The EMSA reaction was performed 
as described in Chapter 2.8 and the labelled EMSA probes and competitor 
sequences can be viewed in Appendix A: Table A.3.  
 
Optimisation of EMSA binding conditions was performed using 200 fmol of either the 
C or T allele labelled probe and 10µg SW872 nuclear protein. This was incubated 
with binding buffer, DTT/2.5% Tween 20 and Poly (dI:dC) (Figure 3.4). Also added to 
individual lanes was 50% glycerol, 1% NP40, 1M KCl, 100mM MgCl2 or 200mM 
EDTA. NP40, MgCl2 and EDTA resulted in increased abundance of protein binding 
and therefore, further optimisations were performed using combinations of these 
conditions (Figure 3.5). Of the different combinations of conditions tested, protein 
complex binding in the presence of NP40 and MgCl2 combined appeared to be 
optimal. Consequently subsequent EMSAs were performed in the presence of NP40 
and MgCl2. 
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Figure 3.4 
Optimisation of EMSA binding conditions with SW872 nuclear protein in the 
presence of rs4836732 C or T labelled probes.  Present in each lane is labelled 
probe, SW872, binding buffer, DTT/2.5% Tween 20 and Poly (dI:dC). The additional 
additive is indicated at the top of each lane.  Arrows indicate SW872 protein complex 
binding to the probes. * Indicates a complex present in some, but not all conditions.   
 
 
 
 
 
 
 
*
*
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Figure 3.5 
Optimisation of binding conditions of proteins to the C and T allele EMSA probes in 
the presence of NP40, MgCl2 and EDTA. Lanes 1-7 contain the C allele labelled 
probe and lanes 8-14, the T allele probe. The arrows indicate SW872 nuclear protein 
complexes binding to the probes.  
 
 
 
 
 
 
 
 
 
 
T probeC probe
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3.3.6 Investigation of protein complex binding to rs4836732 using 
chondrosarcoma, liposarcoma and osteosarcoma cell line nuclear protein 
Having optimised the EMSA binding conditions and noted protein complex binding to 
the C and T probes of rs4836732, the specificity of these complexes was then 
investigated. This was achieved by introducing increasing concentrations (5-, 10-, 
25- or 50- fold excess relative to the labelled probe) of unlabelled competitors with 
identical sequences to the labelled probes (Figure 3.6).  
 
Having noted specific binding of protein complexes, the region of the labelled probe 
involved in binding the protein complex was next investigated. Competitor 
sequences consisting of one region identical to the labelled probe and the remaining 
sequence entirely random were created to achieve this (Figure 3.7). Complex 
binding to the C allele probe was outcompeted by competitor 1 in all three cell lines. 
This therefore suggests it is the 3' region of the C allele probe sequence that is 
required for protein binding. This was also the case with the T allele probe with 
U2OS nuclear protein binding. SW872 and SW1353 protein complex binding to the T 
allele probe was also outcompeted by competitor 1, but not as strongly as compared 
to U2OS nuclear protein.  
 
 
 
 
 
84 
 
Figure 3.6 
Competition EMSAs to investigate allele-specific binding of SW872, SW1353 and 
U2OS nuclear extract to the C and T alleles of rs4836732. Unlabelled competitors 
were added at 0-, 5-, 10-, 25- and 50x concentrations, relative to the labelled probes. 
The experiment was performed with SW872 (A), SW1353 (B) and U2OS (C) nuclear 
protein. Protein: probe complexes which were outcompeted are indicated by the 
arrows, suggesting specific binding to the probes.  
 
 
 
 
 
 
 
A. B.
C.
C probe T probe
0 5x 10x 25x 50x 0 5x 10x 25x 50x 0 5x 10x 25x 50x 0 5x 10x 25x 50x
C probe T probe
C probe T probe
0 5x 10x 25x 50x 0 5x 25x 50x 0 5x 10x 25x 50x 0 5x 10x 25x 50x10x
0 5x 10x 25x 50x 0 5x 10x 25x 50x 0 5x 10x 25x 50x 0 5x 10x 25x 50x
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Figure 3.7 
Competition EMSAs to investigate the regions of the C and T allele probes of 
rs4836732 binding protein complexes in SW872 (A), SW1353 (B) and U2OS (C) 
nuclear extract. The protein and labelled probe mixes were incubated with unlabelled 
competitors containing sections of random sequences (black text) replacing some of 
the original competitor sequence (underlined in red). Competitor concentrations = 10 
or 25 x probe concentration. Each primer was annealed to its reverse complement to 
create double stranded DNA (dsDNA), prior to use in EMSAs. Full length probe = 31 
bp; Comp 1 =  5′ region of the competitor replaced by a 14 bp random sequence; 
Comp 2 = 9 bp random sequence flanking 13 bp competitor; Comp 3 =  3′ region of 
the competitor replaced by a 14 bp random sequence. 
 
 
 
A.
C allele competitors
C 10x 25x 10x 25x 10x 25x
Comp 1 Comp 2 Comp 3
T allele competitors
T 10x 25x10x 25x10x 25x
Comp 1 Comp 2 Comp 3
10x 25x 10x 25x 10x 25x 10x 25x10x 25x 10x 25xC T
Comp 1 Comp 2 Comp 3 Comp 1 Comp 2 Comp 3
C allele competitors T allele competitors
10x 25x10x 25x 10x 25x 10x 25x 10x 25x 10x 25x
Comp 1 Comp 1Comp 2 Comp 2Comp 3 Comp 3
C allele competitors T allele competitors
TC
B.
C.
Full length probe GAGAGACAGCACCTA[C/T]TTTCTGAGGTCTAAG
Comp 1 TAGCACCTCCAGGCA[C/T]TTTCTGAGGTCTAAG
Comp 2 TAGCACCTCCACCTA[C/T]TTTCTGTACGTAGCA
Comp 3 GAGAGACAGCACCTA[C/T]TCTGAGTACGTAGCA
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3.3.7 Predicted differentially binding transcription factor competition EMSAs   
Having used databases to identify transcription factors predicted to bind to the 
rs4836732 SNP region (Section 3.3.4), it was necessary to investigate whether these 
predictions were correct and whether binding is disrupted in the presence of either 
SNP allele.  
 
Increasing concentrations of consensus sequence competitors for GRα and GRβ 
were added to the optimised EMSA reaction in the presence of SW872, SW1353 or 
U2OS nuclear protein (Table 3.4, Figure 3.8).  This did not generate evidence for the 
differential binding of the GRβ consensus sequence to the T allele, as predicted 
using the PROMO database. No competition is seen in the presence of the GRβ 
consensus sequence in any of the cell lines with either the C or T allele probe. GRα 
appears to bind to both the C and T allele probes in the presence of SW872 nuclear 
protein, with increasing concentrations of the competitor resulting in both probes 
being out competed (Figure 3.8 A). However, this was not seen in the presence of 
SW1353 or U2OS nuclear protein. 
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Table 3.4 
Transcription factors selected for competition EMSAs to investigate binding to 
rs4836732. After identifying transcription factors predicted to bind the SNP, 
competitor sequences were designed. These include the protein consensus 
sequence at the site predicted to bind (predicted by the PROMO database), flanked 
by a random sequence. Transcription factor consensus sequences are underlined in 
bold and the random sequences are in black text.  
 
 
 
Transcription Factor Competitor sequence (5'-3') 
 
GRα 
 
TAGCACCTCCAGGCTGTCTTGAGGCGTAGCA 
 
              GRβ 
 
TAGCACCTCCAGCTATTTTGAGTACGTAGCA 
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Figure 3.8 
EMSA competition analysis of GRα and GRβ competition binding to the rs4836732 C 
and T probes in the presence of SW872 (A), SW1353 (B) and U2OS (C) nuclear 
protein.  The protein:probe mixes were combined with increasing concentrations (0, 
5-, 10-, 25- and 50- fold compared to the probe concentration) of competitors 
containing either the GRα or GRβ consensus sequence. Increasing concentrations 
of GRα competitor outcompeted C and T probe binding in the presence of SW872 
nuclear protein (A). No changes in banding patterns was seen upon addition of the 
GRβ competitor sequence in any cell line with either the C or T labelled probe.  
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3.3.8 Supershift analysis  
Having noted protein complex binding to the rs4836732 probes, this was further 
investigated by using supershift EMSAs in an attempt to identify the proteins. Upon 
addition of antibodies raised against specified transcription factors, if an antibody 
were specific for a transcription factor present, the antibody would bind the trans-
acting factor:DNA complex and result in the complex migrating more slowly through 
the gel which would be observed as a ‘supershift’.  As such, the binding of the two 
predicted transcription factors, GRα and GRβ, as well as a panel of trans-acting 
factors known to be expressed in cartilage was investigated. For a list of antibodies 
used, see Appendix C: Table C.1. 
 
No supershifts were observed in any cell line for either of the rs4836732 probes 
(Figures 3.9, 3.10 and 3.11). This therefore means we are not able to identify the 
protein complexes binding to the probes. However, the pattern of protein complex 
binding does differ between the C and T probe in all three cell lines, suggesting that 
the probes do have differential binding capacity.  
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Figure 3.9 
Supershift EMSAs to investigate the transcription factors of SW872 nuclear extract 
binding to the C and T alleles of rs4836732. The protein:probe mixes were incubated 
with 2 μg of antibody, indicated at the top of each well. No changes in the banding 
patterns were observed after incubation with any of the antibodies. C/T indicates 
control wells containing just the labelled probe with no antibody.  
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Figure 3.10 
Supershift EMSAs to investigate the transcription factors of SW1353 nuclear extract 
binding to the C and T alleles of rs4836732. The protein:probe mixes were incubated 
with 2 μg of antibody, indicated at the top of each well. No changes in the banding 
patterns were observed after incubation with any of the antibodies. C/T indicates 
control wells containing just the labelled probe with no antibody.  
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Figure 3.11 
Supershift EMSAs to investigate the transcription factors of U2OS nuclear extract 
binding to the C and T alleles of rs4836732. The protein:probe mixes were incubated 
with 2 μg of antibody, indicated at the top of each well. No changes in the banding 
patterns were observed after incubation with any of the antibodies. C/T indicates 
control wells containing just the labelled probe with no antibody.  
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3.3.9 Identification of candidate genes within the LD block  
The candidate SNPs of interest in the 9q33.1 susceptibility locus all reside within 
introns of ASTN2 (Table 3.1). It is therefore anticipated that the OA susceptibility will 
be mediated through a cis-acting expression quantitative trait locus (cis-eQTL), as 
opposed to the effect of a non-synonymous polymorphism. The UCSC Genome 
Browser, a database providing information regarding the reference sequence of the 
human genome, was therefore utilised to confirm the genes which reside closest to 
the SNPs and so, which may be subject to regulation by the association signal. 
Figure 3.1 is a screenshot from the website covering the 9q33.1 locus. The first track 
displays RefSeq genes and confirms rs4836732, rs4837613 and rs13283416 are 
intronic SNPs, residing within ASTN2. TRIM32 is situated downstream within intron 
12 of ASTN2, while PAPPA is upstream, and both are orientated in the opposite 
direction to ASTN2.   
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3.3.10 Stratification of overall cartilage gene expression by rs4836732 
genotype using qPCR  
Prior to the start of my PhD, expression data in OA hip and OA knee cartilage was 
generated for ASTN2, PAPPA and TRIM32 by Dr Emma Raine (Institute of Cellular 
Medicine, Newcastle University) and normalised to the housekeeping genes 18S, 
GAPDH and HPRT1 (Chapter 2.13.2). The assay positions are detailed in Figure 
3.12 (housekeeping genes) and Figure 3.13 (target genes). All probes and primers 
were designed to the cDNA sequences, excluding intronic regions.  
 
For each donor, I compiled the genotype at rs4836732, age (in years) at the time of 
arthroplasty surgery, joint replaced and sex (Appendix B: Table B1).  I then analysed 
the expression profiles of ASTN2, PAPPA and TRIM32 in cartilage samples from 
patients according to genotype at rs4836732 (Table 3.5 – Table 3.7; Figure 3.14). 
The rs4836732 association signal was discovered when the arcOGEN data was 
stratified by joint and by sex and was highly significant only in the female hip-specific 
stratum. This does not though imply that the functional effect of the association 
signal will only be active in female-hip tissues; the functional effect could be much 
broader but it is only a risk factor for OA development in the hips of females. An 
excellent example of this phenomenon is the association of SNPs at the ALDH1A2 
gene with OA [78]. These SNPs are associated with hand OA but not with hip or 
knee OA and yet they correlate with reduced expression of ALDH1A2 in cartilage 
from hip and knee OA patients. Based on such observations, I therefore included 
analyses of ASTN2, PAPPA and TRIM32 expression in knee OA samples, and of 
neck of femur (NOF) fracture donors, though only TRIM32 expression data was 
available from these samples. Analysis of the expression data according to genotype 
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was assessed using Mann-Whitney U tests and Kruskal Wallis one way ANOVA 
tests.  
 
There was no statistically significant difference in ASTN2, PAPPA, or TRIM32 gene 
expression in OA cartilage when stratified by rs4836732 genotype, though the data 
did confirm that all genes are expressed in cartilage (Tables 3.5, 3.6 and 3.7; Figure 
3.14). Comparison of TRIM32 expression in OA compared to NOF cartilage also did 
not yield any significant differences. Analysis according to the OA risk stratum 
(female hip) in comparison to NOF females also did not indicate any differential 
TRIM32 expression.  
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Figure 3.12 
Location of qPCR housekeeping primers and probes used for quantitative real-time 
PCR. Assays were designed to the exons of A) 18S, B) GAPDH and C) HPRT1.  
Indicated on each image is the genomic location and scale bar. The images were 
produced using the hg19 reference genome in the UCSC Genome Browser.  
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Figure 3.13 
Location of qPCR primers and probes used for quantitative gene expression analysis 
of candidate genes. PrimeTime Quantitative Real-Time-PCR (qPCR) assays were 
purchased, designed for the exons of ASTN2 (A), PAPPA (B) and TRIM32 (C) (IDT, 
Iowa, USA). Assays cover each transcript variant of all three genes. Images were 
generated using the UCSC Genome Browser and hg19 reference genome. 
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Table 3.5 
Analysis of ASTN2 expression in OA hip and OA knee cartilage. Data was stratified 
by rs4836732 genotype or by affected joint. There were no significant differences in 
gene expression for any of the stratifications, though individuals with the C risk allele 
at rs4836732 did show a trend toward increased ASTN2 expression. Statistical 
significance was assessed using a Mann-Whitney U test for two-way comparisons 
and a Kruskal Wallis one-way analysis of variance for a comparison of more than 
two groups. n = number of patients in the comparison. 
 
 
 
 
 
 
 
 
 
 
Stratification for ASTN2 qPCR data p-value 
OA CT (n = 22) vs. OA CC (n = 5) vs. OA TT (n = 14) 0.063 
OA C carriers (n = 14) vs. OA TT (n = 27)  0.862 
OA hip (n = 13) vs. OA knee (n = 28) 
OA females (n = 23) vs. OA males (n = 18)  
OA female hip (n = 11) vs. OA female knee (n = 12) 
0.529 
0.572 
0.601 
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Stratification for PAPPA qPCR data p-value 
OA CT (n = 17) vs. OA CC (n = 3) vs. OA TT (n = 12) 0.969 
OA C carriers (n = 20) vs. OA TT (n = 12) 0.546 
OA hip (n = 10) vs. OA knee (n = 22) 
OA females (n = 17) vs. OA males (n = 15)  
OA female hip (n = 8) vs. OA female knee (n = 9) 
0.823 
0.104 
0.321 
Table 3.6 
Analysis of PAPPA expression in OA hip and OA knee cartilage. Statistical 
significance was assessed using a Mann-Whitney U test for two-way comparisons or 
a Kruskal Wallis one-way analysis of variance for a comparison of more than two 
groups. n = the number of individuals in the comparison group. 
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Stratification for TRIM32 qPCR data p-value 
OA CT (n = 43) vs. OA CC (n = 20) vs. OA TT (n = 20) 0.636 
OA C carriers (n = 63) vs. OA TT (n = 20 )  
All OA (n = 83) vs. NOF (n = 15) 
0.954 
0.375 
OA hip (n = 23) vs. NOF (n = 15) 0.300 
OA female hip (n = 17) vs. NOF female (n = 15) 0.082 
OA hip (n = 23) vs. OA knee (n = 60) 
OA females (n = 46) vs. OA males (n = 37)  
OA female hip (n = 17) vs. OA female knee (n = 29) 
OA male hip (n = 6) vs. OA male knee (n = 31) 
0.407 
0.555 
0.228 
0.789 
Table 3.7 
Analysis of TRIM32 expression in OA hip, OA knee and NOF cartilage. There were 
no significant differences in gene expression when stratified according to affected 
joint, disease status or rs4836732 genotype. Statistical significance was assessed 
using a Mann-Whitney U test for two-way comparisons or a Kruskal Wallis one-way 
analysis of variance for a comparison of more than two groups. n = the number of 
individuals in the comparison group. 
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Figure 3.14 
Analysis of candidate gene expression in OA hip and OA knee cartilage. There were 
no significant differences in gene expression of ASTN2 (A), PAPPA (B), or TRIM32 
(C) between carriers of the rs4836732 C risk allele and TT homozygotes. Statistical 
significance was assessed using a Mann-Whitney U test; n represents the number of 
individuals in the comparison group; error bars represent the mean + SEM. 
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3.3.11 Identification of gene transcript SNPs for AEI  
In the previous section of this chapter, I did not observe any evidence for 
rs4836732 marking a cis-eQTL in this locus within OA cartilage. However, it is 
possible that this may be the result of inter-individual variability concealing the 
effect of the SNP. As such, I therefore deemed it prudent to utilise a more 
specific line of investigation and analysed gene expression at the allelic level. 
To achieve this, I used pyrosequencing to quantify the allelic output of the gene 
transcripts. Given that rs4836732 is intronic, transcript SNPs present in the 
European population within the candidate genes were identified using the 
UCSC Genome Browser to act as discriminators of messenger RNA (mRNA) 
output at the allelic level [124]. A SNAP Pairwise LD search was performed to 
assess the correlation between transcript SNPs and rs4836732 [129], which 
failed to identify any transcript SNP to be in high LD with the sentinel SNP (data 
not shown).  
 
As AEI analysis requires transcript SNP heterozygotes to investigate differential 
allelic outputs, heterozygote frequencies for transcript SNPs were obtained 
from the dbSNP online database [133]. Consequently, transcript SNPs were 
selected based on the heterozygote frequency in order to maximise the AEI 
sample size. Another key consideration was to select transcript SNPs which 
were present in as many transcript isoforms of a gene as possible. In light of 
this, after transcript SNPs had been identified, some were excluded as the 
heterozygote frequency was low (< 20%) and others were rejected owing to the 
fact they were not present in all transcripts. The selected transcript SNPs are all 
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located in the 3'UTR of their respective genes (Table 3.8). For ASTN2 rs7518 
(A/G) was selected, for PAPPA rs2565 (G/T) and for TRIM32 rs2281627 (C/T).   
 
 
 
Gene Transcript 
SNP 
r2 D' Heterozygote 
frequency (%) 
ASTN2 rs7518 0.31 0.917 35 
PAPPA rs2565 0.17 1 40 
TRIM32 rs2281627 0.395 0.884 43 
Table 3.8 
Transcript SNPs within the candidate genes which were selected for use in AEI 
analysis. The r2 and D' were calculated relative to rs4836732.  
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3.3.12 Design and validation of AEI assays  
AEI was performed using pyrosequencing, a real-time sequencing-by-synthesis 
technique (Chapter 2.10.2).  This method uses an additional sequencing 
primer, which extends over the SNP in the direction of the biotinylated primer. 
The first step for AEI was therefore to create and then validate an assay for 
each transcript SNP, to ensure the sequencing primers are able to provide an 
accurate measurement of both alleles relative to each other. Validation was 
achieved by mixing DNA homozygous at the SNP to create specified ratios of 
the major and minor allele of each SNP. Subsequent PCR and pyrosequencing 
was performed and the experimental values were compared to the expected 
values. The three assays were successfully validated, providing evidence that 
the two alleles of each SNP could be reliably distinguished (Figure 3.15). 
Primer sequences can be found in Appendix A: Table A.1.  
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Figure 3.15 
Validation of transcript SNP pyrosequencing assays in the three candidate genes. In 
each reaction 50ng of patient DNA was used which was homozygous at the 
specified transcript SNP. Different ratios of major allele and minor allele homozygous 
DNA were created and measured by pyrosequencing.  
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3.3.13 Statistical analysis of AEI in synovium, cartilage and fat pad  
Genomic DNA and RNA were extracted from the fat pad, cartilage and synovium of 
OA patients. All donors were genotyped at the sentinel SNP, rs4836732, using an 
RFLP assay (Chapter 2.5.2) and at the three transcript SNPs using pyrosequencing 
assays (Chapter 2.6).  For patients who were heterozygous at the transcript SNP, 
RNA was reverse transcribed to cDNA. Allelic expression imbalance (AEI) analysis 
was performed by pyrosequencing and the allelic ratio of cDNA was normalised to 
genomic DNA.  
 
Stratification by rs4836732 genotype enabled the investigation of any correlation 
between AEI and the sentinel SNP.  In the event of AEI being present, clustering of 
compound heterozygotes would occur. This would create two groups, one with an 
allelic ratio of greater than 1:1 and the other less than 1:1. The transcript SNPs are 
not in high LD with the sentinel SNP, so recombination events mean it would not be 
possible to determine the causal allele if AEI were detected.   
 
No evidence was identified which indicates rs4836732 correlates with a cis-eQTL 
acting on ASTN2, PAPPA or TRIM32 in the three tissue types analysed. In all 
tissues, rs4836732 heterozygotes display clustering around the 1:1 expression ratio 
for the analysed genes (Figure 3.16). 
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Figure 3.16 
Allelic expression imbalance of ASTN2, PAPPA and TRIM32 transcript SNPs 
stratified by rs4836732 genotype in cartilage (A), fat pad (B) and synovium (C) from 
OA patients. No AEI was observed to correlate with rs4836732 genotype.  Statistical 
significance was assessed using a Mann-Whitney U test, though none of the 
comparisons proved statistically significant. n indicates the number of patients in 
each comparison group. 
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3.4 Discussion  
In Chapter 3, I have attempted to characterise the 9q33.1 OA susceptibility region 
marked by rs4836732. GWAS association signals often mark disease risk influenced 
by another polymorphism, which acts to modulate gene transcription. Consequently, 
I hypothesised that rs4836732 marks a functional SNP which regulates expression of 
a gene residing in the association locus.  
 
I began by performing database searches to identify SNPs in high LD with the 
association signal, which identified two further candidate SNPs. To dissect any 
functional allelic differences between SNP alleles, I created luciferase reporter 
constructs [134]. This confirmed all three SNPs to have enhancer or repressor 
functions in the cell lines analysed, and identified differential SNP activity for 
rs4837613 in SW872 cells, but did not identify consistent differences in allelic activity 
for any of the three SNPs. Imputed p values for association with the rs4836732 
association signal were subsequently generated by Dr Kalliope Panoutsopoulou 
(Wellcome Trust Sanger Institute) for rs13283416 and rs4837613, as neither were 
present on the arcOGEN array [92]. Given that both of these were less significant 
than for rs4836732, and the fact that the association for rs4836732 had already been 
robustly replicated, this SNP appeared to be the most compelling candidate.  
Furthermore, a true causal polymorphism in high enough LD with rs4836732 to 
detect the effect on a GWAS should assert a strong enough affect to be detected via 
rs4836732.  
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Though differential allelic activity was not seen using the luciferase reporter assays, 
it is potential that allelic differences may be regulated by differential transcription 
factor binding, but that the effects of this are only functional at specific times in joint 
development or repair. EMSAs are a commonly used method to characterise 
protein:DNA binding and so, were performed using rs4836732 C and T allele probes 
with nuclear protein from chondrosarcoma, liposarcoma and osteosarcoma cell lines. 
In particular, binding of two transcription factors, GRα and GRβ, which had been 
predicted to bind the SNP by the online PROMO database was analysed, with GRβ 
predicted to bind the T allele only and GRα to both alleles. These EMSAs suggested 
GRβ did not bind either probe allele, while GRα did appear to outcompete 
probe:protein binding with increasing concentration in the SW872 cell line in the 
presence of both the C and T probes. Protein complexes binding the probes were 
analysed by introduction of antibodies to try and observe supershifts. However, no 
supershifts were observed with the antibodies investigated. Different banding 
patterns were observed in all cell lines in the presence of the C allele probe 
compared to the T allele. This suggests differential protein complex binding 
dependent on the allele present at rs4836732. However, it has not been possible to 
identify these proteins. Furthermore, it is important to highlight that despite numerous 
replications, the EMSAs produced variable results in terms of banding patterns. This 
is potentially a result of the artificial nature of the technique, in that the probe DNA is 
linear. As such, it is not an accurate reflection of the natural chromatin conformation 
and this is likely to affect transcription factor binding. Further experiments using 
techniques such as ChIP, which offers a native representation of the cellular 
interactions therefore allowing investigation of transcription factor binding to the 
endogenous loci rather than the artificial conditions utilised in EMSAs, would 
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therefore be advisable. Additionally, it would be of interest to investigate nuclear 
protein from difference sources, such as HACs, as transcription factors may be 
present in different abundances.  
 
Given its intronic position, if functional, rs4836732 is likely to mediate OA risk by 
acting as an eQTL. I therefore investigated genes residing within the association 
region to try and identify whether rs4836732 was acting as a cis-eQTL.  Overall gene 
expression was quantified in OA cartilage for ASTN2, PAPPA and TRIM32, but this 
did not reveal any difference in gene expression according to rs4836732 genotype. 
Gene expression was subsequently analysed at the allelic level using AEI analysis, a 
method which allows the quantification of mRNA outputs in relation to the different 
alleles of an individual who is heterozygous at the SNP of interest.  AEI was 
performed using nucleic acids from synovium, fat pad and cartilage from OA 
patients. However, the results did not yield any significant differences in gene 
expression in relation to rs4836732 genotype. This may be indicative of the SNP 
acting at a different time in joint development or repair which does not occur in end-
stage disease tissues. Alternatively, it may be that rs4836732 is regulating the 
expression of a different gene given that cis-eQTLs can act up to megabases in 
distance [135]. It is also possible that no effect has been seen as this is not the 
functional polymorphism. 
 
To summarise, in this chapter, I have demonstrated that the three candidate SNPs 
displayed enhancer or repressor effects in the cell lines analysed, and that the main 
functional candidate, rs4836732, displayed allelic differences in EMSA analyses.  
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However, the data indicate that the OA association signal marked by rs4836732 
does not assert its effects in end-stage OA tissues. It is possible that disease risk is 
modulated during joint development and as such, this chapter supports further 
investigation into the candidate gene which is most likely to have a role in joint 
formation.   
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Chapter 4: Investigation of PAPPA as a key candidate gene 
 
4.1 Introduction 
Although there was no correlation observed between rs4836732 genotype and 
expression of candidate genes within the association region, this does not mean that 
the SNP is not functional in OA susceptibility. It is possible that the association signal 
may exert its effects in other tissue types, during joint development or earlier in the 
disease process. It is also possible that the rs4836732 signal modulates gene 
expression outside of the LD region.  
 
A large body of evidence supports abnormal synovial joint development as a key 
predisposing factor for OA risk. Indeed, a cross sectional study identified hip 
dysplasia (HD) as the only individual risk factor to associate with hip OA in males 
upon analysis of the influence of  hip dysplasia, body mass index, smoking and 
occupational exposure to repeated daily lifting [136]. Analysis into the association 
between OA susceptibility loci and variation in proximal femur shape, represented by 
statistical shape model (SSM) modes, in patients with unilateral hip OA identified 
association between rs4836732 and SSM mode 5 (p = 0.0016) [137]. Mode 5, a 
female SSM, captures hip shape variation of the superior aspect of the femoral head. 
As such, this suggests rs4836732 may contribute to OA susceptibility by altering the 
shape of the femoral head, and so promotes further investigation into the association 
signal in relation to joint development.  
 
113 
 
Of the three candidate genes investigated in Chapter 3, PAPPA is arguably the most 
compelling candidate in relation to synovial joint development. PAPPA is the IGF-II-
dependent IGF-binding protein (IGFBP)-4 protease, with IGFBP2, 4 and 5 being the 
PAPPA-cleavable IGFBPs. Murine studies have demonstrated that osteoblast-
specific PAPPA expression causes increased bone size, indicative of PAPPA-
cleavable IGFBPs exerting a regulatory effect over IGF bioavailability in skeletal 
tissues [106].  
 
Furthermore, in a global mouse PAPPA knock-out, a significant decrease in 
trabecular volume was recorded, progressing with age, alongside an age-associated 
decrease in fracture resistance [107]. Measurement of dynamic serum parameters 
associated with bone formation indicated reduced bone formation in young knockout 
mice (4 and 6 months) accompanied by a 45-60% reduction in osteoblasts and 50-
60% reduction in osteoclasts. As such, PAPPA appears to be necessary for both 
embryonic and postnatal bone development and is a promising candidate for 
regulation by the rs4836732 signal during joint development.  
 
A genome wide expression study comparing the gene expression profile of paired 
lesioned and preserved OA cartilage identified increased PAPPA expression in 
lesioned tissue, particularly in hip OA which demonstrated a 2.6-fold increase in the 
lesioned cartilage in the 33 patients analysed [138]. As such, this suggests there is 
aberrant PAPPA expression in OA-affected cartilage during end-stage disease and 
may be indicative of a role in joint repair.  
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Based on the above evidence, I hypothesise that the rs4836732 signal influences 
risk of hip OA in females by regulating PAPPA expression during joint development 
and repair. I consequently sought to characterise PAPPA expression in hMSC 
differentiation into cells found in the synovial joint and to further investigate the 
association between rs4836732 genotype and PAPPA expression. 
 
4.2 Aims 
The aim of this chapter was to explore the potential that rs4836732 confers OA risk 
through a role in synovial joint development owing to aberrant PAPPA regulation. 
This was achieved by: 
• Analysis of PAPPA expression during hMSC differentiation into chondrocytes 
and osteoblasts. 
• Performing in vitro PAPPA siRNA knockdowns in hMSCs, followed by 
chondrogenic and osteogenic differentiation. 
• Characterisation of hMSC differentiation capacity following PAPPA knock-
down by qPCR and histological staining analysis.  
• Quantification of bone-specific PAPPA expression in OA patient samples and 
stratification by rs4836732 genotype to assess whether differential expression 
correlates with the presence of the risk allele. 
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4.3 Results 
 
4.3.1 Examination of the expression profile of PAPPA during hMSC 
differentiation 
In order to examine the developmental role of PAPPA, I first sought to investigate 
expression throughout the differentiation of hMSCs into osteoblasts and 
chondrocytes. Expression during differentiation was essential to support the 
hypothesis that the functional effects of rs4836732 could be exerted at early stages 
of joint development, thus resulting in altered joint structure and increased OA risk. 
 
I tracked overall gene expression throughout chondrogenesis and osteogenesis, 
irrespective of rs4836732 genotype, in both OA and non-OA patients (Table 4.1). For 
details of hMSC isolation and expansion see Chapter 2.11.2. The purpose of this 
was to clarify whether PAPPA had the potential to contribute to joint development, 
reflected by expression during hMSC differentiation. Dr Madhushika Ratnayake and 
Maria Tselepi of Prof. Loughlin’s group (Institute of Cellular Medicine, Newcastle 
University) performed in vitro chondrogenesis and I performed in vitro osteogenesis 
(Chapter 2.11.4). I then performed the qPCR and data analysis of PAPPA 
expression (Chapter 2.13.2). qPCR primer and probe sequences can be found in 
Appendix A: Table A.4, while assay positions are detailed in Figure 3.11 
(housekeeping genes) and Figure 3.12 (target genes).  
 
During chondrogenesis, gene expression was quantified on days 3, 7 and 14 as at 
day 0, MSCs were undifferentiated (Figure 4.1 A). To confirm successful 
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chondrogenic differentiation, expressions of the chondrogenic markers ACAN 
(aggrecan), COL2A1 and SOX9 were confirmed at each time point by Dr 
Madhushika Ratnayake and Maria Tselepi. PAPPA was expressed throughout 
chondrogenesis, though a distinct pattern of expression associated with specific 
stages of differentiation was not seen.  
 
During osteogenesis, PAPPA expression was quantified on days 0, 3 and 14 of 
differentiation (Figure 4.1 B). In this instance, cells had been allowed to adhere in 
osteogenic media for 6 hours prior to harvesting on day 0. Again, PAPPA expression 
was detected at all time points but there was no distinctive pattern of expression. 
 
Together, these data confirm dynamic expression of PAPPA in an in vitro model of 
joint development and therefore, support further investigation into the developmental 
role of this gene and association with rs4836732 genotype.  
 
 
 
 
 
 
 
 
Table 4.1 
Characteristics of donors whose hMSCs were used for chondrogenesis and 
osteogenesis experiments. The age listed is that at the time of joint replacement, or 
Donor Sex Joint Age (years) 
2454E * Female Hip 24 
N2980 Female Hip 82 
3503 Female Hip 61 
4147 Female Knee 51 
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when the aspirate was taken.  The donor marked with an asterisk (*) was a young, 
non-OA donor purchased from Lonza, UK.  
 
Figure 4.1 
Expression of PAPPA during chondrogenesis and osteogenesis. (A) hMSCs were 
differentiated into chondrocytes and gene expression was quantified on days 3, 7 
and 14. (B) hMSCs were differentiated into osteoblasts and PAPPA expression was 
quantified on days 0, 3 and 14 of differentiation. In differentiation into both lineages, 
PAPPA expression was detected at all time points. The notable inter-individual 
variation and the dynamic expression patterns support a potential functional role 
during cartilage development. Blue line = non-OA patient (NOF fracture; patient 
N2980), green line = healthy control (Lonza, UK; patient 2454E) and orange = two 
independent OA patients (patients 3503 and 4147).   
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4.3.2 Knockdown of PAPPA in human cells 
In order to further investigate the role of PAPPA in human joint development, I aimed 
to deplete PAPPA in human MSCs prior to differentiation into cells found within the 
synovial joint. This was achieved using On-TARGETplus SMART pool human 
PAPPA siRNA (Dharmacon, GE Healthcare, UK), targeted to PAPPA mRNA, as 
described in Chapter 2.11.3. Details of the siRNAs used can be found in Appendix D: 
Table D.1.  
 
The ability of the siRNA to knockdown PAPPA was first assessed in the SW1353 cell 
line. The cells were cultured and then transfected with PAPPA siRNA (Dharmacon, 
GE Healthcare, UK). Following 48 hours, efficiency of the knockdown was assessed 
at both the gene expression and protein levels. To ensure the transfection reagent 
was not interfering with PAPPA expression, cells were transfected with non-targeting 
siRNA (NT siRNA). 
 
PAPPA mRNA depletion in SW1353 cells was confirmed by qPCR. A significant 
decrease in PAPPA expression was observed in comparison to both the 
untransfected cells and the NT siRNA controls (p < 0.001) (Figure 4.2 A). No 
statistically significant difference was seen when comparing the untransfected and 
NT siRNA treated cells. Depletion of the protein was confirmed by immunoblotting, 
as described in Chapter 2.12. This confirmed PAPPA protein depletion in PAPPA 
siRNA transfected cells relative to the two control conditions (Figure 4.2 B).  
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These data confirm PAPPA expression at both the mRNA and protein levels is 
depleted following transfection with the selected PAPPA siRNA. As such, the On-
TARGETplus SMART pool human PAPPA siRNA (Dharmacon, GE Healthcare, UK) 
was used for all subsequent PAPPA siRNA knockdown experiments.  
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Figure 4.2 
Knockdown of PAPPA in SW1353 cells using On-TARGETplus SMART pool human 
PAPPA siRNA (Dharmacon, GE Healthcare, UK). Cells were expanded to 80% 
confluency and transfected with 100nM non-targeting siRNA or 100nM siRNA 
targeting PAPPA. For each condition, gene expression was quantified using qPCR 
and normalised against 18S, GAPDH and HPRT1 housekeeper expression (A). 
PAPPA expression was significantly downregulated relevant to both untransfected 
and NT siRNA controls (p < 0.001). Immunoblotting was used to confirm protein 
depletion, with GAPDH used as a loading control (B). This confirmed PAPPA 
knockdown at the protein level in cells transfected with PAPPA siRNA. Three 
technical repeats were performed for each qPCR reading and two biological repeats 
were performed, with one representative immunoblot shown. Error bars represent 
the SEM. Statistical significance was assessed using an unpaired Student’s t test. *** 
p < 0.001.  
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4.3.3 siRNA Knockdown in MSCs undergoing osteogenic differentiation 
Having confirmed the capacity of the PAPPA siRNA to reduce PAPPA mRNA and 
protein expression, the next step was to perform knockdowns using hMSCs from 
healthy donors (Table 4.2). hMSCs from three healthy individuals (purchased from 
Lonza, UK.) were expanded under standard tissue culture conditions to 80% 
confluency and then transfected with siRNA targeting PAPPA or NT siRNA (Chapter 
2.11.3). Untransfected cells were used as a control to confirm successful 
differentiation.  
 
 
 
 
 
 
 
Table 4.2  
hMSCs used for siRNA knockdown experiments. All were iliac crest bone marrow 
aspirates from young, healthy, non-OA individuals, purchased from Lonza UK.  
 
PAPPA was successfully knocked down in hMSCs relative to expression in the NT 
siRNA transfection control (Figure 4.3). The knockdown was observed following the 
48 hour transfection (day 0 of osteogenic differentiation) and persisted through to 
day 10 of differentiation. Depletion of PAPPA was observed at the protein level, as 
assessed by immunoblotting, with quantification relative to the GAPDH loading 
control confirming that this was not a result of unequal protein loading (Figure 4.4). 
 
Donor Sex Age when aspirate 
was taken (years) 
2454E Female 24 
26601 Female 41 
26798 Male 23 
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Figure 4.3 
PAPPA expression in hMSCs differentiating into osteoblasts following siRNA 
knockdown.  Gene expression was quantified using qPCR and normalised to the 
corresponding non-targeting siRNA control for each time point. Gene expression was 
significantly decreased at all time points relative to the non-targeting control. D0 = 
day 0, D3 = day 3 and D10 = day 10. n = Three independent non-OA donors (Lonza, 
UK.). Three technical repeats per donor per time point. qPCR was carried out as 
standard, with three technical replicates. Error bars indicate the SEM and statistical 
significance was assessed using the Mann-Whitney U test. *** p < 0.001. 
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Figure 4.4 
Knockdown of PAPPA protein in hMSCs on day 3 of osteogenic differentiation 
following PAPPA siRNA knockdown. Immunoblotting confirmed protein depletion in 
three independent non-OA donors (A = 2454E, B = 26601 & C = 26798). Each of the 
three knockdowns resulted in a decrease in PAPPA protein levels. The loading 
control, GAPDH, is shown directly beneath the corresponding knockdowns. The 
untransfected control is denoted by ‘un’. Densitometry to calculate the adjusted 
density relative to untransfected cells was performed using IMAGEJ software in 
order to account for unequal protein loading (D). The relative adjusted densities were 
combined for the three donors and confirms successful protein knockdown in cells 
transfected with PAPPA siRNA. NT (non-targeting siRNA control). For image 
analysis the freeware ImageJ v1.4 was used (accessed via the NIH website 
(http://rsb.info.nih.gov/ij). Statistical significance was assessed using an upaired 
Student’s t test and error bars indicate the SEM. * p < 0.05; ** p < 0.01. 
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Having confirmed the successful knockdown of PAPPA at the mRNA and protein 
level, the next necessity was to ensure the osteogenic differentiation had been 
successful. A key feature of osteogenic differentiation of MSCs using the in vitro 
monolayer model is alkaline phosphatase transcription and protein activity, which 
peaks between days 5 to 14 of differentiation [139]. Expression of the ALPL gene, 
coding for alkaline phosphatase, was measured on days 0, 3 and 10 of osteogenesis 
by qPCR and this confirmed significantly increased expression in the untransfected 
and NT controls compared to PAPPA siRNA transfected cells (Figure 4.5). Increased 
translation of the protein was investigated using Fast blue RR salts as an indicator of 
alkaline phosphatase activity (Figure 4.6). Quantification of staining in the three 
donors on day 3 of differentiation confirmed the enzyme’s activity, indicating 
osteogenic differentiation was successful.  
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Figure 4.5 
Alkaline phosphatase (ALPL) gene expression in hMSCs undergoing osteogenic 
differentiation following siRNA transfection. Gene expression was quantified for each 
condition on days 0 (D0), 3 (D3) & 10 (D10) of differentiation using qPCR and 
normalised to the 18S, GAPDH and HPRT1 housekeeping genes in the hMSCs from 
the three Lonza donors (A = 2454E, B = 26601 & C = 26798). ALPL expression 
increased in all three donors by day 10, indicating successful osteogenic 
differentiation. Three technical repeats were performed per time point, per condition 
and qPCR was performed as standard, including three technical replicates. Error 
bars represent the SEM. Statistical significance was assessed using an unpaired 
Student’s t test. * p < 0.05; ** p < 0.01; *** p < 0.001.  
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Figure 4.6 
Tissue nonspecific alkaline phosphatase (TNAP) staining of hMSCs on day 3 of 
osteogenic differentiation. After being fixed in 4% paraformaldehyde, hMSCs from 
three donors (A = 2454E, B = 26601 & C = 26798) were stained for alkaline 
phosphatase enzymatic activity using TNAP staining (required components: napthol 
AS-MX-phosphate, dimethylformamide and Fast blue RR salt) on day 3 of 
osteogenesis. This macroscopically indicated successful differentiation, leading to 
increased alkaline phosphatase translation and therefore activity, in untransfected 
cells (un) and cells transfected with non-targeting (NT) siRNA. Staining appears far 
weaker in PAPPA siRNA transfected cells. Quantification of the percentage of the 
area stained, defined as the number of pixels over a user-determined threshold 
intensity, was measured using ImageJ V1.4 software (accessed via the NIH website 
(http://rsb.info.nih.gov/ij) and is shown in panel D relative to untransfected cells. 
Statistical significance was assessed using the Student’s t test; * p < 0.05. 
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Having confirmed successful osteogenic differentiation, the next step was to assess 
the osteogenic differentiation capacity of PAPPA siRNA transfected cells in 
comparison to the NT siRNA control cells. To achieve this, expression of ALPL, 
COL1A1 and RUNX2 relative to NT siRNA were investigated by qPCR. All three 
genes have a well-defined role in osteogenesis and are induced following osteogenic 
differentiation of hMSCs [140]. Expression of ALPL was re-analysed as, in this phase 
of the experiment, we were attempting to investigate the osteogenic capacity of the 
PAPPA depleted cells as opposed to confirming overall successful differentiation in 
the experiment. mRNA expression of the three osteogenic markers was significantly 
lower in PAPPA siRNA treated cells compared to the NT siRNA control (p ≤ 0.05) 
(Figure 4.7). This therefore suggests osteogenic differentiation is impaired in hMSCs 
following PAPPA depletion.  
 
To further investigate the reduced osteogenic capacity of PAPPA siRNA transfected 
cells, mRNA levels of KLF4 were measured. KLF4 is a neural transcription factor 
identified by Takahashi and Yamanaka as one of the core factors required for 
somatic cell reprogramming to induced pluripotent stem (iPS) cells and is therefore a 
genetic marker of pluripotency [141]. KLF4 expression was significantly higher in 
PAPPA siRNA transfected cells compared to the NT siRNA control on days 3 and 10 
(Figure 4.7). This consequently supports the hypothesis that depletion of PAPPA 
reduces the osteogenic capacity of hMSCs and that these cells, rather than 
differentiation towards a different mesenchymal lineage, maintain their pluripotent 
differentiation capacity.  
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Figure 4.7 
Expression of genetic markers of hMSC differentiation in non-OA hMSCs following 
PAPPA siRNA knockdown.  hMSCs from three separate non-OA donors (Lonza, UK) 
were transfected with non-targeting siRNA, or siRNA targeting PAPPA and cultured 
in osteogenic differentiation media for 10 days. Gene expression of the osteogenic 
markers ALPL (A), RUNX2 (B) and COL1A1 (C), as well as KLF4 (D), a marker of 
pluripotency, were quantified using qPCR and normalised to the corresponding 
expression in the non-targeting siRNA control (y-axis = 1). n = knockdown of three 
independent donors (biological replicates) with three technical replicates each. qPCR 
was performed as standard, including three technical replicates. Error bars represent 
the SEM. Statistical significance was assessed using the Mann-Whitney U test. * p < 
0.05; ** p < 0.01; *** p < 0.001.  
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4.3.4 siRNA Knockdown in MSCs undergoing chondrogenic differentiation 
Having identified that PAPPA depletion results in impaired osteogenic differentiation 
of hMSCs, it was then of interest to investigate whether differentiation into other cells 
of the synovial joint was impaired. In vitro pellet chondrogenesis was performed 
following siRNA transfection, using hMSCs from the three same donors as in 4.3.2, 
as described in Chapter 2.11.5.  
 
qPCR confirmed successful knock down of PAPPA mRNA in cells following 
transfection and throughout the 10 day chondrogenic differentiation relative to the 
corresponding NT siRNA control (p < 0.001) (Figure 4.8).  Furthermore, the resulting 
levels of protein after the siRNA knockdowns were assessed by immunoblotting and 
PAPPA protein depletion was confirmed in all 3 donors in protein extracted from cells 
on day 3 of chondrogenesis, relative to untransfected and NT siRNA controls (Figure 
4.9). Though the GAPDH loading control indicated unequal quantities of protein 
between conditions, densitometry analysis confirmed the depletion of the PAPPA 
protein relative to the controls (Figure 4.9 D).  
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Figure 4.8  
PAPPA expression in hMSCs differentiating into chondrocytes following siRNA 
knockdown.  Gene expression was quantified using qPCR and normalised to the 
corresponding non-targeting siRNA control for each time point. Gene expression was 
significantly decreased at all time points relative to the non-targeting control. D0 = 
day 0, D3 = day 3 and D10 = day 10. n = Three independent non-OA donors (Lonza, 
UK.), three technical repeats per donor per time point. qPCR was carried out as 
standard, with three technical replicates. Error bars indicate the SEM and statistical 
significance was assessed using the Mann-Whitney U test; *** p < 0.001. 
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Figure 4.9 
Knockdown of PAPPA protein in hMSCs on day 3 of chondrogenic differentiation 
following PAPPA siRNA knockdown. Immunoblots were performed to confirm protein 
depletion in three independent non-OA donors (A = 2454E, B = 26601 & C = 26798). 
Each of the three knockdowns resulted in a decrease in PAPPA protein levels. The 
loading control, GAPDH, is shown directly beneath the corresponding knockdowns. 
The untransfected control is denoted by ‘un’. Densitometry to calculate the adjusted 
density relative to untransfected cells was performed using IMAGEJ software in 
order to account for unequal protein loading (D). The relative adjusted densities were 
combined for the three donors and confirms successful protein knockdown in cells 
transfected with PAPPA siRNA. NT (non-targeting siRNA control). For image 
analysis the freeware ImageJ v1.4 was used (accessed via the NIH website 
(http://rsb.info.nih.gov/ij). Error bars indicate the SEM and statistical significance was 
assessed using an unpaired Student’s t test. ** p < 0.01; *** p < 0.001. 
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In order to confirm successful chondrogenic differentiation of the hMSCs, ACAN 
mRNA expression was quantified by qPCR. ACAN codes for aggrecan, a well-
characterised hyaline matrix molecule, which transiently increases during in vitro 
cartilage development, peaking at differentiation day 14 [142]. ACAN expression 
increased in all three donors under all three conditions, with the highest recorded 
expression relative to the housekeeping genes recorded on day 10 of differentiation 
(Figure 4.10).  
 
Figure 4.10 
Aggrecan (ACAN) gene expression in hMSCs undergoing chondrogenic 
differentiation following siRNA transfection. Gene expression was quantified for each 
condition on days 0 (D0), 3 (D3) & 10 (D10) of differentiation by qPCR and 
normalised to the 18S, GAPDH and HPRT1 housekeeping genes in the hMSCs from 
the three Lonza donors (A = 2454E, B = 26601 & C = 26798). ACAN expression 
increased in all three donors by day 10, indicating successful chondrogenic 
differentiation. Three technical repeats were performed per time point, per condition 
and qPCR was performed as standard, including three technical replicates. Error 
bars represent the SEM. Statistical significance was assessed using an unpaired 
Student’s t test. * p < 0.05. 
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Having confirmed successful PAPPA knock-down and chondrogenic differentiation, 
we next sought to interrogate the chondrogenic differentiation capacity of PAPPA 
siRNA transfected cells in comparison to the NT siRNA control cells. This was 
achieved by analysis of ACAN and SOX9 by qPCR. Expression of ACAN was re-
analysed as, in this phase of the experiment, we were attempting to investigate the 
chondrogenic capacity of the PAPPA depleted cells relative to the NT siRNA 
controls, as opposed to confirming overall successful differentiation in the 
experiment. SOX9 was selected along with ACAN as it is a chondrogenic lineage 
marker [143]. No significant difference was found at any time point when analysing 
ACAN expression relative to the NT siRNA control (Figure 4.11 A). A significant 
increase in SOX9 on day 10 of differentiation was noted, however (p = 0.007) (Figure 
4.11 B). This suggests that, unlike during osteogenesis, PAPPA depletion in hMSCs 
does not prevent chondrogenic differentiation and may actually result in enhanced 
chondrogenic capacity.  
 
In order to interrogate the chondrogenic capacity of PAPPA depleted hMSCs further, 
gene expression of COL10A1 was also quantified.  Col10A1 is expressed by 
hypertrophic chondrocytes, is upregulated in OA cartilage and the encoded protein 
(type X collagen) is required for the developmental process of endochondral 
ossification [144].  No significant difference was seen in COL10A1 expression on 
days 0 or 10 of differentiation between PAPPA siRNA and NT siRNA transfected 
cells (Figure 4.11 C). Overall, this investigation revealed that, in vitro, PAPPA 
depletion does not inhibit the chondrogenic capacity of hMSCs, and may increase 
differentiation potential towards normal, non-hypertrophic, chondrocytes.  
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Figure 4.11 
Expression of genetic markers of chondrogenic differentiation in hMSCs following 
PAPPA siRNA knockdown. hMSCs from three separate non-OA donors (Lonza, UK) 
were transfected with non-targeting siRNA, or siRNA targeting PAPPA and cultured 
in chondrogenic differentiation media for 10 days (donor information Table 4.1). 
Gene expression of chondrogenic markers ACAN (A), SOX9 (B) and COL10A1 (C) 
were quantified using qPCR and normalised to the corresponding expression in the 
non-targeting siRNA control (y-axis = 1). No difference in expression of ACAN and 
COL10A1 was detected at any time point, while an increase in SOX9 expression 
was seen on day 10 in PAPPA siRNA transfected cells. n = knockdown of three 
independent donors (biological replicates) with three technical replicates each. qPCR 
was performed as standard, including three technical replicates. Error bars represent 
the SEM. Statistical significance was assessed using the Mann-Whitney U test. ** p 
< 0.01. 
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4.3.5 PAPPA expression in OA bone stratified by rs4836732 genotype 
Having confirmed a potential role for PAPPA in synovial joint development in an in 
vitro model of osteogenesis, it was subsequently of interest to investigate PAPPA 
expression in OA bone.  Stratification by rs4836732 genotype is necessary to 
investigate if an eQTL is operating at this locus. Dr Amanda Villavilla of Prof. 
Loughlin’s group (Institute of Cellular Medicine, Newcastle University) extracted and 
expanded osteoblasts from OA patients who had undergone joint arthroplasty, 
before then extracting nucleic acids. I then genotyped the samples (Chapter 2.5.2) 
and performed qPCR (Chapter 2.13.2). Table 4.3 provides a summary of donor 
information, including genotype at rs4836732. qPCR primer and probe sequences 
can be found in Appendix A: Table A.4, and the assay positions are detailed in 
Figure 3.11 (housekeeping genes) and Figure 3.12 (PAPPA).  
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Table 4.3 
Demographic data and rs4836732 genotype in OA patients used for PAPPA 
expression analysis in bone. 
 
 Sample Number Sex Affected joint rs4836732 genotype 
5918 Male Hip TT 
5928 Male Knee CT 
5930 Male Hip CT 
5931 Male Knee CC 
5935 Male Knee TT 
5937 Female Knee TT 
6002 Male Knee CC 
6018 Male Knee CT 
6019 Female Knee CC 
6062 Female Knee TT 
6111 Male Knee CT 
6132 Female Hip TT 
6168 Female Hip CT 
6192 Female Knee CT 
6197 Male Knee CC 
6201 Male Hip CT 
6209 Male Knee CT 
6213 Female Knee CT 
6222 Female Knee CT 
6223 Male Knee CT 
6241 Female Knee CT 
6247 Male Knee TT 
6252 Female Hip CC 
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qPCR of PAPPA expression in OA bone did not yield any statistically significant 
differences when stratified by rs4836732 genotype (Figure 4.12). Analysis according 
to the genotype at the association signal risk strata, female hip, by rs4836732 
genotype was not possible owing to low sample numbers (Table 4.3). When stratified 
by overall expression, irrespective of genotype, there was no statistically significant 
gene expression in any individual stratum (Figure 4.13).  
 
 
 
 
 
 
 
 
 
 
Figure 4.12 
PAPPA expression in OA bone stratified according to rs4836732 genotype. Gene 
expression is shown relative to 18S, GAPDH and HPRT1 housekeeper expression. 
A box and whisker plot is shown representing the interquartile range (IQR) with 
median, 25th and 75th percentile, minimum and maximum values. No significant 
difference was seen in PAPPA gene expression between the three genotypes. 
Statistical significance was assessed using the Mann-Whitney U test for two-way 
comparisons and a one-way analysis of variance for a comparison of more than two 
groups. n = the number of OA patients in the comparison group.  
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Figure 4.13 
PAPPA expression in OA bone stratified according to sex (A), affected joint (B) and 
both sex and affected joint (C). Gene expression is shown relative to 18S, GAPDH 
and HPRT1 housekeeper expression. A box and whisker plot is shown representing 
the interquartile range (IQR) with median, 25th and 75th percentile, minimum and 
maximum values. No significant difference was seen in PAPPA gene expression in 
any of the comparison groups. Statistical significance was assessed using the Mann-
Whitney U test for two-way comparisons, using all possible comparison 
combinations, and a one-way analysis of variance for a comparison of more than two 
groups. n = the number of OA patients in the comparison group.  
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4.4 Discussion 
The aim of this chapter was to investigate the role of PAPPA in human synovial joint 
development by using lineage-specific hMSC differentiation as an in vitro model of 
joint embryogenesis. Having not identified any evidence for rs4836732 acting as an 
eQTL in end-stage OA tissues, I hypothesised that the SNP mediates disease risk by 
functioning during joint development. Of the genes within the association region, 
PAPPA is arguably the most promising candidate and so, this chapter sought to 
interrogate the role of the gene in a model of human skeletogenesis.  
 
I utilised lineage-specific hMSC differentiation as an in vitro model of synovial joint 
development in order to explore the functional role of PAPPA in human joint cell 
differentiation. I depleted PAPPA gene and protein expression in hMSCs using 
siRNA before inducing osteogenic or chondrogenic differentiation. This confirmed the 
studies performed in murine models, finding that PAPPA depletion resulted in 
impaired osteogenesis, likely resultant of aberrant IGF regulation. Chondrogenesis, 
however, was not inhibited when assessed by qPCR analysis of chondrogenic 
markers. Conversely, an increase in SOX9 expression was seen on day 10 of 
chondrogenesis in PAPPA depleted cells. Given that SOX9 is an upstream regulator 
of ACAN, this suggests PAPPA deletion leads to enhanced chondrogenesis [145].  
As such, these experiments suggest PAPPA is functional during the differentiation of 
cell types which have essential roles in skeletogenesis.  It is well-characterised that 
aberrant skeletogenesis, for example in the instance of congenital hip dysplasias, 
results in increased risk of OA [136]. Consequently, based on the above findings, I 
hypothesised that the rs4836732 signal may increase the risk of female hip OA by 
acting as a cis-eQTL, modulating PAPPA expression during joint development. 
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Although a role for PAPPA in an in vitro model of skeletogenesis has been identified, 
further interrogation into the in vivo function of PAPPA during human embryogenesis 
is not possible. However, given that global mouse PAPPA knock outs display age-
associated trabecular deficiencies, it is possible that aberrant PAPPA expression, 
regulated by the rs4836732 association signal, may also contribute to the abnormal 
bone remodelling present in end-stage OA [107].  Osteoblasts isolated from the bone 
of end-stage OA patients undergoing joint arthroplasty were therefore used to 
analyse overall PAPPA expression, and this data was then stratified by rs4836732 
genotype. Though no statistically significant difference in expression was identified in 
individuals homozygous for the C risk allele, the small sample size and limitations 
caused by inter-individual differences when studying overall gene expression could 
be making any true correlations. Consequently, it would be prudent for future 
research to analyse allelic expression imbalance of PAPPA in bone according to 
rs4836732 genotype.  
 
In Chapters three and four, I have functionally analysed the rs4836732 female hip-
associated OA signal that emerged from the arcOGEN GWAS [92]. I have 
concluded, through both data imputation and luciferase reporter assay studies, that 
the association signal is the most compelling candidate driving the increased OA 
risk. I have not found any evidence of a correlation between the association SNP 
genotype and expression of candidate genes within the LD region (ASTN2, PAPPA 
and TRIM32) in end-stage disease tissue.  Based on published studies, I have 
identified PAPPA as the most compelling gene candidate and subsequently, I have 
identified a functional role for PAPPA in hMSC differentiation into cell types present 
in the synovial joint. Taken together, the data presented in these chapters therefore 
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support the hypothesis that the association signal may regulate OA risk during joint 
development and cell differentiation, as opposed to in end-stage disease tissue. 
Owing to the difficulties presented in studying gene expression during human 
skeletogenesis, I consequently decided to pursue alternative research targets during 
the remainder of my PhD.  
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Chapter 5: Identification of hip and knee OA patients with increased 
cartilage inflammation using methylation analysis by 
pyrosequencing 
 
5.1 Introduction 
A high-density CpG methylation array, which analysed cartilage DNA from 23 hip OA 
patients, 73 knee OA patients and 21 hip control patients with a neck of femur 
fracture (NOF), identified numerous differentially methylated loci (DMLs) between the 
patient cohorts [43]. Interestingly, hip OA samples formed two distinctive clusters, 
displaying a total of 15,239 DMLs enriched for genes involved in inflammation and 
immunity. Knee OA samples were also found to form two distinct clusters, though 
less defined than in the hip samples. In knee OA, 5,769 DMLs were identified, many 
of which are within genes coding for inflammatory factors. This indicates 
inflammation is crucial to OA pathogenesis and potentially presents an exciting 
therapeutic opportunity for anti-inflammatory treatments in OA. In order to carry 
forward these intriguing findings, which were generated by our group, it is vital to 
identify whether the inflammatory signature is present in blood, thus enabling for 
patient stratification in future clinical trials and patient diagnostics.  
 
In light of this, I sought to create pyrosequencing assays to CpG sites which have 
the capacity to differentiate OA cartilage samples into the inflammatory or non-
inflammatory clusters. The principle being that it would then be possible to negate 
the requirement for a costly and time-consuming genome-wide methylation array, 
and new samples could be easily clustered solely using methylation analysis by 
pyrosequencing. This would therefore provide the capacity to further interrogate the 
inflammatory status of the cartilage samples, and of matched blood, in an attempt to 
143 
 
better comprehend the mechanism and implications of the increased inflammation. 
This chapter therefore focuses on the identification of CpG sites which are able to 
discriminate between the non-inflammatory and inflammatory cluster, creation of a 
logistic function in order to predict cluster membership using methylation at these 
sites and the design of pyrosequencing assays against the selected CpGs. This 
would consequently enable quantification of CpG methylation in new cartilage DNA 
samples and subsequent prediction of cluster membership. 
 
Further to differential methylation, quantitative real-time PCR (qPCR) of non-
inflammatory and inflammatory OA hip samples confirmed these subgroups to not 
only display epigenetic differences, but to also be transcriptiomically distinct [121]. In 
the inflammatory group, promoter hypomethylation of inflammatory factors was 
associated with increased expression of these genes, as was discussed in Chapter 
1.6.3. Consequently, this chapter also sought to replicate and confirm these findings 
in cartilage samples available from the microarray, and to subsequently analyse 
inflammatory gene expression in new hip cartilage samples to assist in the validation 
of our new methylation assays and discriminant function. Moreover, this chapter 
aimed to also analyse inflammatory gene expression in OA knee samples present on 
the microarray, in order to confirm whether the transcriptome of knee OA 
inflammatory samples also differs when compared to non-inflammatory knee OA 
samples. 
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5.2 Aims 
This chapter sought to assist in the investigation of an inflammatory subgroup of OA 
patients who have altered methylation of inflammatory genes, by creating a method 
to determine cluster membership of new patients. It also intended to further 
interrogate the inflammatory transcriptome of patients in the divergent methylation 
clusters. This was achieved by:  
• Selection of CpG methylation sites analysed on the high-density CpG 
methylation array for categorisation of new hip OA cartilage samples into the 
non-inflammatory or inflammatory subgroup.  
• Selection of CpG methylation sites analysed on the high-density CpG 
methylation array for categorisation of new knee OA cartilage samples into 
the non-inflammatory or inflammatory subgroup.  
• Creation and testing of multiple logistic regression models predicting cluster 
membership, based on methylation at the selected CpG sites, as determined 
by CpG methylation array, to determine cluster membership in hip and knee 
OA patients, performed with JMP Pro Version 11.2 Statistical Data 
Visualization Software. 
• Design of pyrosequencing assays to the selected hip and knee CpGs for 
analysis of CpG methylation by pyrosequencing. 
• Validation of CpG assays using bisulphite converted DNA from cartilage 
samples analysed on the high-density methylation array. 
• CpG site methylation analysis by pyrosequencing using new cohorts of both 
hip and knee OA patients, with subsequent application of the logistic functions 
to predict cluster membership.  
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• Replication of inflammatory gene expression analysis in hip OA cartilage 
samples analysed on the high-density methylation array.  
• Validation of the multiple logistic regression models predicting cluster 
membership by inflammatory gene expression analysis in new hip OA 
cartilage.  
• Inflammatory gene expression analysis in knee OA cartilage samples 
analysed on the high-density methylation array and in new knee OA cartilage 
samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
5.3 Results 
5.3.1 Selection of CpG sites for cluster differentiation in OA hip cartilage 
CpG sites analysed on the high-density methylation array were assessed according 
to both their p values and β values, in order to determine the best candidates to take 
forward and use to determine cluster membership in OA hip cartilage. Methylation 
data from the array was provided as β values, ranging from 0 (no methylation) to 1 
(100% methylation). Large differences in the average β values between the clusters 
would increase the likelihood of successfully designing pyrosequencing assays that 
have the sensitivity to also discriminate between the clusters, whilst significant p 
values would provide reassurance that the methylation differences are genuine and 
not artefactual. Based on these criteria, cg14818279 and cg03278514 were selected 
(Table 5.1). It is to be noted that the CpG sites were selected based purely on their p 
values and β values when comparing methylation in the non-inflammatory and 
inflammatory subgroups in hip OA cartilage, and their genomic location is entirely 
unrelated to the study.  
 
A subsequent post-publication re-analysis of the CpG methylation array data by our 
group (performed by Andrew Skelton and Dr Louise Reynard; Institute of Cellular 
Medicine, Newcastle University), resulted in the removal of six samples from the 
original 23 hip OA cohort. However, this has not altered the capacity of the selected 
CpG sites to discriminate between the subgroups; Figure 5.1 presents the data for 
the discriminatory capacity of the two CpG in the 17 hip OA patients subsequently 
studied. 
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Table 5.1 
Hip CpG sites selected from the high-density array to take forward for logistic 
analysis. The data shown was generated by Dr Michael Rushton using the Illumina 
Infinium HumanMethylation450 BeadChip array and is derived from all 23 hip OA 
patient samples analysed on the array [43]. The p values shown are those following 
Benjamini-Hochberg correction for multiple testing when comparing methylation in 
the non-inflammatory and inflammatory subgroups. 
 
Probe Chromosome Adjusted p 
value 
Non-inflammatory 
cluster mean β value 
Inflammatory cluster 
mean β value 
cg14818279 5 0.07x10-7 0.32 0.61 
cg03278514 15 0.002 0.71 0.44 
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Figure 5.1 
Analysis of methylation at the selected CpG sites in the revised cohort of 17 hip OA 
patient samples. The data shown was generated by Dr Michael Rushton using the 
Illumina Infinium HumanMethylation450 BeadChip array [43]. The mean cluster β 
values and p values are shown in panel (A), following removal of six of the original 
cohort of 23 patients. β values for the 17 patients are plotted in panel (B) according 
to the inflammatory subgroup for both CpG sites. Each data point represents a single 
patient sample; horizontal lines and error bars show the mean ± SEM. Statistical 
significance was assessed using a Mann-Whitney U test. *** p ≤ 0.001. Non-
inflammatory n = 10, inflammatory n = 7 (where n = number of patient samples in 
each comparison).  
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5.3.2 Logistic regression modelling to predict hip cartilage inflammatory 
cluster membership 
Having identified CpG sites which appear to discriminate between the inflammatory 
subgroups in hip OA cartilage samples, based on the β values from the high-density 
methylation array, I then sought to create a logistic function utilising these CpG sites 
in order to predict cluster membership for future samples. Statistical analyses were 
performed with JMP Pro Version 11.2 Statistical Data Visualization Software with the 
assistance of Dr Dennis Lendrem (Institute of Cellular Medicine).  
 
A multiple logistic regression model predicting cluster membership was built using β 
values at both CpG sites from the cohort of 10 non-inflammatory and 7 inflammatory 
cluster patients analysed on the high-density methylation array.  This model  is a 
multivariable function which predicts classification, in this case the non-inflammatory 
or inflammatory hip OA groups, based on the observed values of continuous 
variables, in this case methylation at the selected CpG sites.  A model using 
cg14818279 and cg03278514 methylation permitted successful prediction of cluster 
membership using these two sites (p ≤ 0.001) (Figure 5.2).  Consequently, a full 
logistic regression model using a linear combination of both cg14818279 and 
cg03278514 was created and demonstrates separation of clusters according to 
methylation at these sites (Figure 5.3).  
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Figure 5.2 
Logistic regression plots for the selected CpG sites: cg14818279 (A) and 
cg03278514 (B).  The y axis shows the probability of belonging to cluster 1 (non-
inflammatory) according to methylation at cg14818279 (A) or cg03278514 (B), and 
refers only to the blue regression line, not to the individual data points. Samples are 
plotted according to the β value at cg14818279 (A) or cg03278514 (B), demarcated 
on the x axis, as determined by the high-density CpG methylation array [43]. Each 
data point represents a single sample, where blue donates non-inflammatory cluster 
membership (cluster 1; n = 10) and red the inflammatory cluster samples (cluster 2; 
n = 7). The logistic regression analyses show that methylation at cg14818279 and 
cg03278514 both provide perfect separation of inflammatory and non-inflammatory 
samples (p ≤ 0.001). 
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Figure 5.3 
Hip OA cartilage cluster separation achieved using a linear combination of 
methylation at cg03278514 and cg14818279. Hip sample β values from the high-
density CpG methylation array are plotted for cg03278514 (x axis) and cg14818279 
(y axis). Non-inflammatory samples are denoted in green (cluster 1; n = 10) and 
inflammatory samples in red (cluster 2; n = 7).  Methylation at these two sites 
provides clear separation of samples into the inflammatory and non-inflammatory 
clusters.  
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While the logistic regression model permits prediction of cluster membership, 
inspection of the plotted data permitted the creation of a simple heuristic decision 
tool. This would enable the cluster prediction model to be applied more easily by 
other researchers. Consequently, a heuristic cluster index (CI), was formulated using 
hip OA cartilage β values from the high-density CpG methylation array (Figure 5.4).  
Methylation β values were converted to percentage methylation values (0 = 0% 
methylation and 1 = 100% methylation) in order to create the CI. This allows for the 
CI to be applied to future samples, which will be analysed by pyrosequencing, a 
method that provides CpG methylation as a percentage value. Subsequent 
application of the CI successfully predicted cluster membership of all 17 hip OA 
samples, with zero misclassification (Figure 5.5). 
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Figure 5.4 
The cluster index (CI) created to predict hip cluster membership. The CI is based on 
methylation at cg14818279 and cg03278514 in hip OA cartilage, as determined 
based on the β values previously generated using the high-density CpG methylation 
array. The CI dictated that when methylation at cg14818279 is greater than 50% and 
at cg03278514 is less than 59%, samples are assigned as inflammatory (cluster 2). 
If methylation at cg14818279 is less than 60% and is greater than 50% at 
cg03278514, the sample is assigned as non-inflammatory (cluster 1). If methylation 
values fit neither category, the sample is not classified as belonging to either 
subgroup (unknown). 
 
Figure 5.5 
JMP screenshot of cluster index (CI) cluster membership predictions for patients 
analysed on the high-density CpG methylation array. The CI correctly identified 
10/10 samples as non-inflammatory (cluster 1) and 7/7 as inflammatory (cluster 2).  
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5.3.3 Design of pyrosequencing assays to determine methylation at 
cg14818279 and cg03278514 
Having identified two CpGs that can successfully determine the inflammatory cluster 
of hip OA cartilage, the next step was to design pyrosequencing assays to 
cg14818279 and cg03278514 (Chapter 2.14.1).  Primer sequences for the assays 
can be found in Appendix A: Table A.5. 
 
After designing the primer sequences, validation of the assays was performed. This 
was necessary as pyrosequencing assays use a third primer, known as the 
sequencing primer, along with the forward and reverse primers of a standard PCR. 
The sequencing primer binds adjacent to the CpG and then extends over the site in 
the direction of the captured biotinylated primer. It is consequently necessary to 
validate the ability of the sequencing primer to quantify methylation at the CpG site. 
Validation was performed, in duplicate, using genomic DNA (gDNA) extracted from 
the cartilage of neck of femur fracture (NOF) patients analysed on the original 
genome-wide methylation array (patients used are listed in the tables in Figure 5.6). 
The gDNA was bisulphite treated, to convert unmethylated cytosine bases to 
thymine bases, allowing the reaction to quantify methylation at the sites. Comparison 
of the detected proportion of protected cytosine bases to the expected percentage, 
as determined by the high-density array, therefore allows for assay validation 
(Chapter 2.14.2; Figure 5.6). A positive correlation was seen for the observed 
methylation values, each with a goodness of fit r2 ≥ 0.85, and so the assays were 
deemed suitable for further use.  
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Figure 5.6 
Validation of pyrosequencing assays used for methylation quantification in hip 
cartilage at CpG sites cg03278514 (A) and cg14818279 (B). gDNA from NOF patient 
cartilage samples analysed on the high-density methylation array were bisulphite 
converted and the region surrounding the selected CpG site amplified by PCR. The 
average observed methylation levels as determined by the pyrosequencer, were 
then compared to the expected methylation β values from the high-density 
methylation array. The table lists the patient sample, β value from the array, 
expected methylation value (derived from the β value) and average observed 
methylation value, as determined by pyrosequencing.  The data for both CpG assays 
is also presented as a graph, with the corresponding expected methylation value and 
average observed methylation value for each patient represented in the same colour. 
Statistical analyses confirmed both validations had a positive correlation, with a 
goodness of fit r2 ≥ 0.85. 
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5.3.4 Cluster membership analysis of new hip OA cartilage samples  
The pyrosequencing assays validated in Chapter 5.3.3 were subsequently used to 
determine methylation at cg14818279 and cg03278514 in a cohort of 25 new hip OA 
cartilage DNA samples, with subsequent application of the CI (Chapter 5.3.2) to 
determine inflammatory cluster membership (Table 5.2). This identified 15 samples 
as non-inflammatory (cluster 1), 6 as inflammatory (cluster 2), but was unable to 
classify 4 of the samples. A scatter plot analysis of the average methylation values at 
cg14818279 and cg03278514 according to the predicted cluster membership is 
shown in Figure 5.7.  
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
 
 
Table 5.2 
Table showing methylation values at cg14818279 and cg03278514 in bisulphite 
converted OA hip cartilage DNA from 25 new patients, along with cluster 
membership as predicted using the CI. Cluster 1 denotes the non-inflammatory 
subgroup and cluster 2 the inflammatory. ‘Unknown’ indicates patients that the CI 
was unable to classify.  
Patient cg14818279 
average 
methylation (%) 
cg03278514 
average 
methylation (%) 
Predicted cluster 
according to CI 
4963 43 50.5 Cluster 1 
5072 29 91.5 Cluster 1 
5152 42.5 69 Cluster 1 
5216 29 83 Cluster 1 
5268 45 82 Cluster 1 
5343 61.5 37.5 Cluster 2 
5405 33 62.5 Cluster 1 
5430 43 58.5 Cluster 1 
5431 49 58 Cluster 1 
5483 63.5 51.5 Cluster 2 
5667 37 94 Cluster 1 
5707 49 70.5 Cluster 1 
5749 45.5 48 Unknown 
5756 46 48.5 Unknown 
5865 47 60 Cluster 1 
5866 67.5 53.5 Cluster 2 
5870 40 92.5 Cluster 1 
5924 68 59 Unknown 
5977 70 40.5 Cluster 2 
6024 64.5 51.5 Cluster 2 
6101 24.5 49 Unknown 
6109 30.5 64 Cluster 1 
6110 27.5 89 Cluster 1 
6129 40 53 Cluster 1 
6130 52 50 Cluster 2 
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Figure 5.7 
Average methylation, as determined by pyrosequencing, at cg03278514 and 
cg14818279 for the new OA hip cartilage patient samples. The 15 samples predicted 
by the CI to belong to the non-inflammatory cluster (cluster 1) are denoted in green 
and the six inflammatory samples in red (cluster 2). The y axis indicates average 
methylation at cg14818279 and the x axis, cg03278514. 
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5.3.5 Differences in inflammatory gene expression between the predicted hip 
clusters  
Having created a discriminant function based on methylation analysis by 
pyrosequencing to predict cluster membership of new hip cartilage samples, I next 
sought to test for differences in inflammatory gene expression. I first replicated the 
inflammatory gene expression qPCR performed by Rushton et al (2015) on hip OA 
patient samples analysed on the array (Chapter 2.17) [121]. This was performed 
using RNA from the cartilage of 10 of the revised cohort of 17 hip OA patients 
analysed on the array, as RNA was only available from these individuals. (Figure 
5.8). Primer sequences for the assays are listed in Appendix A: Table A.6. 
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Figure 5.8 
Expression of inflammation-associated genes in hip OA cartilage in five non-
inflammatory cluster patients and five inflammatory cluster patients who were 
analysed on the high-density methylation array. Gene expression was measured by 
qPCR in five genes previously shown to display differential expression between the 
clusters [119]. Data are presented as 2−ΔΔCt, having been normalised to the GAPDH 
housekeeper gene. Error bars represent the SEM. Statistical significance was 
assessed using the Student’s t test. *p<0.05.  
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Subsequently, expression of these genes was analysed by qPCR using RNA 
extracted from the cartilage of the 21 new hip OA patients, who had been 
subgrouped using the CI (Figure 5.9). All five genes demonstrated greater 
expression in the samples that had been subgrouped into the inflammatory cluster 
and for IL1A, IL6 and TNF the increases were significant. This data therefore 
supports the capacity of the CI to place hip OA cartilage samples into the non-
inflammatory or inflammatory cluster.   
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Figure 5.9 
Expression of inflammation-associated genes in the 21 new hip OA patients who had 
been categorised into the non-inflammatory or inflammatory cluster using the CI, 
based on methylation at cg14818279 and cg03278514. Gene expression was 
measured by qPCR and is presented as 2−ΔΔCt, having been normalised to the 
GAPDH housekeeper gene. Error bars represent the SEM. Statistical significance 
was assessed using the Student’s t test. *p<0.05 ** p < 0.01; *** p < 0.001. Non-
inflammatory n = 15, inflammatory n = 6 (where n = number of samples in each 
comparison). 
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5.3.6 Selection of CpG sites for cluster differentiation in OA knee cartilage 
Despite both forming distinct non-inflammatory and inflammatory clusters, the knee 
and hip cartilage methylomes displayed clear heterogeneity when analysed by high-
density CpG methylation array [43]. As such, it was not possible to use the same 
cluster-differentiating CpG sites in hip and knee cartilage and separate sites had to 
be identified for subgrouping the knee OA patients. Consequently, CpG sites 
analysed on the array in 73 knee OA cartilage samples were assessed according to 
both their p values and β values, in order to determine the best candidates to design 
pyrosequencing assays to. Based on these criteria, cg12245706 and cg21944234 
were selected (Table 5.3).  
 
As for our hip samples, subsequent analysis of the array data by our group resulted 
in 14 of the 73 knee OA samples being removed from the data set. Re-analysis of 
the data for the 59 remaining samples confirmed the capacity of the selected CpG 
sites to still discriminate between the inflammatory subgroups (Figure 5.10).  
 
 
 
 
 
 
 
 
164 
 
 
 
Table 5.3  
Knee CpG sites selected from the high-density array to take forward for logistic 
analysis. The data shown was generated by Dr Michael Rushton using the Illumina 
Infinium HumanMethylation450 BeadChip array and is derived from all 73 of the 
knee OA patient samples [43]. The p values shown are those following Benjamini-
Hochberg correction for multiple testing when comparing methylation in the non-
inflammatory and inflammatory subgroups. 
 
 
 
 
 
 
Probe Chromosome Adjusted p 
value 
Non-inflammatory 
cluster mean β value 
Inflammatory cluster 
mean β value 
cg12245706 2 4.08E-11 0.34 0.53 
cg21944234 3 7.01E-11 0.29 0.48 
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Figure 5.10 
Analysis of methylation at the selected CpG sites in the revised cohort of 59 knee 
OA patient samples. The data shown was generated by Dr Michael Rushton using 
the Illumina Infinium HumanMethylation450 BeadChip array [43]. The mean cluster β 
values and p values are shown in panel (A), following the removal of 14 of the 
original 73 patients. The β values for the 59 patients are plotted in panel (B), 
according to the inflammatory subgroup, for both CpG sites. Each data point 
represents a single patient sample; horizontal lines and error bars show the mean ± 
SEM. Statistical significance was assessed using a Mann-Whitney U test. *** p ≤ 
0.001. Non-inflammatory n = 32, inflammatory n = 27 (where n = number of patient 
samples in each comparison).  
 
 
Probe Chromosome p value Non-inflammatory 
cluster mean β value
Inflammatory cluster 
mean β value
cg12245706 2 < 0.0001 0.37 0.57
cg21944234 3 < 0.0001 0.43 0.53
A.
B. 
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5.3.7 Logistic regression modelling to predict knee cartilage inflammatory 
cluster membership 
Logistic regression analyses were performed with the two selected CpG sites, based 
on the β values for the 59 samples analysed on the high-density methylation array, in 
order to assess their capacity to predict inflammatory cluster membership in knee 
OA cartilage.  Statistical analyses were performed with JMP Pro Version 11.2 
Statistical Data Visualization Software with the assistance of Dr Dennis Lendrem 
(Institute of Cellular Medicine). 
 
Stepwise discriminant analysis identified both cg12245706 and cg21944234 to 
successfully predict cluster membership to a statistically significant degree (p < 0.05) 
(Figure 5.11).  A linear combination of both cg12245706 and cg21944234 
demonstrates separation of the inflammatory clusters according to methylation at 
these sites, though the separation is not total and a degree of overlap is apparent 
(Figure 5.12).  
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Figure 5.11 
Logistic regression plots for the selected CpG sites: cg12245706 (A) and 
cg21944234 (B).  The y axis shows the probability of belonging to cluster 1 (non-
inflammatory) according to methylation at cg12245706 (A) or cg21944234 (B), and 
refers only to the blue regression line, not to the individual data points. Samples are 
plotted according to the β value at cg12245706 (A) or cg21944234 (B), demarcated 
on the x axis, as determined by high-density CpG methylation array. Each data point 
represents a single sample, where red donates non-inflammatory cluster 
membership (cluster 1; n = 32) and blue the inflammatory cluster samples (cluster 2; 
n = 27). The logistic regression analyses show that methylation at cg12245706 and 
cg21944234 both provide good separation of inflammatory and non-inflammatory 
samples (p < 0.05).  
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Figure 5.12 
Knee OA cartilage cluster separation achieved using a linear combination of 
methylation at cg12245706 and cg21944234. The 59 patients analysed on the high-
density CpG methylation array are plotted according to their β values at cg12245706 
(x axis) and cg21944234 (y axis). Non-inflammatory samples are denoted in green 
(cluster 1; n = 32) and inflammatory samples in red (cluster 2; n = 27). 
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5.3.8 Design of pyrosequencing assays to determine methylation at 
cg12245706 and cg21944234 
Having identified two CpGs that can discriminate between the knee OA cartilage 
inflammatory clusters, the next step was to design pyrosequencing assays to 
cg12245706 and cg21944234 (Chapter 2.14.1).  Primer sequences for the assays 
can be found in Appendix A: Table A.5.  
 
As discussed when previously designing pyrosequencing assays to the selected hip 
CpG sites (Chapter 5.3.3), it was necessary to validate the assays to ensure the 
sequencing primer was able to correctly quantify methylation at the CpG site. 
Validation was performed, in duplicate, using gDNA extracted from the cartilage of 
neck of NOF patients analysed on the genome-wide methylation array (Chapter 
2.14.2; patients are listed in the tables in Figure 5.13). Both validations had a 
positive correlation, with r2 values of ≥ 0.91, and were therefore deemed suitable for 
use. 
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Figure 5.13 
Validation of pyrosequencing assays used for methylation quantification in knee 
cartilage at CpG sites cg12245706 (A) and cg21944234 (B). gDNA from NOF patient 
cartilage samples analysed on the high-density methylation array were bisulphite 
converted and the region surrounding the selected CpG site amplified by PCR. The 
average observed methylation levels as determined by the pyrosequencer 
(observed) were then compared to the expected methylation β values from the high-
density methylation array (expected). The table lists the patient sample, β value from 
the array, expected methylation value (derived from the β value) and average 
observed methylation value, as determined by pyrosequencing, for cg12245706 (A) 
and cg21944234 (B).  The data for both CpG assays is also presented as a graph, 
with the corresponding expected methylation value and average observed 
methylation value for each patient represented in the same colour. Statistical 
analyses confirmed both validations had a positive correlation, with a goodness of fit 
r2 ≥ 0.91. 
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5.3.9 Batch correction of knee cartilage β values and logistic regression 
modelling to predict cluster membership  
The pyrosequencing assays designed to determine methylation at cg12245706 and 
cg21944234 both demonstrated positive correlations between the array methylation 
β value and observed methylation. However, the observed average methylation 
values, as determined by the pyrosequencer, differed to the expected values from 
the array, and these differences were greater at higher β values (Figure 5.13). 
Accordingly, a batch correction was performed from a regression of the difference in 
observed and expected values as a function of the β values, for both cg12245706 
and cg21944234 in the 59 knee samples (Chapter 2.14.3).  This permits batch 
correction of methylation values as determined by the array prior to using the 
prediction model to assign cluster membership for new samples analysed by 
pyrosequencing.  
 
After batch correction, a cluster prediction formula was generated from the 
methylation at cg12245706 and cg21944234 in the 59 knee OA samples analysed 
on the array using the JMP software (JMP, Version 11, SAS Institute Inc., Cary, NC). 
Briefly, the software creates a weighted function minimizing the unexplained 
variability assuming a logistic relationship between the probability of cluster 
membership based on methylation at cg12245706 and cg21944234. This value is 
subsequently used to generate a probability for membership to cluster 1 and for 
membership to cluster 2. When applied to the 59 batch corrected knee samples 
analysed on the array, the prediction formula correctly predicted cluster membership 
in 49 of the 59 knee samples on the array (Figure 5.14).  
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Figure 5.14 
JMP screenshot of cluster membership predictions for knee OA patients analysed on 
the high-density CpG methylation array, according to the prediction formula created 
using JMP (JMP, Version 11, SAS Institute Inc., Cary, NC). This correctly identified 
the cluster of 31/32 non-inflammatory patients (cluster 1), and 18/27 inflammatory 
patients (cluster 2).  
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5.3.10 Cluster membership analysis of new knee OA cartilage samples 
The pyrosequencing assays validated in Chapter 5.3.8 were subsequently used to 
determine methylation at cg12245706 and cg21944234 in a cohort of 24 new knee 
cartilage DNA samples, with subsequent cluster prediction analysis using the 
formula created in Chapter 5.3.9.  This identified 14 samples as non-inflammatory 
(cluster 1) and 10 as inflammatory (cluster 2), as shown in Table 5.4.  A scatter plot 
analysis of the average methylation values at cg12245706 and cg21944234 
according to the predicted cluster membership is shown in Figure 5.15.  
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Table 5.4 
Table showing methylation values at cg12245706 and cg21944234 in bisulphite 
converted OA knee cartilage DNA from 24 new patients, along with cluster 
membership as predicted using the prediction model created using JMP (JMP, 
Version 11, SAS Institute Inc., Cary, NC). Cluster 1 denotes the non-inflammatory 
subgroup and cluster 2 the inflammatory.  
Sample cg12245706 average 
methylation (%) 
cg21944234 
average 
methylation (%) 
Predicted 
cluster 
4851 14 16.5 Cluster 1 
4943 41.5 24.5 Cluster 1 
4969 67 52 Cluster 2 
5003 50.5 36 Cluster 2 
5007 48.5 40.5 Cluster 2 
5012 47 37 Cluster 2 
5057 59 38.5 Cluster 2 
5066 34 33.5 Cluster 1 
5101 59 42.5 Cluster 2 
5139 25 21 Cluster 1 
5140 46 34.5 Cluster 2 
5146 36 27 Cluster 1 
5166 50.5 35.5 Cluster 2 
5272 46 37 Cluster 2 
5654 26 21.5 Cluster 1 
5846 40 11.5 Cluster 1 
5854 42.5 17 Cluster 1 
6014 43.5 18 Cluster 1 
6018 44.5 15.5 Cluster 1 
6052 41.5 16.5 Cluster 1 
6062 20 17 Cluster 1 
6111 41.5 15.5 Cluster 1 
6125 55 42 Cluster 2 
6135 38 32.5 Cluster 1 
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Figure 5.15 
Average methylation, as determined by pyrosequencing, at cg12245706 and 
cg21944234 for the 24 new OA knee cartilage patient samples. The 14 samples 
predicted by the JMP prediction model to belong to the non-inflammatory cluster 
(cluster 1) are denoted in green and the 10 inflammatory samples in red (cluster 2). 
The y axis indicates average methylation at cg21944234 and the x axis, 
cg12245706. 
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5.3.11 Differences in inflammatory gene expression between the predicted 
knee clusters 
As noted earlier, Rushton et al. concluded that the hip cartilage methylome identifies 
an inflammatory subgroup of individuals with hip OA, who also display concurrent 
differential cartilage expression of inflammatory genes [121]. It was therefore of 
interest to investigate whether differential inflammatory gene expression was also 
present in OA knee, as this assessment had not been performed by Rushton et al. 
The expression of the inflammatory genes analysed in hip OA cartilage (Chapter 
5.3.5) were measured by qPCR in available cDNA from 16 non-inflammatory and 11 
inflammatory patients from the revised cohort of 59 who had been analysed on the 
high-density array (Chapter 2.17). For primer sequences see Appendix A: Table A.6. 
CXCR2 and IL1A displayed significantly higher expression in the inflammatory 
cluster patients, while expression of CCL5, IL1B, IL6 and TNF was not significantly 
different between the two clusters (Figure 5.16).   
 
Analysis of the new knee OA cartilage samples listed in Table 5.4 did not show any 
significant differences between the subgroups in expression of any of the genes 
analysed, with a large degree of inter-individual variability in the inflammatory group 
(Figure 5.17).  However, a trend was seen toward higher expression of all genes 
analysed in the predicted inflammatory samples when compared to the predicted 
non-inflammatory samples. This indicates the inflammatory transcriptome is not as 
consistently altered in OA knee patients as in OA hip patients, thus re-emphasising 
the disparity between knee and hip OA cartilage pathology.  The considerable inter-
individual variability within the knee cartilage may also reflect the heterogeneous 
nature of the pathophysiological changes occurring. 
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Figure 5.16 
Expression of inflammation-associated genes in knee OA cartilage in 16 non-
inflammatory cluster patients and 11 inflammatory cluster patients who were 
analysed on the high-density methylation array. Data are presented as 2−ΔΔCt, having 
been normalised to the GAPDH housekeeper gene. Error bars represent the SEM. 
Statistical significance was assessed using the Student’s t test. *p<0.05.  
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Figure 5.17 
Expression of inflammation-associated genes in the 24 new knee OA patients who 
had been categorised into the non-inflammatory or inflammatory cluster, based on 
methylation at cg12245706 and cg21944234. Gene expression was measured by 
qPCR and is presented as 2−ΔΔCt, having been normalised to the GAPDH 
housekeeper gene. Error bars represent the SEM. Statistical significance was 
assessed using the Student’s t test. Non-inflammatory n = 14, inflammatory n = 10 
(where n = number of samples in each comparison). 
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5.4 Discussion 
The overarching aim of this chapter was to generate a method to enable the 
classification of new hip and knee OA patient samples into the non-inflammatory or 
inflammatory subgroups previously identified by our group, without the need for a 
genome-wide methylation array. This was to be achieved by identifying CpG sites 
that in the original array analysis, showed a significant difference in methylation 
between the two hip subgroups and the two knee subgroups, followed by logistic 
analyses to create models predicting cluster membership based on methylation at 
these sites. Subsequent design, and validation, of pyrosequencing assays to the 
selected CpG sites would then enable for methylation analysis and clustering of new 
cartilage samples.  
 
I first selected CpG sites which displayed differential methylation between the non-
inflammatory and inflammatory groups in the high-density array and performed 
logistic analyses in order to assess the capacity of methylation at the sites to predict 
cluster membership. This was performed separately for the hip and knee OA 
patients. A heuristic cluster index (CI) using methylation at cg14818279 and 
cg03278514 was formulated to identify cluster membership in hip OA patients. 
Owing to the knee subgroups separating less well according to methylation, a 
prediction formula generated using statistical software was used to assign samples 
to a cluster according to methylation at cg12245706 and cg21944234. 
Pyrosequencing assays were designed to the selected CpG sites and then validated 
using bisulphite converted DNA from samples present on the array. Following 
validation, the assays were used on a new cohorts of hip and knee OA patient 
180 
 
cartilage DNA and the samples were then assigned to the non-inflammatory or 
inflammatory subcluster by the CI or prediction formula respectively.  
 
I then went on to analyse overall inflammatory gene expression in OA hip cartilage 
samples. Firstly, I confirmed that there was significantly higher expression of the 
inflammatory genes CCL5, CXCR2, IL1A, IL6 and TNF in five inflammatory OA 
cartilage samples which had been analysed on the array, when compared to five 
non-inflammatory samples, as previously reported by Rushton et al. [121]. 
Inflammatory gene expression analysis was then performed in 21 new hip OA patient 
cartilage samples, subgrouped using the CI, in order to help determine whether the 
discriminatory function had correctly identified the inflammatory samples. This 
confirmed significantly increased inflammatory gene expression of IL1A, IL6 and 
TNF in the six samples categorised as inflammatory when compared to the 15 
samples categorised as non-inflammatory. Though not statistically significant, this 
was accompanied by elevated expression of CCL5 and CXCR2 in the inflammatory 
samples. There was a degree of inter-individual expression variability in the 
inflammatory cohort, which may explain why statistical significance was not achieved 
for all five genes analysed. However, the increase in inflammatory gene expression 
seen in the new samples acts to further validate the cluster index and its capacity to 
accurately determine cluster membership.  
 
Subsequently, I performed the same inflammatory gene expression analysis in knee 
OA samples. Analysis of the knee cartilage transcriptome according to inflammatory 
subgroup had not previously been performed. I initially ascertained whether the 
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divergent knee cartilage methylome was translated into an altered inflammatory 
transcriptome, as had been demonstrated in hip cartilage. Both CXCR2 and IL1A 
displayed significantly increased expression in the inflammatory patient group when 
analysed in 16 non-inflammatory and 11 inflammatory patients who were studied on 
the high-density methylation array. However, a statistically significant difference in 
expression was not seen for CCL5, IL1B, IL6 or TNF. Analysis of the new patient 
samples did not identify any significant differences in gene expression, when 
analysed in 14 samples categorised as non-inflammatory and the 10 categorised as 
inflammatory. However, in all cases the predicted inflammatory samples 
demonstrated a trend towards higher inflammatory gene expression when compared 
to the predicted non-inflammatory samples. Taken together, these data indicate that, 
although they possess a distinct cartilage inflammatory methylome, knee OA 
cartilage is not as transcriptionally distinct when comparing the non-inflammatory 
and inflammatory subgroups, especially in comparison to hip OA.  
 
Overall, this chapter has successfully seen the creation of a methodology to assign 
new hip or knee OA patients into the non-inflammatory or inflammatory subgroup 
based on cartilage methylation. It has also emphasised the fact that hip and knee OA 
cartilage display significant differences in reference to gene methylation and 
expression, reflecting the heterogeneity of disease pathology occurring within the 
joints. The capacity to distinguish cluster membership of new patient samples will 
enable the further interrogation of the subgroups and the upstream factor, or factors, 
driving the divergent methylomes.  
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Chapter 6: Investigation into the systemic inflammation status and 
metabolic status in individuals displaying increased cartilage 
inflammation  
 
6.1 Introduction 
Having developed methylation assays and a discriminant function to categorise new 
hip and knee OA patients into the inflammatory or non-inflammatory subgroups, I 
subsequently sought to analyse a new cohort of patients. Cartilage and blood serum 
was obtained from 19 individuals undergoing hip arthroplasty and 23 knee 
arthroplasty patients. The patients were designated as either inflammatory or non-
inflammatory using the methodology developed in Chapter 5 in order to further 
analyse these individuals.  
 
The main intention of this chapter was to investigate the systemic inflammatory 
status of OA patients according to their cartilage inflammatory group. The purpose of 
this was to determine whether those patients displaying aberrant methylation of 
inflammatory genes also had higher systemic levels of inflammation. As such, this 
would assist in our comprehension of the inflammatory group of patients and would 
suggest local cartilage inflammation may be occurring secondary to elevated 
systemic inflammation.  
 
We also attempted to investigate the upstream regulator of the disparate cartilage 
methylomes and inflammatory gene expression profiles. Studies have shown 
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cultured OA chondrocytes express higher levels of leptin compared to non-OA 
cartilage and that leptin can stimulate chondrocytes to express increased levels of 
inflammatory genes such as TNF, IL1B and IL6 [146]. Interestingly, increased leptin 
concentrations in mice are associated with DNA hypomethylation of inflammation-
associated genes [147]. Further to this, in a meta-analysis of 13 studies, patients 
with rheumatoid arthritis, a systemic inflammatory arthritis, were found to have 
significantly higher circulating leptin expression when compared to healthy controls 
[148]. Consequently, I intended to analyse the levels of circulating leptin in our 
inflammatory and non-inflammatory OA patients in order to investigate whether 
elevated circulating leptin may be influencing the different inflammatory status in the 
two groups. In addition, patient demographics were collected in order to identify 
whether there was any association between elevated serum leptin and sex, or BMI. 
This therefore sought to explore the hypothesis that increased circulating leptin, 
resultant of increased age, female sex or high BMI, may result in increased systemic 
inflammation and aberrant inflammatory gene expression in OA cartilage in the 
inflammatory subgroup of patients.  
 
Further to improving our comprehension of the inflammatory subgroup, the indication 
that inflammation plays a critical role in OA pathogenesis has important therapeutic 
implications. Specifically, it is possible that the inflammatory subgroup of patients 
could benefit from anti-inflammatory drug treatment. It is therefore essential to 
identify an accessible biomarker, for example in blood, which distinguishes between 
the subgroups in order to facilitate patient stratification for future clinical trials and 
diagnostic purposes.  
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6.2 Aims 
The aim of this chapter was to explore the inflammatory sub-group of both hip and 
knee OA patients and investigate systemic inflammation, as well as potential 
regulators of the distinct inflammatory methylomes. Further to this, this chapter 
sought to identify circulating biomarkers which could distinguish between the 
inflammatory subgroups in order to facilitate patient stratification in future clinical 
trials. These aims were achieved by: 
• Categorising new OA hip and knee patients into the inflammatory or non-
inflammatory subgroups using the methods developed in Chapter 5.  
• Analysis of markers of systemic inflammation, such as CRP, in patient serum 
and stratification according to inflammatory subgroup. 
• Analysis of patient demographic data according to inflammatory subgroup. 
• Quantification of circulating serum leptin and stratification by inflammatory 
subgroup, sex and BMI. 
 
 
 
 
 
 
 
 
185 
 
6.3 Results 
 
6.3.1 Assigning new hip OA patients into the inflammatory or non-
inflammatory subgroup according to cartilage methylation 
Matched cartilage and blood serum were obtained for 19 patients who had 
undergone hip arthroplasty (patient details are listed in Appendix B: Table B.3). 
Cartilage methylation at cg14818279 and cg03278514 were quantified by 
pyrosequencing, and patients were subsequently assigned to the inflammatory or 
non-inflammatory cluster using the discriminant function created in Chapter 5 
(Chapter 5.3.2). Nine patients were identified as belonging to the non-inflammatory 
group (cluster 1) and eight to the inflammatory group (cluster 2), while two patients 
could not be categorised (Table 6.1).  
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Table 6.1 
Average cartilage methylation at cg14818279 and cg03278514 in 19 OA hip patients 
and designated inflammatory subgroup, where cluster 1 is the non-inflammatory and 
cluster 2 the inflammatory group. CpG methylation was analysed by pyrosequencing 
and statistical analyses were performed with JMP Pro Version 11.2 Statistical Data 
Visualization Software (SAS Institute Inc., Cary, NC) to determine the subcluster by 
using the discriminant function described in Chapter 5.3.2.  
 
 
 
Patient cg14818279 
average 
methylation 
(%) 
cg03278514  
average 
methylation 
(%) 
Cluster 
5989 60 50 Cluster 2 
5996 45 60 Cluster 1 
6011 67 34 Cluster 2 
6013 41.5 62 Cluster 1 
6027 59.5 78.5 Cluster 1 
6031 54.5 72 Cluster 1 
6033 45.5 51 Cluster 1 
6089 59 41 Cluster 2 
6105 55 38.5 Cluster 2 
6127 59 38.5 Cluster 2 
6132 30.5 61.5 Cluster 1 
6136 30 52.5 Cluster 1 
6148 28 56.5 Cluster 1 
6163 45.5 49 Unknown 
6166 44 35 Unknown 
6191 54 45 Cluster 2 
6207 52 51 Cluster 2 
6226 51 57.5 Cluster 2 
6229 55 62 Cluster 1 
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6.3.2 Investigation of systemic markers of inflammation in hip OA patients 
Systemic inflammation was assessed by analysis of serum CRP, which is a well-
established and clinically used marker of systemic inflammation [149]. This was 
achieved using the MSD V-PLEX Human CRP Kit, as described in Chapter 2.16. A 
calibration curve was created using dilutions generated using the Vascular Injury 
Panel 2 (human) calibrator blend (Mesco Scale Discovery (MSD), Gaithersburg, 
USA) (Figure 6.1). Having created a calibration curve in order to allow for 
quantification of unknown samples, patient samples were analysed to ensure the 
patient samples generated a signal within the limits detected using the calibrator 
blend, from which the concentration is derived. Patient samples were diluted 1000 
fold as recommended by MSD in order to ensure all signals generated were within 
the detectable limits. The majority of values were recorded above the lower limit of 
detection (LLOD), which is the lowest concentration of a substance (in this instance 
CRP) that can be distinguished from the absence of the substance (the blank value) 
and is derived using the signal strength. It was deemed acceptable to take forward 
all data, including those falling above and below the limits of detection, given that the 
data is not being used in a clinical diagnostic context.  
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Figure 6.1  
CRP standard curve generated using the Vascular Injury Panel 2 (human) calibrator 
blend (MSD, Gaithersburg, USA). Blue squares indicate CRP calibration standards 
of known concentration, with each standard run in duplicate. OA patient samples, are 
depicted by the red diamonds and had been diluted 1000 fold, as recommended by 
MSD to ensure the signal is within the detectable limits. Both knee and hip 
arthroplasty patients shown on the graph. The concentration (X axis) is derived using 
the signal strength (y axis).  
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Analysis of circulating serum CRP levels did not reveal any difference between the 
non-inflammatory and inflammatory OA patients (Figure 6.2). The data did indicate a 
number of patients as having a CRP outside of the healthy range (0-10mg/dL), 
however these patients were present in both in the inflammatory and non-
inflammatory subcluster. Given that CRP is a non-specific marker of systemic 
inflammation, it is not possible to speculate the reason for the elevated readings in 
these individuals.  
 
 
 
 
 
 
 
 
 
 
Figure 6.2 
Analysis of serum CRP levels in hip OA patients, stratified according to inflammatory 
subcluster. There was no significant difference in serum CRP between the two 
groups, as assessed using a Mann-Whitney U test. n represents the number of 
individuals in the comparison group; error bars represent the mean ± SEM.  
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Though no difference in serum CRP was seen in hip OA when comparing the patient 
subgroups, I next investigated circulating levels of inflammatory proteins which had 
displayed significant differences in gene expression between the groups when 
analysed in cartilage.  
 
Given that IL6 displayed the most significant difference in expression in hip cartilage 
between the non-inflammatory and inflammatory groups (Chapter 5.3.3), circulating 
IL6 was selected for analysis using the V-PLEX Human Proinflammatory Panel 1 Kit 
(MSD, Gaithersburg, USA). A calibration curve was generated and all hip OA patient 
serum samples contained a detectable IL6 concentration, which was recorded within 
the limits of detection (Figure 6.3).  
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Figure 6.3 
IL6 standard curve generated using the Proinflammatory Panel 1 (human) calibrator 
blend (MSD, Gaithersburg, USA). Blue squares indicate IL6 calibration standards of 
known concentration, with each standard run in duplicate. OA patient samples are 
depicted by the red diamonds, with both knee and hip arthroplasty patient serum 
samples shown on the graph. All patient sample values fall within the reference 
range.  
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Serum IL6 concentrations displayed no difference between the non-inflammatory 
and inflammatory groups (Figure 6.4 A). Quantification of IL6 gene expression in hip 
cartilage from matched patients, where available, by qPCR (Chapter 2.17). For 
primer sequences see Appendix A: Table A.6. The gene displayed significantly 
higher expression in patients in the inflammatory group (Figure 6.4 B). 
 
Figure 6.4 
Analysis of serum IL6 concentration (A) and cartilage IL6 gene expression in hip OA 
patients (B). There was no significant difference in circulating IL6 between the non-
inflammatory and inflammatory groups (A). IL6 gene expression was measured by 
qPCR in hip cartilage samples from matched patients, where nucleic acid was 
available, and displayed significantly higher expression in patients in the 
inflammatory group (B). Statistical significance was assessed using a Mann-Whitney 
U test; * p < 0.05.  n represents the number of individuals in the comparison group; 
error bars represent the mean ± SEM. 
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TNF-α was selected for analysis as TNF had shown a reproducible significant 
difference in gene expression between the inflammatory and non-inflammatory hip 
OA patient groups (Chapter 5.3.3).  A calibration curve was generated using dilutions 
of the Proinflammatory Panel 1 (human) calibrator blend (MSD, Gaithersburg, USA) 
and all analysed patient samples provided values within the calculated limits of 
detection (Figure 6.5). 
 
Analysis of circulating TNF-α did not reveal any significant difference in 
concentration when comparing the inflammatory and non-inflammatory hip OA 
patients (Figure 6.6 A). TNF expression was also measured in matched hip cartilage, 
where nucleic acid was available, by qPCR (Chapter 2.17; for primer sequences see 
Appendix A: Table A.6). This confirmed, as previously demonstrated, that there was 
a significant difference in gene expression between the two patient subgroups 
(Figure 6.6 B).  
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Figure 6.5 
TNF-α standard curve generated using the Proinflammatory Panel 1 (human) 
calibrator blend (MSD, Gaithersburg, USA). Blue squares indicate TNF-α calibration 
standards of known concentration, with each standard run in duplicate. OA patient 
samples are depicted by the red diamonds, with both knee and hip arthroplasty 
patients shown on the graph. All patient sample values fall within the reference 
range.  
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Figure 6.6 
Analysis of serum TNF-α concentration (A) and cartilage TNF gene expression in hip 
OA patients (B). There was no significant difference in circulating TNF-α between the 
non-inflammatory and inflammatory groups (A). TNF gene expression was measured 
by qPCR in hip cartilage samples from matched patients, where nucleic acid was 
available, and displayed a significant difference in expression between the two 
groups. Statistical significance was assessed using a Mann-Whitney U test; * p < 
0.05.  n represents the number of individuals in the comparison group; error bars 
represent the mean ± SEM. 
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6.3.3 Analysis of circulating leptin and BMI in hip OA patients 
Having confirmed that changes in the cartilage methylome translate into altered 
cartilage transcription of inflammatory genes in a subgroup of hip OA patients, we 
sought to probe the upstream influences driving this altered inflammatory status. The 
focus of this investigation was BMI and serum leptin. BMI, as a surrogate marker of 
body fat percentage and so, increased serum leptin, has been shown to have a 
regulatory role in the inflammatory state of certain patient groups [150]. 
 
Serum leptin was measured using the MSD V-PLEX Human Leptin Kit (MSD, 
Gaithersburg, USA), as detailed in Chapter 2.16 (Figure 6.7). Patient BMI data was 
recorded prior to arthroplasty surgery and was provided by Mr Kenneth Rankin 
(Honorary Consultant, Northern Institute for Cancer Research). Neither circulating 
leptin nor BMI showed a significant difference between the two patient subgroups 
(Figure 6.8). Given that BMI varies between males and females, it was not 
appropriate to further stratify data by sex owing to low patient numbers (n = 2 for 
non-inflammatory males, n = 1 for inflammatory females).  
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Figure 6.7 
Leptin standard curve generated using the Leptin (human) Calibrator blend (MSD, 
Gaithersburg, USA). Blue squares indicate Leptin calibration standards of known 
concentration, with each standard run in duplicate. OA patient samples are depicted 
by the red diamonds, with both knee and hip arthroplasty patients shown on the 
graph. One hip OA patient recorded a serum leptin concentration above the limit of 
detection, but given that the data is not being used for clinical diagnostic purposes, 
was included in the analysis.  
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Figure 6.8 
Analysis of serum leptin levels (A) and BMI (B) in hip OA patients, stratified 
according to inflammatory subcluster. There were no significant differences in either 
serum leptin or BMI between the two groups, as assessed using a Mann-Whitney U 
test. n represents the number of individuals in the comparison group; error bars 
represent the mean ± SEM.  
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6.3.4 Assigning new knee OA patients into the inflammatory or non-
inflammatory subgroup according to cartilage methylation 
Matched cartilage and blood serum were obtained for 29 patients who had 
undergone total knee arthroplasty. Patient details are listed in Appendix B: Table 
B.3. Cartilage methylation at cg12245706 and cg21944234 was quantified by 
pyrosequencing (Chapter 2.14.2), and patients were subsequently assigned to the 
inflammatory or non-inflammatory cluster using the discriminant function created in 
Chapter 5 (Chapter 5.3.5). This identified 18 patients as belonging to the non-
inflammatory group (cluster 1) and 11 to the inflammatory group (cluster 2), with 
none of the samples failing to be categorised (Table 6.2). 
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Table 6.2 
Average cartilage methylation at cg12245706 and cg21944234 in 29 knee OA 
patients and designated inflammatory subgroup, where cluster 1 is the non-
inflammatory and cluster 2 the inflammatory group. CpG methylation was analysed 
by pyrosequencing and statistical analyses were performed with JMP Pro Version 
11.2 Statistical Data Visualization Software (SAS Institute Inc., Cary, NC) to 
determine the subcluster by using the discriminant function described in Chapter 
5.3.5.  
Sample cg12245706 
average 
methylation 
(%) 
cg21944234 
average 
methylation 
(%) 
Cluster 
5994 58 37 Cluster 2 
6002 36.5 25.5 Cluster 1 
6003 65 29 Cluster 2 
6006 18.5 22.5 Cluster 1 
6007 59.5 33.5 Cluster 2 
6008 43 34.5 Cluster 1 
6012 75.5 40 Cluster 2 
6015 51.5 27.5 Cluster 1 
6054 59 36.5 Cluster 2 
6057 35.5 33.5 Cluster 1 
6090 31.5 27 Cluster 1 
6095 45.5 21.5 Cluster 1 
6104 22 23.5 Cluster 1 
6114 27 32.5 Cluster 1 
6146 62 27 Cluster 2 
6150 18.5 25 Cluster 1 
6153 66 28 Cluster 2 
6164 60.5 23 Cluster 2 
6165 41.5 26.5 Cluster 1 
6175 49 24 Cluster 1 
6190 20.5 22 Cluster 1 
6203 40 25 Cluster 1 
6204 63.5 30.5 Cluster 2 
6208 54.5 30 Cluster 2 
6209 43 21.5 Cluster 1 
6223 38 22 Cluster 1 
6225 67.5 34 Cluster 2 
6227 45 20 Cluster 1 
6228 36 23.5 Cluster 1 
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6.3.5 Investigation of systemic markers of inflammation in knee OA patients 
Although knee OA patients did not display significant differences in cartilage 
inflammatory gene expression when stratified according to the non-inflammatory and 
inflammatory clusters (Chapter 5.3.6), the two groups are clearly distinguished 
according to their cartilage methylome [43]. This may have important implications for 
patient subgrouping in future clinical trials, in respect to having a potential impact on 
response to treatment. Analysis of the cartilage methylome however, requires a 
cartilage sample and would limit subgrouping of patients to those who had already 
undergone arthroplasty. As such, identification of a circulating factor that can 
discriminate between the two clusters could prove highly beneficial for patient 
subgrouping for future research.   
 
Given that methylation differences were enriched in inflammatory genes, the focus 
for a circulating biomarker was centred on circulating inflammatory factors. Serum 
CRP, IL6 and TNF-α were analysed using the MSD MULTI-SPOT V-PLEX Assay 
System (MSD, Gaithersburg, USA), as detailed in Chapter 2.16. Samples were 
analysed along with the previously discussed hip OA samples (Figures 6.1, 6.3 and 
6.5 respectively). Comparison of the 18 non-inflammatory and 11 inflammatory knee 
OA patients did not reveal any difference in circulating levels of CRP, nor of 
circulating levels of the selected cytokines (Figure 6.9). 
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Figure 6.9 
Analysis of serum CRP (A), IL6 (B) and TNF-α (C) levels in knee OA patients, 
stratified according to inflammatory subcluster. There were no significant differences 
in circulating CRP, IL6 or TNF-α between the two groups, as assessed using a 
Mann-Whitney U test. n represents the number of individuals in the comparison 
group; error bars represent the mean ± SEM.  
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6.3.6 Analysis of circulating leptin and BMI in knee OA patients 
Having not identified a circulating inflammatory factor which distinguishes the two 
knee OA inflammatory groups, circulating leptin levels were next interrogated. As 
noted earlier, circulating leptin may be driving the differential gene methylation in the 
two knee OA groups and would prove an easily quantifiable marker for patient 
subgrouping. Further to this, leptin is known to correlate with BMI [151]. Owing to the 
fact that it is an easy and non-invasive measurement, BMI would be a preferential 
measurement to use for future patient stratification.  
 
Serum leptin was measured using the MSD V-PLEX Human Leptin Kit (MSD, 
Gaithersburg, USA), as detailed in Chapter 2.16 (Figure 6.7). Patient BMI data was 
recorded prior to arthroplasty surgery and was provided by Mr Kenneth Rankin. As 
with circulating inflammatory markers, neither serum leptin nor BMI showed a 
significant difference between the patient subgroups (Figure 6.10). Further 
stratification by sex, to account for the natural variation in BMI between males and 
females, also did not identify any significant differences in either parameter (Figure 
6.11). 
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Figure 6.10 
Analysis of serum leptin levels (A) and BMI (B) in knee OA patients, stratified 
according to inflammatory subcluster. There were no significant differences in either 
serum leptin or BMI between the two groups, as assessed using a Mann-Whitney U 
test. n represents the number of individuals in the comparison group; error bars 
represent the mean ± SEM.  
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Figure 6.11 
Analysis of serum leptin levels (A) and BMI (B) in knee OA patients, stratified 
according to both inflammatory subcluster and sex. There were no significant 
differences in neither serum leptin nor BMI, having performed two-way comparisons 
for all possible group combinations, as assessed using a Mann-Whitney U test. n 
represents the number of individuals in the comparison group; error bars represent 
the mean ± SEM.  
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6.4 Discussion 
The aim of the research in this chapter was to investigate circulating inflammatory 
and metabolic factors in hip and knee OA patients, in response to the identification 
that a subgroup of patients display altered cartilage methylation of inflammatory 
genes [43]. Given that increased leptin has been shown to correlate with a 
heightened inflammatory state [150], I hypothesised that, in hip patients, increased 
cartilage expression of inflammatory genes may be driven by increased systemic 
inflammation, potentially caused by high BMI and so, high circulating leptin.  I also 
hypothesised that a circulating inflammatory or metabolic marker may be able to 
differentiate between our two patient subgroups in both hip and knee OA patients, 
thus allowing patient stratification for future clinical trials and diagnostic purposes. 
This may also have implications for patient treatment, for example the inflammatory 
subgroup may benefit from repurposing of existing anti-inflammatory drugs. Both 
lines of investigation were achieved by methylation analysis of new patient samples 
to create a new patient hip and knee cohort, followed by analysis of selected factors 
in blood serum using Electrochemiluminescent Meso Scale Discovery (MSD) assays 
(MSD, Gaithersburg, USA).  
 
I first theorised that increased cartilage inflammatory gene expression in hip OA 
patients belonging to the inflammatory subgroup may be secondary to increased 
systemic inflammation. I analysed serum CRP, a general marker of inflammation, as 
well as IL6 and TNF-α in nine non-inflammatory and eight inflammatory hip OA 
patients. This did not identify any difference in circulating inflammatory factors, 
though qPCR analysis of matched cartilage did show a significant difference in 
inflammatory gene expression in the inflammatory subgroup, as shown previously. 
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Consequently, this implies increased inflammation in the inflammatory hip subgroup 
is a primary event in the cartilage as opposed to a result of elevated systemic 
inflammation. It also indicates that the selected markers do not distinguish the 
patient subgroups in view of subgrouping future patients by use of blood sample 
analysis.  
 
I next analysed serum leptin and BMI in the non-inflammatory and inflammatory hip 
patients to investigate if elevated BMI or circulating leptin may be driving aberrant 
methylation and cartilage gene expression in the inflammatory group, or may be a 
method to determine subcluster membership of future patients. Circulating leptin nor 
BMI were able to distinguish our hip OA subgroups, therefore suggesting that altered 
metabolic status is not what is driving the divergent methylome and cartilage gene 
expression in our inflammatory subgroup.  
 
Subsequently, I analysed serum inflammatory markers in knee OA patients. 
Methylation analysis by pyrosequencing and subsequent discriminant analysis using 
JMP Pro Version 11.2 Statistical Data Visualization Software (SAS Institute Inc., 
Cary, NC) was performed. This identified a new cohort of 18 non-inflammatory and 
11 inflammatory knee OA patients. I then explored whether the inflammatory 
subgroup could be identified based on blood inflammatory and metabolic markers. 
Serum CRP, IL6, TNF-α and leptin were unable to distinguish the inflammatory from 
the non-inflammatory groups. Likewise, BMI was not significantly different between 
the subgroups, even following further stratification by sex to account for the fact that 
females have naturally higher BMI.  
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Overall, this chapter indicates that abnormal inflammatory gene regulation is a local, 
as opposed to a systemic, event in both knee and hip OA inflammatory cluster 
patients. We did not find any evidence of elevated systemic inflammation in the 
blood serum of the inflammatory subgroup cohort. This research also shows that 
circulating CRP, IL6, TNF-α and leptin are not suitable biomarkers to enable for 
stratification of the inflammatory subgroup in hip or knee OA patients. However, 
given that peripheral blood DNA methylation levels have been shown to correlate to 
that of internal tissues including skeletal muscle and brain, further investigations into 
the blood methylome are warranted, particularly in reference to hip OA where we 
have demonstrated increased cartilage inflammatory gene expression [152,153].  A 
DNA methylation signature in peripheral blood would provide an easy, accessible 
method to distinguish inflammatory subgroup patients and therefore, facilitate easy 
patient stratification for OA clinical trials.  
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Chapter 7. General discussion 
 
7.1 Perspective 
Osteoarthritis is a progressive, painful disease which is increasing in prevalence as 
the global expected life expectancy increases [154]. Both pharmacologic and non-
pharmacologic therapeutic options, however, remain suboptimal [155]. To improve 
the likelihood of successful clinical trials being designed, a more comprehensive 
understanding of OA pathophysiology is vital. Given the highly heterogeneous nature 
of the disease, molecular research must therefore retain a broad focus, 
encompassing genetics, epigenetics and transcriptomics, in order to provide the 
most comprehensive disease understanding possible.  
 
Genetic studies have entailed from candidate gene studies, linkage studies and 
GWAS, which have indicated several regions of the genome are harbouring OA 
susceptibility. However, association alone does not benefit our comprehension of the 
disease and it is therefore vital to functionally analyse each signal in an attempt to 
dissect the mechanisms driving OA association. As the most powerful OA GWAS 
performed to date, the arcOGEN consortium study identified five genomic regions to 
be associated with OA [92].  Subsequently, our group has focused on the functional 
investigation of these loci. One of the association SNPs has been identified to act as 
a cis-eQTL, with the genotype associating with GNL3 and SPCS1 gene expression 
[156]. Combined molecular and bioinformatics studies into the association signal 
marked by rs835487, residing in an enhancer of CHST11, have identified the 
polymorphism to mediate OA risk owing to differential protein binding to its alleles, 
which may therefore affect expression of CHST11 or an alternative gene [157]. 
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Analysis of two other signals identified in the arcOGEN study did not find any 
evidence for functionality in end-stage disease tissue, suggesting the OA 
associations are modulated in joint development or early disease [158, 159].   
 
Residing in an intron of the ASTN2 gene, the final signal discovered by the arcOGEN 
study is rs4836732. The region demarcated by this polymorphism has been 
identified to be associated with height in individuals of European descent [160]. 
Furthermore, genome-wide analysis for copy number variants (CNVs) using single-
nucleotide polymorphism arrays in patients with short stature identified CNVs in the 
rs4836732 association region which segregated with short stature [161]. These 
findings provide evidence that the locus is important in skeletal development and, 
with the results presented in this thesis, may indicate the OA association signal 
regulates OA susceptibility during joint development.  
 
Epigenetic research in OA has gained momentum over the past 10 years and there 
is a growing body of work focusing on genome-wide methylation studies, particularly 
in cartilage [77]. These have identified that not only is the OA cartilage methylome 
distinct compared to non-OA cartilage, but also that patients with the same affected 
joint can display distinct differences in their cartilage methylome [43, 118, 122].  
Having identified a subgroup of OA patients who have altered methylation and 
expression of inflammatory genes in cartilage, the study by Rushton et al., supported 
by the research generated for this thesis, provides an exciting direction for future 
clinical trials, with specific patients potentially benefiting from re-purposing of current 
anti-inflammatory treatments [43, 121].  
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7.2 Key results 
My PhD had two overall aims: to functionally dissect the OA associated locus 
marked by rs4836732 (aim one) and to characterise a subgroup of OA patients 
displaying differential methylation of inflammatory genes in cartilage DNA (aim two). 
The key findings of this thesis are as follows:   
Aim one  
• Two SNPs are in LD at r2 > 0.7 with rs4836732, but functional studies using 
luciferase reporter assays, electrophoretic mobility shift assays (EMSAs) and 
a range of transformed cell lines did not identify any differential allelic activity 
between any of the SNP alleles 
• Differential EMSA banding patterns for the C allele of rs4836732 were 
observed, when compared to the T allele 
• All three candidate genes, ASTN2, PAPPA and TRIM32, are expressed in 
synovial joint tissues 
• No correlation between the association SNP and expression of candidate 
genes was observed in end-stage disease tissue 
• PAPPA expression is required for osteogenic and chondrogenic differentiation 
of human mesenchymal stem cells 
 
Aim two 
• CpG methylation analysis by pyrosequencing using cartilage DNA can be 
used to predict inflammatory cluster membership of OA patients  
• There is no difference in circulating leptin or BMI when comparing patients 
according to their inflammatory subgroup 
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• Inflammatory subgroup patients with knee OA display increased cartilage 
expression of some inflammatory genes, though this is not as pronounced as 
for the hip OA patients 
• Increased local expression of inflammatory genes is not accompanied by 
increased systemic inflammation 
 
Together, the data in this thesis emphasise the heterogeneity of OA pathophysiology 
and support the notion that various different pathological pathways are converging 
onto the same end disease phenotype. Specifically, this research will allow for 
further analysis of the rs4836732 association signal in relation to joint development, 
with a particular focus on PAPPA. It also supports continued work to fully 
characterise the inflammatory phenotype of a subgroup of OA patients, having found 
that elevated expression of inflammatory genes appears to be localised to the joint, 
rather than being a systemic event.  
 
7.3 Investigating the functionality of the rs4836732 OA susceptibility locus 
In Chapter 3, I hypothesised that rs4836732 marks the action of a cis-eQTL which 
increases OA susceptibility by mediating the expression of a nearby gene.  It is 
plausible for SNPs to regulate genes megabases in distance away, but many 
functional studies of signals have found them to act as eQTLs on nearby genes. An 
excellent example of this is the regulation of RUNX3 expression by rs4648889 in 
association with ankylosing spondylitis, whereby presence of the risk allele resulted 
in impaired transcription factor binding, thus reducing RUNX3 expression [162]. In 
relation to OA, this has been demonstrated with GNL3 and SPCS1, as well as 
GDF5, ALDH1A2 and NCOA3 [78, 120, 153, 163].  
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Consequently, investigations were focused on ASTN2, PAPPA and TRIM32, which 
reside nearby to rs4836732. However, quantification of overall gene expression and 
allelic expression in OA cartilage did not identify any such correlations, as has been 
the case with other similar studies [159, 164]. Analysis by Raine et al., of the 7q22 
OA association signal identified tissue-specific eQTL effects [165]. As such, I also 
performed allelic expression analysis of gene expression in synovium and fat pad 
samples, though this also did not yield any positive correlations. A key limitation of 
analysing overall gene expression is that inter-individual variability may conceal any 
true correlations, which could only be overcome by using a very large sample size. 
Both the overall gene expression analysis and allelic analysis may also have been 
limited by the fact that, owing to availability, a variety of OA patient samples were 
used, rather than only hip OA samples. Taken together, it cannot be dismissed that 
an eQTL acting in end stage disease tissues may have gone undetected. A further 
important limitation is that the research was conducted using end-stage disease 
tissues. As such, the possibility remains that susceptibility may be acting during joint 
development, or disease initiation/ progression.  
 
Differential protein binding has been identified to mediate the rs835487 OA 
susceptibility signal within intron 2 of CHST11 and differential transcription factor 
binding has been identified in the context of GDF5 regulation by rs143383 [157, 
166]. As such, I hypothesised that the rs4836732 susceptibility signal may function in 
a similar manner. While EMSA analysis indicated differential protein binding to the 
SNP when comparing binding to either the C or T rs4836732 allele, supershifts did 
not manage to identify the proteins. Consequently, this may suggest that the region 
is functional, but verifying the identity of the protein complexes differentially binding 
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the alleles has not been possible during the course of my PhD. However, this could 
be achieved in the future using an oligonucleotide pull down assay, followed by mass 
spectrometry [166].  
 
7.4 The role of PAPPA in joint development 
A possible explanation as to why no eQTL was detected in this study is that the 
effects are being exerted during joint development, as opposed to in end stage 
disease tissue. A study analysing radiographs and genotype data from a subset of 
929 of the arcOGEN patients with unilateral hip OA generated statistical shape 
modes to capture the shape variation of the OA-unaffected proximal femur [137]. A 
significant association was found between rs4836732 and one of the female modes, 
suggesting the SNP may have an effect on the superior orientation and size of the 
femoral head. Of the candidate genes, PAPPA was deemed the most compelling 
gene for a role in hip joint development, given that it has been described to have an 
anabolic role in bone formation both in vitro and in vivo [106, 107].   
 
Knock-down of PAPPA in hMSCs resulted in impaired osteogenic differentiation, as 
assessed by expression analysis of genes upregulated during osteogenesis and 
cellular staining to assess alkaline phosphatase activity [139]. Assessment of 
chondrogenic differentiation also indicated PAPPA knock-down resulted in 
alterations to the chondrogenic differentiation capacity of hMSCs, reflected in 
increased SOX9 expression during late stages of pellet chondrogenesis. Pappa 
expression has been identified to be higher during very early-stage bone 
development compared to later stages of joint development, when analysed in 
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collagen-induced arthritis mouse models [108].  Combined with the data presented in 
this thesis, this therefore invites the hypothesis that dysregulation of PAPPA during 
early joint development may affect normal joint shape formation. It may therefore be 
the case that, although the OA association marked by rs4836732 does not contribute 
to disease susceptibility by modulating gene expression in end-stage diseased 
synovial joint tissue, it may act during joint development and as such, PAPPA is the 
most promising gene candidate analysed to date for this locus.  
 
7.5 Characterising an inflammatory subgroup of OA patients 
Heterogeneity within OA patients extends beyond pure genetic variation, and 
subgroups of OA patients display altered genome-wide methylation of inflammatory 
genes in cartilage [43]. In Chapter 5, I proposed that these patients could be 
identified by analysis of individual differentially methylated CpG sites and accordingly 
selected appropriate CpGs for both hip and knee cartilage analysis. The subsequent 
design of both assays and statistical methodology to determine cluster membership 
has enabled me to further characterise the inflammatory subgroup in new samples 
which were not analysed on the high-density Illumina array. This was not only 
beneficial in acting to increase my sample size, but it will enable future research to 
continue without requiring ongoing high-density CpG methylation arrays to determine 
the inflammatory group of new patients.  
 
Altered expression of inflammatory genes in the subgroup of OA hip patients in the 
absence of increased systemic inflammation presents the potential that the abnormal 
inflammatory response is localised to the affected joint. Indeed, a recent novel study 
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employing fluorescence optical imaging (FOI) of wrist and finger joints in 23 OA 
patients detected active local inflammation [167]. This poses the question as to 
whether patients in the inflammatory subgroup perhaps display either more severe, 
or a different pattern, of detectable inflammation compared to the non-inflammatory 
subgroup. Were it possible to characterise patients belonging to the inflammatory 
cluster using a non-invasive method such as FOI, this may present an exciting 
clinical opportunity to identify such patients and to help assist in determining the 
course of therapeutic intervention. These same differences in cartilage expression of 
inflammatory genes were not seen to as great an extent in knee cartilage, indicating 
that investigation of a different panel of inflammatory genes may be indicated in 
inflammatory cluster knee OA.  
 
Further to identifying inflammatory patients in order to inform therapeutic options, it is 
also vital to understand the cause of increased localised inflammation in these 
patients. Along with altered inflammatory gene expression, Rushton et al. also 
identified differential methylation and expression of zinc transporter genes, such as 
ZIP8 [121]. Not only do matrix-degrading enzymes such as MMPs and ADAMTSs 
require Zn2+ for their catalytic activity, but research in mice has indicated the zinc 
transporter ZIP8 plays a vital role in upregulating matrix-degrading enzymes, MMP3, 
MMP13, and ADAMTS5, thus inducing cartilage damage [167]. During the normal 
wound-healing response, damage to articular cartilage is succeeded by a so called 
‘auto-debridement response’. Research in chondrocytes has identified that mediators 
such as IL1 can be induced by cartilage damage and result in increased abundance 
of ZIP8, ultimately enhancing MMP activity to induce cartilage break-down and assist 
in the removal of damaged cartilage [168]. Having not found any evidence for 
217 
 
increased systemic inflammation, it may therefore be the case that the inflammatory 
subgroup of patients I studied are demonstrating an impaired wound-healing 
response, mediated by abnormal zinc transporter expression [169].  
Looking to the future, a key aim is to transfer our expanding knowledge of 
inflammation in OA to help develop effective therapeutic treatment. While previous 
clinical trials of anti-inflammatory therapeutics in OA have proved unfruitful, a recent 
review identified that trials thus far have failed to identify or stratify patients 
accordingly [170]. Failing to select appropriate patient populations in clinical trials 
can clearly have a negative impact on the trial outcome, highlighted by studies into 
epidermal growth factor receptor (EGFR)-targeted therapy for non–small cell lung 
cancer patients [171]. Here, the drug Iressa (AstraZeneca), initially failed to progress 
beyond Phase II trials, yet was later approved when subsequent analysis showed 
those patients with an EGFR mutation had improved survival. Given that a vast bank 
of evidence already exists as to the heterogeneity of OA, there is clear need for 
patient stratification in clinical trials if they are to prove successful. As such, despite 
no evidence of altered systemic inflammatory markers, continued investigations 
using peripheral blood of inflammatory subgroup patients is essential in attempts to 
identify patient-selection biomarkers.  
 
7.6 Future work 
In order to identify the SNP marked by the rs4836732 association signal which is 
mediating increased disease risk, I would extend the analyses performed in chapter 
three. Owing to the timeframe of my PhD, only rs4836732 was taken forward to 
investigate protein binding using EMSA analysis. While this was an informed 
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decision, based on lack of evidence favouring either of the other identified SNPs 
over the discovery SNP, it would be prudent to perform these experiments on 
rs4837613 and rs13283416 as well. Not only this, but in all cases the EMSA 
experiments could be furthered by using nuclear protein extracted from hip cartilage, 
in light of the fact that it is a female hip association signal. An additional improvement 
to the EMSA experiments could be to increase the length of the probes in an attempt 
to ensure proteins which bind over larger distances are also identified. However, the 
benefits of this approach may be offset by increased non-specific binding. As 
mentioned previously, a hypothesis-free approach to identify proteins differentially 
binding the EMSA probes would be to perform an oligonucleotide pull down assay 
followed by quantitative mass spectrometry [166]. This would therefore enable both 
the identification and quantification of any proteins binding the different SNP alleles.  
 
Recently, DNA and cDNA from OA patient subchondral bone has been made 
available within our group. As such, it would be advisable to extend the allelic 
expression imbalance analysis to include this tissue type. Targeted deletions of the 
candidate SNPs using the clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 system are already being performed within our group in relevant cell 
lines [172]. This approach will allow for the comparison of candidate gene expression 
in the cell lines on the same genetic background, except one will have the deletion 
and the other will not. As such, it may provide new evidence as to both the functional 
SNP, and the gene regulated by the potential cis-eQTL. 
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A fundamental limitation of the functional analysis of the association signal is that the 
hypothesis employed is that rs4836732 marks a cis-eQTL. Consequently, the 
investigation focused solely on the genes surrounding the signal. While a sensible 
line of research, the lack of positive data correlating genotype at the signal with gene 
expression may support the notion of also looking outside of the region. The in vivo 
chromosome conformation is essential to transcriptional regulation [173]. As such, 
the gene regulated by the association signal may indeed be located outside of the 
association locus, even up to megabases away [174]. Employing Chromosome 
Conformation Capture (3C), Circularized Chromosome Conformation Capture (4C), 
or Carbon-Copy Chromosome Conformation Capture (5C) would facilitate the 
characterisation of chromosome folding and identify other genomic loci that the 
association region may interact with [175].  Were interactions identified, this would 
greatly influence future research depending on the genes present in these regions. 
Subsequent experiments could then include knock-down of the identified proteins in 
order to assess the effect on the expression of candidate genes.  
 
Having identified that knock-down of PAPPA in mesenchymal stem cells impairs 
osteogenic and chondrogenic differentiation, the next stage of this line of 
investigation would be to attempt to identify whether the susceptibility region is 
perhaps functional during joint development. One approach would therefore be to 
quantify expression of the candidate gene(s) during mesenchymal stem cell 
differentiation and also, to perform AEI during differentiation. Furthermore, highly 
efficient Pappa gene deletion has been achieved in bone in a conditional knock-out 
mouse model, though studies with this model to date have been limited to analyses 
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of vascular injury [176, 177]. As such, this model presents another mechanism to 
assess PAPPA functionality in the skeleton at different developmental stages.  
 
In relation to Chapters 5 and 6, it is essential to definitively confirm the ability of the 
developed methodology to determine inflammatory cluster membership of new 
patient samples. To achieve this, new cartilage DNA samples assigned to the 
inflammatory or non-inflammatory cluster using methylation data generated by 
pyrosequencing should also be analysed by high-density CpG methylation array. 
Further to this, a basic improvement to the systemic inflammation study would be to 
increase the sample size.  
 
Though higher expression of some of the analysed inflammatory genes was seen in 
knee OA cartilage when comparing the two subgroups, the differential expression 
was not as striking as in hip OA. This may reflect a higher degree of heterogeneity 
within the knee inflammatory group, which would be supported by the fact that fewer 
differentially methylated loci were identified between the clusters in comparison to 
the hip samples [43]. However, it would be best to tailor the inflammatory gene 
expression analysis to the knee methylation data, as the inflammatory genes 
displaying the greatest methylation difference in hip samples are not necessarily the 
same as in the knee samples.  
 
Having not identified any association between metabolic status, in terms of body fat 
and systemic inflammation, and the inflammatory OA subgroup, future work should 
focus on characterising the upstream regulator of the localised inflammation. As 
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discussed in Chapter 6.5, inflammatory cluster patients also demonstrated altered 
methylation and expression of zinc transporter genes [121]. Consequently, it is 
important to determine whether zinc transporter gene expression is increased in OA 
knee cartilage, as has been identified in hip cartilage. I have shown in my research 
that IL1A is differentially expressed in inflammatory cluster patients. Given that IL-1α 
increases intracellular IL-1β in chondrocytes in vitro and is proposed to be an 
essential mediator of early OA, it would be interesting to determine whether IL-1α 
can also mediate the in vivo ZIP8 inflammatory response in mouse models, as has 
been shown for IL-1β [169].  
 
Research is currently limited to end-stage OA cartilage, obtained post operatively. 
Evidently, to truly exploit the findings to benefit patients, a biomarker to identify 
inflammatory subgroup patients is essential. As such, future research must continue 
to include analysis of patient blood to try and characterise a circulating factor, or 
methylation signature, which allows for early non-invasive subgrouping of OA 
patients and to potentially enable for differential clinical treatment of individuals. As 
such, this would allow for the true translation of this research from bench to bedside.  
 
7.7 Concluding summary 
In overall conclusion, I have achieved the aims of my PhD: to functionally analyse 
the OA association signal marked by the rs4836732 polymorphism and to investigate 
a subgroup of OA patients who display altered methylation of inflammatory genes in 
cartilage DNA. The functionality of the OA association region could not be correlated 
with the genotype at the rs4836732, and no cis-eQTL was identified in end-stage OA 
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tissue. As such, it is more likely that the OA risk is mediated during joint 
development, or early-stage disease, and as such, I have provided evidence to 
support further research focusing on the PAPPA gene.  In reference to my second 
aim, I have created methodology to determine the inflammatory subgroup of new 
patient cartilage samples and provided evidence that elevated inflammation appears 
to be local to the synovial joint, as opposed to a secondary event caused by 
increased systemic inflammation.  
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Appendix A. Primer sequences 
 
 
 
 
 
 
Table A.1 Primer sequences and conditions used for PCR, restriction digest and pyrosequencing. Top panel: primer 
sequences used for genotyping and allelic expression imbalance analysis by pyrosequencing. Bottom panel: primer sequences and 
restriction enzymes used for rs4836732 genotyping by restriction fragment length polymorphism analysis.  
 
      SNP 
 
 
Forward primer (5′ - 3′) 
 
 
Reverse primer (5′ - 3′) 
 
 
Sequencing primer (5′ - 3′) 
 
MgCl2 
(mM) 
 
Anneal 
(oC) 
 rs2565 [Btn]TGACTGGGCAGTGCTTTCT AATAAAGAGATCCCCAAAGTGGT CCCAAAGTGGTGGG 2.0 57.5 
rs7518 [Btn]GCTTGGTCTCCACCTGAA TTTCTTATGGATGGCTGTCAATC ATGGCTGTCAATCCC 2.0 57.5 
rs2281627 [Btn]GCTATGCCATTTTGCTTCCTTAT GGGGGATGATTCTGTACACATG GGGAGAAAGATTTGGATTA 2.0 57.5 
 
SNP 
 
 
Forward primer (5′ - 3′) 
 
 
Reverse primer (5′ - 3′) 
Restriction 
enzyme 
 
MgCl2 
(mM) 
 
Anneal 
(oC) 
 rs4836732 GAAAGAAGGGAAGGTAAGATGGGAGAGACAGCACCT 
 
CTATCTTACACTCTCAAG 
 
RsaI 2.0 55.0 
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Table A.2 Primer sequences and conditions used for the cloning of fragments into pGL3 promoter vectors. PCR primers 
and conditions used for cloning into pGL3 vectors between the restriction sites MluI and XhoI. Restriction sites are in red text, 
preceded by a 5′ GGGG.  
 
 
 
 
 
 
SNP 
 
 
Forward primer (5′ - 3′) 
 
 
Reverse primer (5′ - 3′) 
MgCl2 
(mM) 
 
Anneal 
(oC) 
 rs13283416 GGGGACGCGTTAGGTTAGTGGTTGCATAGGGTT 
 
GGGGCTCGAGCTGTGCATCGTTCTTGTGCTATA 
 
2.0 63.9 
rs4836732 GGGGACGCGTTGTCTACAATTGGAATGGTGAGC GGGGCTCGAGCTACAGATGCACGATACAACACC 2.0 69.7 
rs4837613 GGGGACGCGT CCTCTTTGTACTTTACCCAGCTG GGGGCTCGAGATTCCAAAGTTCAGCCTCTTAGC 2.0 63.9 
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Table A.3 Primer sequences used for EMSAs to investigate SW872, SW1353 and U2OS nuclear protein binding to the 
rs4836732 SNP. The original competitor sequences are underlined in red and the random sequences are in black text. 
 
 
 
 
 
Sequence name Forward primer (5′ - 3′) Reverse primer (5′ - 3′) 
Random primer full length TAGCACCTCCAGGCTGTCTGAGTACGTAGCA TGCTACGTACTCAGACAGCCTGGAGGTGCTA 
C allele probe and competitor GAGAGACAGCACCTACTTTCTGAGGTCTAAG CTTAGACCTCAGAAAGTAGGTGCTGTCTCTC 
T allele probe and competitor GAGAGACAGCACCTATTTTCTGAGGTCTAAG CTTAGACCTCAGAAAATAGGTGCTGTCTCTC 
Competitor 1: C allele TAGCACCTCCAGGCACTTTCTGAGGTCTAAG CTTAGACCTCAGAAAGTGCCTGGAGGTGCTA 
Competitor 1: T allele TAGCACCTCCAGGCATTTTCTGAGGTCTAAG CTTAGACCTCAGAAAATGCCTGGAGGTGCTA 
Competitor 2: C allele TAGCACCTCCACCTACTTTCTGTACGTAGCA TGCTACGTACAGAAAGTAGGTGGAGGTGCTA 
Competitor 2: T allele TAGCACCTCCACCTATTTTCTGTACGTAGCA TGCTACGTACAGAAAATAGGTGGAGGTGCTA 
Competitor 3: C allele GAGAGACAGCACCTACTCTGAGTACGTAGCA TGCTACGTACTCAGAGTAGGTGCTGTCTCTC 
Competitor 3: T allele GAGAGACAGCACCTATTCTGAGTACGTAGCA TGCTACGTACTCAGAATAGGTGCTGTCTCTC 
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Table A.4 Primer and probe sequences used for gene expression analysis by real-time PCR using PrimeTime® 
predesigned assays. Top panel: primer sequences used for validation of cDNA synthesis. Bottom panel: primer and probe 
sequences used for quantification of gene expression 
 
Gene 
 
Forward primer (5′ - 3′) 
 
 
Reverse primer (5′ - 3′) 
cDNA/gDNA 
fragment size (bp) 
 
MgCl2 
(mM) 
 
Anneal 
(oC) 
 HBP1 TCGAAGAGTGAACCAGCCTT 
 
GAAGGCCAGGAATTGCACCATCC 
 
152/570 
 
2.0 60 
Gene Probe sequence (5′-3′) Primer 1 (5′-3′) 
 
Primer 2 (5′-3′) 
18S 
 
    56-FAM/TCCTTTGGTCGCTCGCTCCTCTCCC/TAMRA TATTAGCTCTAGAATTACCACAGTTA
 
 
CGAATGGCTCATTAAATCAGTTATG
 
 
ACAN 56-FAM/CTGGGTTTT/ZEN/CGTGACTCTGAGGGT/3IABkFQ TGTGGGACTGAAGTTCTTGG AGCGAGTTGTCATGGTCTG 
ALPL 56-FAM/AGTGGGAGTGCTTGTATCTCGGTTTG/3IABkFQ GATGTGGAGTATGAGAGTGACG GGTCAAGGGTCAGGAGTTC 
ASTN2 56-FAM/CCTCAGCGC/ZEN/CTTTGATGCCAATG/IABkFQ TGATCGATGACTGGTGCAG TCCAAGGAGACCACAGTACT 
COL1A1 56-FAM/TTCCGGGCA/ZEN/ATCCTCGAGCA/3IABkFQ CCCCTGGAAAGAATGGAGATG TCCAAACCACTGAAACCTCTG 
COL10A1 56-FAM/CCAAGACACACAGTTCTTCATTCCCTACACC/36-TAMSp 
 
GTACCTTGCTCTCCTCTTACTG CATAAAAGGCCCACTACCCA 
GAPDH 
 
56-FAM/AAGGTCGGAGTCAACGGATTTGGTC/IABkFQ/36-TAMSp 
 
TGTAGTTGAGGTCAATGAAGGG 
 
ACATCGCTCAGACACCATG 
 HPRT1 
 
56-FAM/AGGACTGAACGTCTTGCTCGAGATG/36-TAMSp 
 
ACAGAGGGCTACAATGTGATG 
 
TGCTGAGGATTTGGAAAGGG 
 KLF4 56-FAM/TGGAAATTCGCCCGCTCAGATGA/3IABkFQ GTTTACGGTAGTGCCTGGTC AAGAGTTCCCATCTCAAGGC 
PAPPA 56-FAM/ACTTTTTGG/ZEN/CTCCGGGCGTATTTTTC/3IABkFQ TGATGGTCTCCTGCTTTTGG CATCAGCTACCCATATTCCCAG 
RUNX2 56-FAM/CTGTTGGTC/ZEN/TCGGTGGCTGGTAG/3IABkFQ TGTTTGATGCCATAGTCCCTC AATGGTTAATCTCCGCAGGTC 
SOX9 56-FAM/TCTGGAGAC/ZEN/TTCTGAACGAGAGCGA/3IABkFQ ACTTGCACAACGCCGAG CTGGTACTTGTAATCCGGGTG 
TRIM32 56-FAM/TGGCTTGGG/ZEN/AGCAGAAGAAACTGAT/IABkFQ TGGACTGTTGGATCATTGC ACAACCAAGAACTAAGGGAAGG 
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Table A.5 Primer sequences and conditions used for PCR and methylation quantification.  PCR primer sequences and 
conditions used for methylation quantification by pyrosequencing; primers target bisulphite converted DNA.  
 
 
 
 
 
 
 
 
 
CpG 
 
 
Forward primer (5′ - 3′) 
 
 
Reverse primer (5′ - 3′) 
 
 
Sequencing primer (5′ - 3′) 
 
Anneal 
(oC) 
 cg03278514 
 
TGAGGAGTTATTTTTATTGATGGGAAATT [Btn]ACCTCTACTCTCTCTAACCTCAATCATAATAT ATGGGGATTTATTTTGAGATA 60 
cg14818279 
  
GGGAGAAAAGTTTTTTTAATTTAGTAGGT [Btn]AAAACTATCCCTTACAACACTCT TTGGGTTTAGGGTTAGAT 60 
cg12245706 
 
AGAGAATTTTTTTAGGTTTTAGTAAGG [Btn]AAAATACTACCAACACCAATACAAC ATAAGTATGAGGGTTTTAGAT 60 
cg21944234 
 
AGTAAGGTTGATTAATAGAAGAGTTAGAT [Btn]ACCAAAAATTCTTTAACTAAACTAACACT TTTTGTTTTGGTATTAGTTGT 60 
228 
 
 
Gene Forward primer (5′ - 3′) Reverse primer (5′ - 3′) 
CCL5 CCCTCGCTGTCATCCTCAT AGTGGGCGGGCAATGTA 
CXCR2 TCTGGATGCCACCGAGATTCT AGTCCATGGCGAAACTTC 
IL1A AACCAGTGCTGCTGAAGGA TTCTTAGTGCCGTGAGTTTCC 
IL6 GGTACATCCTCGACGGCATCT GTGCCTCTTTGCTGCTTTCAC 
TNF GGAGAAGGGTGACCGACTCA CTGCCCAGACTCGGCAA 
 
Table A.6 Primer sequences used for measuring inflammatory gene expression by real-time PCR using SYBR® green 
chemistry.  
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Appendix B. Patient details and genotypes 
 
Patient 
 
Sex 
 
Age (years) 
 
Joint 
 
rs4836732 genotype 
 669 F 75 H TT 
988 M 69 K CT 
1059 F 77 H CC 
1349 F 73 K CC 
1350 M 71 K CC 
1520 F 73 K CT 
1595 F 51 H CT 
1604 M 71 H TT 
1651 F 60 K CT 
1658 F 67 K CT 
1724 M 74 K TT 
1744 M 50 K CC 
1820 F 76 H TT 
1874 F 71 K CT 
1922 F 67 H TT 
1939 F 70 H CT 
1951 F 70 H CT 
1955 F 60 H CC 
3028 F 78 H TT 
3033 F 81 K TT 
3060 M 76 K TT 
3085 F 55 K CT 
3244 M 57 K CC 
3288 M 57 H CT 
3330 M 69 K CT 
3335 M 74 K CT 
3340 F 67 K CT 
3343 F 69 K CT 
3355 M 57 K CT 
3365 F 61 H CT 
3377 F 66 K CT 
3379 M 63 K CT 
3388 M 82 K CC 
3389 u u K CT 
3390 F 78 K CT 
3391 M 82 K TT 
3396 M 56 K TT 
3399 F 54 K CT 
3411 M 71 K TT 
 
Table B.1 Characteristics and genotypes of patients whose cartilage was used 
for gene expression analysis. Donors denoted by a ‘T’ in the patient number are 
NOF patients, all other donors are OA patients. Age (age at joint replacement); Joint 
(joint replaced). (u) indicates information unavailable. Continued overleaf. 
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Patient 
 
Sex 
 
Age (years) 
 
Joint 
 
rs4836732 genotype 
 3417 F 58 H CT 
3452 F 69 H CT 
3472 M 63 K CC 
3475 F 71 H CT 
3478 M 70 K TT 
3502 M 67 K TT 
3510 F 80 K TT 
3555 M 71 K CC 
3558 F 46 K CC 
3661 F 62 K CT 
3664 F 58 K CT 
3666 M u K CT 
3667 M 59 K TT 
3672 M 64 K CT 
3682 F 81 K CT 
3686 F 80 K CC 
3697 F 64 K CC 
3700 F 78 K CT 
3701 F 61 K CC 
3703 F 80 K CC 
3705 F 80 K CC 
3714 F 59 K CT 
3727 F 71 H CT 
3729 M 74 K TT 
3771 M 72 K CT 
3772 M 72 K CC 
3773 M 68 H CC 
3777 F 72 H CC 
3802 F 63 H CT 
3834 M 77 K CT 
3838 M 71 H CC 
3862 M 71 H CC 
3912 F 73 K TT 
3916 F 82 K CT 
3920 M 71 K CT 
3921 M 80 K TT 
3930 M 66 H CT 
3931 M 69 K TT 
3933 F 58 K CT 
 
Table B.1 Characteristics and genotypes of patients whose cartilage was used 
for gene expression analysis. Donors denoted by a ‘T’ in the patient number are 
NOF patients, all other donors are OA patients. Age (age at joint replacement); Joint 
(joint replaced). (u) indicates information unavailable. Continued overleaf.  
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Patient 
 
Sex 
 
Age (years) 
 
Joint 
 
rs4836732 genotype 
 3975 F 60 K TT 
4012 F 62 K CT 
4064 F 67 H CT 
207218 M 68 K CT 
333031 M 75 K CT 
T007 F 71 H CT 
T012 F 81 H TT 
T013 F 72 H CT 
T014 F 84 H TT 
T018 F 94 H CT 
T020 F 84 H CC 
T021 F 84 H CT 
T023 F 52 H CC 
T024 F 80 H CT 
T028 F u H CC 
T031 F 89 H TT 
T034 F u H CT 
T035 F 82 H CC 
T037 F u H CT 
T059 F 82 H TT 
 
Table B.1 Characteristics and genotypes of patients whose cartilage was used 
for gene expression analysis. Donors denoted by a ‘T’ in the patient number are 
NOF patients, all other donors are OA patients. Age (age at joint replacement); Joint 
(joint replaced). (u) indicates information unavailable. 
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Table B.2 Characteristics and genotypes of patients whose tissues were used for allelic expression imbalance analysis. 
Age (age at joint replacement); Joint (joint replaced). Individuals heterozygous for the PAPPA (rs2565), ASTN2 (rs7518) or TRIM32 
(rs2281627) were analysed. Continued overleaf.  
Patient Sex Age (years) Joint rs4836732 genotype rs2565 genotype rs7518 genotype rs2281627 genotype 
1828 F 72 K CT   CT 
1874 F 71 K CT  AG CT 
1888 F 42 K CT GT   
1902 M 61 K TT   CT 
3055 M 69 K CT GT  CT 
3082 M 82 K CC   CT 
3085 F 55 K CT  AG CT 
3136 F 81 K CT GT AG CT 
3210 M 75 K TT GT   
3281 F 64 K CC GT   
3297 F 78 K CC GT   
3305 F 60 K CT GT   
3312 M 63 K CC GT   
3330 M 69 K CT GT   
3335 M 75 K CT GT  CT 
3348 M 56 K CT GT  CT 
3383 M 77 K CT GT   
3384 F 71 K CT GT  CT 
3410 F 61 K CT GT AG  
3411 M 71 K TT   CT 
3458 F 71 K CC GT   
3662 M 67 K CT GT AG CT 
4244 M 78 K CT GT AG CT 
4277 F 79 K CT GT   
4278 M 67 K TT GT  CT 
4285 F 64 K CC  AG CT 
4286 M 65 K CT   CT 
4288 M 85 K CT GT   
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Table B.2 Characteristics and genotypes of patients whose tissues were used for allelic expression imbalance analysis. 
Age (age at joint replacement); Joint (joint replaced). Individuals heterozygous for the PAPPA (rs2565), ASTN2 (rs7518) or TRIM32 
(rs2281627) were analysed. Continued overleaf. 
Patient  Sex Age (years) Joint rs4836732 genotype rs2565 genotype rs7518 genotype rs2281627 genotype 
4290 M 71 H TT   CT 
4295 F 68 H TT GT  CT 
4304 M 70 K CT  AG CT 
4308 F 55 K CT  AG CT 
4356 F 48 K CC  AG  
4383 F 64 K CC GT   
4388 M 67 K TT   CT 
4432 F 72 K CT GT AG  
4448 F 61 K CT   CT 
4452 M 60 K CT  AG  
4457 F 54 K TT GT   
4459 F 76 K TT GT  CT 
4459 F 76 K TT GT   
4475 F 70 K CT GT AG CT 
4480 F 71 K CT   CT 
4483 F 72 K CT GT   
4495 F 78 K CT  AG CT 
4507 F 73 K TT  AG  
4510 F 68 K CC  AG  
4545 M 81 K CT GT AG CT 
4552 F 82 K CT GT AG CT 
4569 F 68 K TT GT  CT 
4576 F 81 K CT   CT 
4580 F 70 K TT   CT 
4588 F 34 K TT  AG  
4608 M 57 K CT   CT 
4631 F 73 H CT GT AG CT 
4637 F 79 K CC  AG  
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Table B.2 Characteristics and genotypes of patients whose tissues were used for allelic expression imbalance analysis. 
Age (age at joint replacement); Joint (joint replaced). Individuals heterozygous for the PAPPA (rs2565), ASTN2 (rs7518) or TRIM32 
(rs2281627) were analysed. Continued overleaf. 
Patient  Sex Age (years) Joint rs4836732 genotype rs2565 genotype rs7518 genotype rs2281627 genotype 
4639 F 78 K TT GT AG  
4645 F 77 K CC GT   
4657 M 69 K CC  AG  
4659 
 
 
 
F 62 K CT   CT 
 
 
4660 F 69 K CC GT  
4661 F 79 K CC  AG 
4664 M 69 K CT GT AG CT 
4676 M 67 K TT GT   
4706 M 65 K CT  AG  
4708 M 77 K TT GT AG  
4761 F 82 K TT GT AG  
4773 F 76 K TT GT  CT 
4803 M 54 K TT  AG CT 
4804 M 54 K TT  AG CT 
4805 F 65 K TT   CT 
4836 M 73 K TT   CT 
4849 F 67 H CT GT AG  
4851 M 58 K CC GT AG  
4864 F 67 H TT   CT 
4901 F 68 K TT GT   
4923 M 82 K CC  AG  
4962 M 67 K CT GT  CT 
4963 F 68 H CT GT   
4966 F 87 K CT  AG  
4984 M 62 K CT GT AG  
5000 M 54 K CT   CT 
5009 F 54 K CT   CT 
5019 M 50 K CT   CT 
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Table B.2 Characteristics and genotypes of patients whose tissues were used for allelic expression imbalance analysis. 
Age (age at joint replacement); Joint (joint replaced). Individuals heterozygous for the PAPPA (rs2565), ASTN2 (rs7518) or TRIM32 
(rs2281627) were analysed. Continued overleaf. 
Patient Sex Age (years) Joint rs4836732 genotype rs2565 genotype rs7518 genotype rs2281627 genotype 
5023 M 75 K CC GT   
5050 F 61 K CC GT AG  
5097 M 66 K CT  AG  
5139 F 64 K CT  AG CT 
5160 M 74 H CT  AG CT 
5171 F 68 K TT GT AG  
5240 F 61 K CT   CT 
5254 F 62 K CT  AG CT 
5271 F 68 K CC GT AG CT 
5281 F 59 K CT  AG CT 
5291 M 77 K CT GT AG CT 
5299 F 75 K CT GT   
5300 M 87 K CC  AG  
5380 M 72 K CC  AG  
5482 M 91 K CC  AG CT 
5504 M 68 K CT   CT 
5509 M 62 K CT  AG CT 
5541 M 53 K CT GT   
5550 M 57 K TT   CT 
5551 M 49 K CT GT   
5569 F 63 K TT GT  CT 
5613 M 75 K CC GT AG  
5643 M 76 K TT GT   
5645 M 76 H CT  AG  
5648 F 66 K TT GT   
5652 F 82 K CC  AG  
5655 F 49 H CT  AG  
5667 F 68 H CT  AG  
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Table B.2 Characteristics and genotypes of patients whose tissues were used for allelic expression imbalance analysis. 
Age (age at joint replacement); Joint (joint replaced). Individuals heterozygous for the PAPPA (rs2565), ASTN2 (rs7518) or TRIM32 
(rs2281627) were analysed.  
 
Patient Sex Age (years) Joint rs4836732 genotype rs2565 genotype rs7518 genotype rs2281627 genotype 
5677 M 54 K TT GT   
5679 F 65 H CT  AG  
5680 F 70 K TT   CT 
5681 F 51 K CC   CT 
5694 F 81 K CC GT   
5710 F 70 K CC  AG  
5725 M 81 K TT   CT 
5729 F 48 K CC  AG CT 
5747 F 87 K TT   CT 
5748 M 67 K CC  AG  
5809 M 79 K CC  AG  
5834 M 71 K TT   CT 
333031 M 75 K CT  AG CT 
406459   K CT GT  CT 
8157410 F 82 K CT  AG  
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Table B.3 Characteristics of patients for whom matched cartilage and blood 
serum were analysed. Age (age at joint replacement); Joint (joint replaced); BMI 
(body mass index at time of pre-operative assessment). Continued overleaf.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Sex Age (years) Joint BMI 
5989 M 68 H 24.6 
5996 F 82 H 24.1 
6011 M 66 H 26.0 
6013 F 70 H 30.3 
6027 F 46 H 26.1 
6031 M 66 H 23.4 
6033 F 61 H 33.6 
6089 M 77 H 27.3 
6105 M 81 H 21.0 
6127 F 87 H 28.7 
6132 F 61 H 37.3 
6136 F 57 H 33.9 
6148 M 50 H 27.8 
6163 F 75 H 27.0 
6166 M 65 H 27.4 
6191 M 72 H 24.8 
6207 M 67 H 33.0 
6226 M 58 H 38.6 
6229 F 63 H 31.2 
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Table B.3 Characteristics of patients for whom matched cartilage and blood 
serum were analysed. Age (age at joint replacement); Joint (joint replaced); BMI 
(body mass index at time of pre-operative assessment). 
 
 
 
 
 
 
 
Patient Sex Age (years) Joint BMI 
5994 M 58 K 37.4 
6002 M 58 K 37.9 
6003 M 65 K 32.1 
6006 F 75 K 28.0 
6007 F 64 K 37.7 
6008 M 68 K 27.2 
6012 F 79 K 41.3 
6015 M 74 K 23.6 
6054 F 60 K 33.4 
6057 F 76 K 24.9 
6090 F 72 K 40.0 
6095 M 84 K 25.9 
6104 F 53 K 25.2 
6114 F 56 K 33.0 
6146 F 72 K 28.6 
6150 F 78 K 29.1 
6153 F 72 K 19.7 
6164 M 73 K 26.1 
6165 M 64 K 29.3 
6175 M 80 K 30.4 
6190 F 70 K 32.0 
6203 M 47 K 35.5 
6204 F 71 K 29.0 
6208 F 73 K 24.1 
6209 M 73 K 39.7 
6223 M 78 K 29.8 
6225 M 60 K 35.8 
6227 M 56 K 30.5 
6228 M 78 K 23.4 
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Appendix C. Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table C.1 Antibodies used for supershift EMSAs to investigate protein binding 
to rs4836732. All antibodies were purchased from Santa Cruz Biotechnology (USA).  
Antibody Cat. number 
E2A sc-349 
FOXP1 sc-66896 
GR sc-1003 
GRα Sc-1002 
HEB sc-357 
HNF4α sc-8987 
IRF2 sc-498 
KLF16 sc-131168 
LEF1 sc-28687 
MEF2A sc-10794 
MEF2C sc-13268 
NFATC3 sc-1152 
NFkB sc-372 
NFYA sc-10779 
Oct2 sc-25400 
PAPPA sc-365226 
Pax9 sc-7746 
Poc4 sc-48778 
PR sc-538 
Sox9 sc-20095 
Sp3 sc-644 
TCF4 sc-13027 
XBP1 sc-7160 
240 
 
 
Appendix D. siRNAs 
 
 
 
Table D.1 siRNA (Dharmacon, GE Healthcare, UK) used for the knockdown of PAPPA. 
 
 
 
 
siRNA Cat. number siRNA target sequences 
SMARTpool: ON-TARGETplus PAPPA siRNA  
 
L-005130-00-0005 GAACCAAGGUGAUAGAUCU 
AGACAYGGAUCUAAAUCUU 
GUACAGAGGGCAAGUGGAA 
GCAAAGUGCUCAUGUUAGG 
ON-TARGETplus Non-targeting Pool  
 
D-001810-10-20 UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
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Presentations 
• April 2014: World Congress on Osteoarthritis, Paris, France (poster 
presentation). 
• September 2014: UK-German Connective Tissue Meeting, Allendale, UK (oral 
presentation). 
• September 2015: 21st Northern and Yorkshire Rehumatology Meeting, York, 
UK (oral presentation). 
• October 2015: North East Postgraduate Conference, Newcastle Upon Tyne, 
UK (oral presentation). 
• February 2016: MRC Dermatology/Rheumatology Proximity to Discovery 
(PtD) week, Newcastle Upon Tyne, UK (poster presentation). 
• April 2016: World Congress on Osteoarthritis, Amsterdam, Netherlands 
(poster presentation). 
• April 2017: World Congress on Osteoarthritis, Las Vegas, USA (oral 
presentation). 
 
Publications 
• Rogers, E.L, Reynard, L.N., Loughlin, J. (2015) The role of inflammation-
related genes in osteoarthritis. Osteoarthritis Cartilage 23(11):1933-8. 
• Rogers, E.L., Reynard, L.N., Rankin, K., Loughlin, J. (2016) Functional 
Investigation of an OA susceptibility locus at chromosome 9q33.1 associated 
with female hip osteoarthritis. Presented at the 2016 World Congress on 
Osteoarthritis. Osteoarthritis and Cartilage 24:S232.  
• Rogers, E.L, Lendrem, D. Using methylation data for the predictive modelling 
of increased cartilage inflammation in hip osteoarthritis (manuscript in 
preparation). 
• Rogers E.L., Reynard, L., Loughlin, J. Functional analysis of the osteoarthritis 
susceptibility locus marked by the polymorphism rs4836732 (manuscript in 
preparation). 
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• Rogers, E.L., Reynard, L., Loughlin, J. Investigation into the metabolic status 
and systemic inflammation in a subgroup of osteoarthritis patients displaying 
elevated cartilage inflammation (manuscript in preparation). 
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